
    <html>
        <body>
            <search-app>
                <article class="result" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
    <h1 itemprop="pageTitle">US20070232586A1 - Hydrazino-Substituted Heterocyclic Nitrile Compounds and Use Thereof 
        - Google Patents</h1><section itemprop="abstract" itemscope="">
<h2>Abstract</h2>
<div html="" itemprop="content"><abstract lang="EN" load-source="patent-office" mxw-id="PA49793926">
<div class="abstract" id="p-0001" num="0000">
A compound having an inhibitory activity against cysteine protease, represented by formula (I):  
<chemistry id="CHEM-US-00001" num="1"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/53/3e/17/2db448877b792b/US20070232586A1-20071004-C00001.png"><img alt="Figure US20070232586A1-20071004-C00001" class="patent-full-image" file="US20070232586A1-20071004-C00001.TIF" he="16.68mm" height="67" id="EMI-C00001" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/53/3e/17/2db448877b792b/US20070232586A1-20071004-C00001.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00001.CDX" idref="CHEM-US-00001"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00001.MOL" idref="CHEM-US-00001"> </attachment> </attachments> </chemistry>
<br/>
(wherein ring X is a heterocyclic group which may contain 1 to 4 hetero atoms selected from an nitrogen atom(s), a oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to said nitrogen atom in the ring; J is a bond or a spacer having from 1 to 8 atoms; R, R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is each independently hydrogen atom or a substituent; n is 0 or an integer of 1 to 10), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof; and an agent for prevention and/or treatment for a cysteine protease-related disease, such as osteoporosis, comprising it as an active ingredient are provided. 
</div>
</abstract>
</div>
</section><section itemprop="description" itemscope="">
<h2>Description</h2>
<div html="" itemprop="content"><ul class="description" lang="EN" load-source="patent-office" mxw-id="PDES14137385">
<heading id="h-0001">TECHNICAL FIELD </heading>
<li> <para-num num="[0001]"> </para-num> <div class="description-line" id="p-0002" num="0001"> The present invention relates to hydrazino-substituted heterocyclic nitrile compounds which are useful for the treatment of bone diseases such as osteoporosis, a method for the preparation thereof and use thereof. </div>
</li> <heading id="h-0002">BACKGROUND OF ART </heading>
<li> <para-num num="[0002]"> </para-num> <div class="description-line" id="p-0003" num="0002"> Cysteine protease is a generic name of proteases which have a cysteine residue in the activity center and catalyze protein degradation thereat. In animal cells, many cysteine proteases are known; for example, cathepsin family, calpain, caspase, etc. Cysteine protease exists in various kinds of cells extensively and plays a basic and essential role in the homeostasis, such as conversion of precursor protein into its active form (processing) and degradation of proteins which have become out of use, etc. Until now, its physiological effects are being vigorously studied, and as the studies progress and characters of the enzymes are revealed, cysteine proteases came to be taken as a cause of really various kinds of diseases. </div>
</li> <li> <para-num num="[0003]"> </para-num> <div class="description-line" id="p-0004" num="0003"> It is revealed that cathepsin S (see <i>J. Immunol., </i>161, 2731 (1998)), cathepsin L (see <i>J. Exp. Med., </i>183, 1331 (1996)) and cathepsin F (<i>J. Exp. Med., </i>191, 1177 (2000)) play a role in processing of major histocompatibility complex class-II in antigen presenting cells which play an important role in the early stage of immune responses. In an experimental inflammatory response model induced by antigens, a specific inhibitor of cathepsin S showed an inhibitory effect (see <i>J. Clin. Invest., </i>101, 2351 (1998)). It is also reported that in a leishmania-infected immune response model a cathepsin B inhibitor controlled an immune response and by means of this effect it inhibited the proliferation of protozoans (see <i>J. Immunol., </i>161, 2120 (1998)). In vitro, a result is given that a calpain inhibitor and a cysteine protease inhibitor E-64 inhibited apoptosis which is induced by stimuli on T cell receptors (see <i>J. Exp. Med., </i>178, 1693 (1993)). And cathepsin W, which is expressed in CD8 T cells and NK cells specifically, is known to increase its expression by stimuli of IL-2 by 7 times and so it is conceived that it is concerned with immune responses (see <i>J. Immunol., </i>167, 2172 (2001)). It is also reported that in leukemia patients, gene expression of cathepsin C and cathepsin W increase and cytotoxic T cells are activated (see <i>Int. J. Oncol., </i>22, 33 (2003)). Therefore, it is conceivable that cysteine proteases are much concerned with the progress of immune responses. </div>
</li> <li> <para-num num="[0004]"> </para-num> <div class="description-line" id="p-0005" num="0004"> It is speculated that caspase or a similar cysteine protease thereto occupies an important position in the mechanism of cell death including apoptosis. Therefore it is expected for a cysteine protease inhibitor to be used as an agent for the prophylaxis and/or treatment of those diseases concerning apoptosis, such as infectious diseases, deterioration or sthenia of immune function and brain function, or tumors etc. </div>
</li> <li> <para-num num="[0005]"> </para-num> <div class="description-line" id="p-0006" num="0005"> Diseases concerning apoptosis include, acquired immune deficiency syndrome (AIDS), AIDS-related complex (ARC), adult T cell leukemia, hairy cell leukemia, spondylopathy, respiratory apparatus disorder, arthritis, virus-related diseases (HIV, HTLV-1 related diseases (uveitis, etc.) and hepatitis C, etc.), cancer, collagenosis (systemic lupus erythematosus, rheumatoid arthritis, etc.), autoimmune diseases (inflammatory bowel diseases, Sjoegren syndrome, primary biliary cirrhosis, spontaneous thrombocytopenic purpura, autoimmune hemolytic anemia, myasthenia gravis, insulin dependent (type-I) diabetes, etc.), diseases accompanied by thrombocytopenia (osteomyelodysplasia syndrome, periodic thrombocytopenia, aplastic anemia, spontaneous thrombocytopenia, disseminated intravascular coagulation (DIC), etc.), hepatic diseases such as viral hepatitis (C, A, B, F, etc.) or hepatitis medicamentosa and cirrhosis, dementia (Alzheimer's disease, Alzheimer's senile dementia, etc.), cerebrovascular injury, nerve degeneration diseases, adult acute respiratory distress syndrome, infectious diseases, prostate hypertrophy, hysteromyoma, bronchial asthma, arteriosclerosis, all kinds of lusus naturae, nephropathy, senile cataract, chronic fatigue syndrome, myodystrophy, peripheral neuropathy, etc. </div>
</li> <li> <para-num num="[0006]"> </para-num> <div class="description-line" id="p-0007" num="0006"> Moreover, caspase-1 is concerned with various inflammatory diseases and those diseases caused by immune disorders, by means of interleukin-1β (IL-1β) production. A lot of diseases are shown to be involved with caspase-1; for example, inflammatory bowel diseases such as ulcerative colitis, inflammatory diseases and autoimmune disease (insulin-dependent (type-I) diabetes, autoimmune thyroid diseases, infectious diseases, rejection of an organ transplant, graft versus host diseases, psoriasis, periodontitis (above, see <i>N. Eng. J. Med., </i>328, 106 (1993)), pancreatitis (see <i>J. Interferon Cytokine Res., </i>17, 113 (1997)), hepatitis (see <i>J. Leuko. Biol., </i>58, 90 (1995)), glomerulonephritis (see <i>Kidney Int., </i>47, 1303 (1995)), endocarditis (see <i>Infect. Immun., </i>64, 1638 (1996)), myocarditis (see <i>Br. Hearat J., </i>72, 561 (1995)), systemic lupus erythematosus (see <i>Br. J. Rheumatol., </i>34, 107 (1995)), Hashimoto's diseases (see <i>Autoimmunity, </i>16, 141 (1993)), etc.), etc. Experimentally, it is reported that in liver injury model induced by lipopolysaccharide and D-galactosamine, a caspase-1 inhibitor improved the symptoms, and it is expected that a caspase inhibitor shows an effect in sepsis, ischemic reperfusion and hepatitis gravis (see <i>Am. J. Respir. Crit. Care Med., </i>159, 1308 (1999)). </div>
</li> <li> <para-num num="[0007]"> </para-num> <div class="description-line" id="p-0008" num="0007"> It is also shown that cysteine protease is concerned with rheumatoid arthritis. IL-1β is shown to be concerned with this disease (see <i>Arthritis Rheum., </i>39, 1092 (1996)), and in addition, as autoantibody toward calpastatin (endogenous calpain inhibitor) was found in the serum of the patients (see <i>Proc. Natl. Acad. Sci. USA, </i>9, 7267 (1995)), it is thought that increase of calpain activity leads to the cause of diseases. Also, it is reported that cathepsin B and cathepsin C activity is increased in leukocyte of patients suffering from rheumatoid arthritis (see <i>Biol. Chem., </i>383, 865 (2002)). It is reported that in experimental arthritis model the production of inflammatory cytokine is suppressed and affection of arthritis completely in cathepsin C knock-out mice, so it is expected that cathepsin C inhibition leads to treatment of rheumatoid arthritis (see <i>J. Clin. Invest., </i>109, 357 (2002)). </div>
</li> <li> <para-num num="[0008]"> </para-num> <div class="description-line" id="p-0009" num="0008"> It is also known that cysteine protease causes a disease symptom by decomposing various proteins which compose the organism. </div>
</li> <li> <para-num num="[0009]"> </para-num> <div class="description-line" id="p-0010" num="0009"> It is reported that cathepsin B plays a role in decomposing muscular protein in the chronic phase of sepsis (see <i>J. Clin. Invest., </i>97, 1610 (1996)), and in decomposing muscular protein in myodystrophy model (see <i>Biochem. J, </i>288, 643 (1992)). At the same time it is reported that calpain decomposes the myocyte cell proteins of myodystrophy patients (see <i>J. Biol. Chem., </i>270, 10909 (1995)). </div>
</li> <li> <para-num num="[0010]"> </para-num> <div class="description-line" id="p-0011" num="0010"> In ischemic reperfusion model, a result is given that calpain causes degeneration of brain tissues by means of degradation of protein kinase C-β (see <i>J. Neurochem., </i>7, 2556 (1999)) and that a cathepsin B inhibitor inhibits nerve injury (see <i>Eur. J. Neurosci., </i>10, 1723 (1998)). </div>
</li> <li> <para-num num="[0011]"> </para-num> <div class="description-line" id="p-0012" num="0011"> In the brain ischemic model, it is known that the degradation of spectrin by calpain causes a damage and its function disorder in the neurocyte (see <i>Brain Res., </i>790, 1 (1998)) and it is reported that an IL-1β receptor antagonist relieved the symptoms (see <i>Brain Res. Bull., </i>29, 243 (1992)). </div>
</li> <li> <para-num num="[0012]"> </para-num> <div class="description-line" id="p-0013" num="0012"> In myocardial ischemic model it is confirmed that cathepsin B activity increases in the lesion (see <i>Biochem. Med. Metab. Biol., </i>45, 6 (1991)). </div>
</li> <li> <para-num num="[0013]"> </para-num> <div class="description-line" id="p-0014" num="0013"> In the experiment utilizing ischemic liver injury model, it proved that necrosis and apoptosis of hepatocyte were induced by means of protein-decomposing activity of calpain (see <i>Gastroenterology, </i>116, 168 (1999)). </div>
</li> <li> <para-num num="[0014]"> </para-num> <div class="description-line" id="p-0015" num="0014"> Otherwise, it is known that calpain causes cornea turbid by means of degradation of crystalline (see <i>Biol. Chem., </i>268, 137 (1993)) and that in the lesion of contracted gut mucosa model it was confirmed that the activity of cathepsin B, H and L increased (see <i>J. Parenter. Enteral Nutr., </i>19, 187 (1995)) and it is shown that cysteine protease is a cause of the diseases resulting from these protein degradation. </div>
</li> <li> <para-num num="[0015]"> </para-num> <div class="description-line" id="p-0016" num="0015"> It has been revealed that cysteine protease is concerned with systemic disorders of organs and tissues by shock. </div>
</li> <li> <para-num num="[0016]"> </para-num> <div class="description-line" id="p-0017" num="0016"> It is shown that IL-1β is concerned with septic shock and systemic inflammatory response syndrome (see <i>Igakuno Ayumi, </i>169, 850 (1994)) and besides, it is reported that in endotoxin shock model induced by lipopolysaccharide, a calpain inhibitor prevented circulatory system disorder, disorders of liver and pancreas and acidosis by means of inhibitory effect of activation of nuclear factor κB (see <i>Br. J. Pharmacol., </i>121, 695 (1997)). </div>
</li> <li> <para-num num="[0017]"> </para-num> <div class="description-line" id="p-0018" num="0017"> Since it is reported that calpain is concerned with platelet coagulation process and a calpain inhibitor prevented platelet coagulation (see <i>Am. J. Physiol., </i>259, C862 (1990)), it is conceivable that a cysteine protease inhibitor is useful for the disorder of blood coagulation. From the fact that calpain activity increased in the serum of the patients of purpura (thrombocytopenia) resulting from marrow transplantation, so it is conceivable that calpain is concerned with the actual disease symptoms (see <i>Bone Marrow Transplant., </i>24, 641 (1999)). </div>
</li> <li> <para-num num="[0018]"> </para-num> <div class="description-line" id="p-0019" num="0018"> Caspase-1 inhibitor suppressed apoptosis of blood vessel endothelial cells, which is seen in the early phase of purpura (thrombocytopenia) and is thought to be important for the progression of the pathology afterwards (see <i>Am. J. Hematol., </i>59, 279 (1998)), so it is expected that a cysteine protease inhibitor makes effect on purpura and hemolytic uremic syndrome. </div>
</li> <li> <para-num num="[0019]"> </para-num> <div class="description-line" id="p-0020" num="0019"> The effect of cysteine protease and its inhibitor is being investigated in the area of cancer and metastasis of cancer. </div>
</li> <li> <para-num num="[0020]"> </para-num> <div class="description-line" id="p-0021" num="0020"> Since the proliferations of pancreas cancer cells (see <i>Cancer Res., </i>59, 4551 (1999)) and acute myeloid leukemia cells (see <i>Clin. Lab. Haematol., </i>21, 173 (1999)) were inhibited by a caspase-1 inhibitor or its receptor antagonist, it is expected that caspase-1 activity is essential for the process of proliferation of tumor cells, and that an inhibitor thereof is effective for these cancers. Also, from the facts that cathepsin B activity increased in colon cancer metastasis model (see <i>Clin. Exp. Metastasis, </i>16, 159 (1998)), that cathepsin L activity increased in urine of bladder cancer patients (see <i>Urology, </i>59, 308 (2002)), that cathepsin Z expression was recognized in tumor cells (see <i>J. Biol. Chem., </i>273, 16816 (1998)), that cathepsin K protein expression recognized in human breast cancer cells proved the relationship of cathepsin K and bone metastasis (see <i>Cancer Res., </i>57, 5386 (1997)), and that a calpain inhibitor suppressed migration of the cells, which implies that calpain inhibition might be able to inhibit metastasis of cancer (see <i>J. Biochem., </i>272, 32719 (1997)), a cysteine protease inhibitor is expected to exhibit an inhibitory effect on the metastasis of various malignant tumors. </div>
</li> <li> <para-num num="[0021]"> </para-num> <div class="description-line" id="p-0022" num="0021"> As to AIDS (see <i>AIDS, </i>10, 1349 (1996)) and AIDS-related complex (ARC) (see <i>Arch. Immunol. Ther. Exp</i>. (Warsz), 41, 147 (1993)), it is implied that IL-1 is concerned with the progress of symptoms, and so it is conceivable that cysteine protease inhibition leads to an effective therapy of AIDS and its complication. </div>
</li> <li> <para-num num="[0022]"> </para-num> <div class="description-line" id="p-0023" num="0022"> Some parasites have cysteine protease activity in their bodies. Cysteine protease in the phagosome of malaria protozoan is an essential enzyme for supplying nutrition of the parasites. Its inhibitor show an inhibitory effect of the proliferation of the protozoan (see <i>Blood, </i>87, 4448 (1996)). Cystein protease inhibitor is thought of as drug for treatment of malaria. </div>
</li> <li> <para-num num="[0023]"> </para-num> <div class="description-line" id="p-0024" num="0023"> In Alzheimer-type dementia, it is said that adhesion of non-physiological protein called amyloid to brain is deeply involved with nervous function disorders. Cysteine protease has an activity of generating amyloid by decomposing its precursor protein. Clinically, it is shown that cathepsin B possesses a processing activity of amyloid proteins in the brains of Alzheimer-type dementia patients (see <i>Biochem. Biophys. Res. Commun., </i>177, 377 (1991)). And expressions of cathepsin B protein (see <i>Virchows Arch. A. Pathol. Anat. Histpathol., </i>423, 185 (1993)), cathepsin S protein (see <i>Am. J. Pathol., </i>146, 848 (1995)) and calpain protein (see <i>Proc. Natl. Acad. Sci. USA, </i>90, 2628 (1993)) and increase of caspase-1 activity (see <i>J. Neuropathol. Exp. Neurol., </i>58, 582 (1999)) were confirmed in the brain lesions. And it is implied that cysteine protease is concerned with the disease symptoms, by the fact that calpain is concerned with the formation of paired helical filaments which accumulate in Alzheimer dementia patients and production of protein kinase C which stabilizes the protein (see <i>J. Neurochem., </i>66, 1539 (1996)) and by the knowledge that caspase is concerned with neurocyte death by β amyloid protein adhesion (see <i>Exp. Cell Res., </i>234, 507 (1997)). </div>
</li> <li> <para-num num="[0024]"> </para-num> <div class="description-line" id="p-0025" num="0024"> As to Huntington's chorea, cathepsin H activity increased in the patient's brain (see <i>J. Neurol. Sci., </i>131, 65 (1995)), and the ratio of activated form of calpain (see <i>J. Neurosci., </i>48, 181 (1997)) increased. In Parkinson's disease, the increase of expression of m-calpain was recognized in the mesencephalon in the patients (see <i>Neuroscience, </i>73, 979 (1996)) and IL-1β protein was expressed in brain (see <i>Neurosci. Let., </i>202, 17 (1995)). Therefore, it is speculated that cysteine protease is concerned with the genesis and progress of these diseases. </div>
</li> <li> <para-num num="[0025]"> </para-num> <div class="description-line" id="p-0026" num="0025"> Otherwise, in the central nervous system, spectrin degradation by calpain is found in the process of injury on neurocyte observed in the traumatic brain injury model (see <i>J. Neuropathol. Exp. Neurol., </i>58, 365 (1999)). </div>
</li> <li> <para-num num="[0026]"> </para-num> <div class="description-line" id="p-0027" num="0026"> In spinal cord injured model it was recognized that in glia cells calpain messenger RNA increased and its activity increased in the lesion and the possibility was shown that calpain had much to do with the degeneration of myelin and actin (see <i>Brain Res., </i>816, 375 (1999)). And IL-1β was shown to be concerned with the genesis of multiple sclerosis (see <i>Immunol. Today, </i>14, 260 (1993)). Therefore, it is conceivable that a cysteine protease inhibitor is hopeful as an agent for the treatment of these nerve-injured diseases. </div>
</li> <li> <para-num num="[0027]"> </para-num> <div class="description-line" id="p-0028" num="0027"> Normally, cathepsin S and cathepsin K do not exist in human arterial walls, but it was confirmed that they expressed in arteriosclerosis lesion and they had an decomposing activity of alveolus elastica (see <i>J. Clin. Invest., </i>102, 576 (1998)) and a calpain inhibitor and antisense of m-calpain inhibited the proliferation of human blood vessel smooth muscle cells and it is shown that m-calpain is concerned with the proliferation of smooth muscle (see <i>Arteioscler. Thromb. Vssc. Biol, </i>18, 493 (1998)), so it is conceivable that a cysteine protease inhibitor is hopeful for the treatment of blood vessel lesion such as arteriosclerosis, restenosis after percutaneous transluminal coronary angioplasty (PTCA), etc. And it is also reported that LDL induces cathepsin H expression in human monocyte and cathepsin H is concerned with LDL transformation and it is implied that LDL is concerned with circulatory disorder (arteriosclerosis) (see <i>Arterioscler. Thromb. Vasc. Biol., </i>27 (2003)). </div>
</li> <li> <para-num num="[0028]"> </para-num> <div class="description-line" id="p-0029" num="0028"> It is reported that in liver, cathepsin B is activated in the process of injuring hepatocyte by bile acid (see <i>J. Clin. Invest., </i>103, 137 (1999)) and so it is expected that a cysteine protease inhibitor is useful for cholestatic cirrhosis. </div>
</li> <li> <para-num num="[0029]"> </para-num> <div class="description-line" id="p-0030" num="0029"> It is reported that in spleen, cathepsin Y is concerned with production of bradykinin potentiating peptide (BPP) which plays some role in converting kinin into bradykinin (see <i>Immunopharmacology, </i>45, 207 (1999)). Therefore, it is expected that cathepsin Y inhibitor has anti-allergy effect. </div>
</li> <li> <para-num num="[0030]"> </para-num> <div class="description-line" id="p-0031" num="0030"> In lungs and respiratory system, it is shown that cathepsin S is an enzyme that plays a role in elastin degradation by alveolus macrophages (see <i>J. Biol. Chem., </i>269, 11530 (1994)), so it is probable that cysteine protease is a cause of pulmonary emphysema. In IL-13 transgenic mice in which COPD-like pathology is recognized, increase of cathepsin B, S, L, H and K expression is recognized and it is also reported that administration of a cysteine protease inhibitor suppresses lung inflammation and lung emphysema (see <i>J. Clin. Invest., </i>106, 1081 (2000)). And it is also shown that lung injury (see <i>J. Clin. Invest., </i>97, 963 (1996)), lung fibrosis (see <i>Cytokine, </i>5, 57 (193)) and bronchial asthma (see <i>J. Immunol., </i>149, 3078 (1992)) are caused by way of production of IL-1β by caspase-1. It is also shown that blood cathepsin H concentration is increased in asthma patients, so antiasthma effect by cathepsin H inhibitor is expected (see <i>Clin. Chim. Acta, </i>310, 113 (2001)). It is known that cathepsin H functions in the excision of surfactant protein C which is synthesized by type-2 pneumonia cells (see <i>Am. J. Respir. Cell Mol. Biol., </i>26, 659 (2002)). </div>
</li> <li> <para-num num="[0031]"> </para-num> <div class="description-line" id="p-0032" num="0031"> It is pointed out that cysteine protease is also concerned with diseases concerning bones and cartilages. Cathepsin K is specifically recognized in osteoclast and it has a decomposing activity against bone matrix (see <i>J. Biol. Chem., </i>271, 12517 (1996)), so cathepsin K inhibitor is expected to show an effect in bone diseases where pathologic bone resorption is recognized, such as osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcaemia, osteometastasis of cancer, periodontitis, bone Paget's disease, etc. Also, since IL-1β is shown to be concerned with bone resorption and cartilage degradation, and a caspase-1 inhibitor and IL-1β receptor antagonist inhibit the symptoms of bone resorption and arthritis, so it is expected that it is effective for arthritis (see <i>Cytokine, </i>8, 377 (1996)) and osteoporosis (see <i>J. Clin. Invest., </i>9, 1959 (1994)). And it is also reported that IL-1β is concerned with osteoarthritis (see <i>Life Sci., </i>41, 1187 (1987)). </div>
</li> <li> <para-num num="[0032]"> </para-num> <div class="description-line" id="p-0033" num="0032"> Cysteine protease is involved with production of various hormones. Since increase of messenger RNA of cathepsin S was recognized by stimuli of thytropin on thyroid epitheliocyte strains (see <i>J. Biol. Chem., </i>267, 26038 (1992)), it is conceivable that a cysteine protease inhibitor is effective for hyperthyrodism. </div>
</li> <li> <para-num num="[0033]"> </para-num> <div class="description-line" id="p-0034" num="0033"> Since quantity and activity of cathepsin B protein increased in the gingival sulcus liquid of periodontitis patients (see <i>J. Clin. Periodontol., </i>25, 34 (1998)), it is pointed out that cysteine protease is concerned with periodontitis. Cathepsin G is concerned with abnormal connective tissue decomposition. </div>
</li> <li> <para-num num="[0034]"> </para-num> <div class="description-line" id="p-0035" num="0034"> Therefore, those compounds which have an inhibitory activity against cysteine proteases, are useful as agents for the prophylaxis and/or treatment of inflammatory diseases (periodontitis, arthritis, inflammatory bowel diseases, infectious diseases, pancreatitis, hepatitis, glomerulonephritis, endocarditis, myocarditis, ulcerative colitis, etc.), diseases induced by apoptosis (graft versus host diseases, rejection in transplantation, acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), adult T cell leukemia, hairy cells leukemia, spondylopathy, disorders of respiratory apparatus, arthritis, HIV or HTLV-1 related diseases (uveitis etc.), virus related diseases (hepatitis C etc.), cancer, collagenosis (systemic lupus erythematosus, rheumatoid arthritis, etc.), ulcerative colitis, Sjoegren syndrome, primary biliary cirrhosis, spontaneous thrombocytopenic purpura, autoimmune hemolytic anemia, myasthenia gravis, autoimmune diseases (insulin dependent (type I) diabetes, etc.), diseases accompanied by thrombocytopenia (myelodysplastic syndrome, cyclic thrombocytopenia, aplastic anemia, spontaneous thrombocytopenia, disseminated intravascular coagulation (DIC), etc.), viral hepatitis (A, B, C, F, etc.) or hepatitis medicamentosa and cirrhosis, etc., dementia such as Alzheimer's disease, Alzheimer-type senile dementia, cerebrovascular injury, neurodegenerative disease, adult acute respiratory distress syndrome, infectious diseases, prostatomegaly, hysteromyoma, bronchial asthma, arteriosclerosis, hyperlipidemia, all kinds of lusus naturae, nephritis, senile cataract, chronic fatigue syndrome, myodystrophy, peripheral nerve injury, etc.), diseases induced by immune response disorder (graft versus host diseases, rejection in transplantation, allergic diseases (asthmatic bronchitis, atopic dermatitis, allergic rhinitis, hay fever, diseases by house dust, hypersensitive pneumonia, food allergy, etc.), psoriasis, rheumatoid arthritis, etc.), autoimmune diseases (insulin dependent (type I) diabetes, systemic lupus erythematosus, Hashimoto's diseases, multiple sclerosis, etc.), diseases induced by decomposition of proteins which compose a body (myodystrophy, cataract, periodontitis, hepatocyte injury by bile acid (cholestatic cirrhosis etc.), etc., decomposition of alveolus elastica (emphysema etc.), ischemic diseases (brain ischemia, brain disorder by ischemic reperfusion, cardiac infarction, ischemic liver damage, etc.), etc.), shock (septic shock, systemic inflammatory responsive syndrome, endotoxin shock, acidosis, etc.), circulatory disorder (arteriosclerosis, restenosis after PTCA (percutaneous transluminal coronary angioplasty), etc.), disorder of blood coagulation system (thrombocytopenic purpura, hemolytic uremic syndrome, etc.), malignant tumor, acquired immune deficiency syndrome (AIDS, AIDS-related complex (ARC), etc.), parasitic diseases (malaria etc.), neurodegenerative disease (Alzheimer-type senile dementia, Huntington's chorea, Parkinson's disease, multiple sclerosis, traumatic encephalopathy, traumatic spondylopathy, etc.), lung disorder (fibroid lungs, etc.), bone diseases (osteoporosis, bone fracture, rheumatoid arthritis, arthritis, osteoarthritis, hypercalcaemia, osteometastasis of cancer, periodontitis, bone Paget's disease, etc.), endocrinesthenia (hyperthyroidism etc.), etc. </div>
</li> <li> <para-num num="[0035]"> </para-num> <div class="description-line" id="p-0036" num="0035"> On the other hand, what is the most important for inhibitors in inhibiting the activity of proteases is, the special reaction site which interacts with the amino acid residues the activity center of proteases. The surrounding structure of the reaction sites are represented by - - - P3P2P1-P1′P2′P3′ - - - , centering peptide binding (P1-P1′) of the reaction site, and at P1 site there exist amino acid residues which fit the substance specificity of proteases which the inhibitors aim. Some reaction sites against cysteine proteases are known, for example, in the specification of WO99/54317, the followings are described; P1 position against calpain I, II such as norvaline, phenylalanine, etc.; P1 position against calpain I such as arginine, lysine, tyrosine, valine, etc.; P1 position against papain such as homophenylalanine, arginine, etc.; P1 position against cathepsin B such as homophenylalanine, phenylalanine, tyrosine, etc.; P1 position against cathepsin S such as valine, norleucine, phenylalanine, etc.; P1 position against cathepsin L such as homophenylalanine, lysine, etc.; P1 position against cathepsin K such as arginine, homophenylalanine, leucine, etc.; P1 position against caspase such as aspartic acid, etc. </div>
</li> <li> <para-num num="[0036]"> </para-num> <div class="description-line" id="p-0037" num="0036"> As a compound having an inhibitory activity against cathepsin K, known is a compound represented by formula (a):  
<chemistry id="CHEM-US-00002" num="2"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/d9/15/f0f7824fd0d325/US20070232586A1-20071004-C00002.png"><img alt="Figure US20070232586A1-20071004-C00002" class="patent-full-image" file="US20070232586A1-20071004-C00002.TIF" he="27.43mm" height="110" id="EMI-C00002" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/97/d9/15/f0f7824fd0d325/US20070232586A1-20071004-C00002.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00002.CDX" idref="CHEM-US-00002"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00002.MOL" idref="CHEM-US-00002"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0037]"> </para-num> <div class="description-line" id="p-0038" num="0037"> wherein R<sup>a </sup>is hydrogen, R<sup>4a</sup>, OR<sup>4a </sup>or NR<sup>3a</sup>R<sup>4a</sup>; R<sup>1a </sup>is CO—NR<sup>5a</sup>R<sup>6a</sup>, NH—COR<sup>5a</sup>, CH<sub>2</sub>—NH—C(O)—R<sup>5a</sup>, —CO—R<sup>5a</sup>, —S(O)—R<sup>5a</sup>, —S(O)<sub>2</sub>—R<sup>5a</sup>, —CH<sub>2</sub>—CO_R<sup>5a</sup>, —CH<sub>2</sub>—NR<sup>5a</sup>R<sup>6a</sup>; R<sup>2a </sup>is hydrogen or lower alkyl, aryl, aryl-lower alkyl, C3-10 cycloalkyl, C3-10 cycloalkyl-lower alkyl, a heterocyclic group or heterocyclic group-lower alkyl, which each may be substituted; and R<sup>2a </sup>is halo, hydroxy, oxo, lower alkoxy, CN, NO<sub>2</sub>, or amino substituted with mono- or di-lower alkyl which may be substituted (WO03/020278).</div>
</li> <heading id="h-0003">DISCLOSURE OF THE INVENTION </heading>
<li> <para-num num="[0038]"> </para-num> <div class="description-line" id="p-0039" num="0038"> A task of the present invention is to provide medicaments which are useful for the prevention and/or treatment of bone diseases such as osteoporosis. </div>
</li> <li> <para-num num="[0039]"> </para-num> <div class="description-line" id="p-0040" num="0039"> Based on the above problems, the present inventors have energetically investigated to find such compounds having an inhibitory activity against cysteine protease, to find out that the hydrazino-substituted heterocyclic nitrile compound of formula (I) accomplishes the purpose. </div>
</li> <li> <para-num num="[0040]"> </para-num> <div class="description-line" id="p-0041" num="0040"> The compound in the present invention has an inhibitory activity against cysteine protease, so it is useful for the treatment and/or prevention of bone metabolic diseases and the like. </div>
</li> <li> <para-num num="[0041]"> </para-num> <div class="description-line" id="p-0042" num="0041"> That is, the present invention relates to the followings: 
<br/>
 1. A compound represented by formula (I):  
<chemistry id="CHEM-US-00003" num="3"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/25/24/973895cac9c62d/US20070232586A1-20071004-C00003.png"><img alt="Figure US20070232586A1-20071004-C00003" class="patent-full-image" file="US20070232586A1-20071004-C00003.TIF" he="16.68mm" height="67" id="EMI-C00003" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/15/25/24/973895cac9c62d/US20070232586A1-20071004-C00003.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00003.CDX" idref="CHEM-US-00003"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00003.MOL" idref="CHEM-US-00003"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0042]"> </para-num> <div class="description-line" id="p-0043" num="0042"> wherein ring X is a heterocyclic group which may contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring; <div class="patent-image small-patent-image"><a href="https://patentimages.storage.googleapis.com/81/7d/16/18ae46c2ba08a8/US20070232586A1-20071004-P00003.png"><img alt="Figure US20070232586A1-20071004-P00003" class="patent-full-image" file="US20070232586A1-20071004-P00003.TIF" he="2.79mm" height="11" id="custom-character-00001" img-content="character" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/81/7d/16/18ae46c2ba08a8/US20070232586A1-20071004-P00003.png" wi="4.91mm" width="20"/></a></div> is a single bond or a double bond; J is a bond or a spacer having from 1 to 8 atoms of the principle chain; R is hydrogen atom or a substituent, and if R is plural, Rs are the same or different, and two Rs may form, together with the atom on the ring to which they bind, a cyclic group which may have a substituent(s); R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is each independently a hydrogen atom or a substituent; n is 0 or an integer of 1 to 10, and wherein R<sup>1 </sup>and R<sup>2 </sup>may form, together with the nitrogen atom to which they bind, a cyclic group which may have a substituent(s), and R<sup>2 </sup>and R<sup>3 </sup>may form, together with the nitrogen atom to which they bind, a cyclic group which may have a substituent(s), a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. </div>
</li> <li> <para-num num="[0043]"> </para-num> <div class="description-line" id="p-0044" num="0043"> 2. The compound according to the above-described 1, wherein the ring X is a 5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring. 
<br/>
 3. The compound according to the above-described 1, wherein the ring X is  
<chemistry id="CHEM-US-00004" num="4"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/36/fa/6e263ec6937a41/US20070232586A1-20071004-C00004.png"><img alt="Figure US20070232586A1-20071004-C00004" class="patent-full-image" file="US20070232586A1-20071004-C00004.TIF" he="12.95mm" height="52" id="EMI-C00004" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/3c/36/fa/6e263ec6937a41/US20070232586A1-20071004-C00004.png" wi="18.71mm" width="75"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00004.CDX" idref="CHEM-US-00004"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00004.MOL" idref="CHEM-US-00004"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0044]"> </para-num> <div class="description-line" id="p-0045" num="0044"> wherein ring A is a carbocyclic group or a heterocyclic group; ring B is a nitrogen-containing heterocyclic group; Y and Z is each independently a carbon atom or a nitrogen atom; and other symbols have the same meanings as in the above-described 1. </div>
</li> <li> <para-num num="[0045]"> </para-num> <div class="description-line" id="p-0046" num="0045"> 4. The compound according to the above-described 2, wherein the ring X is a ring selected from tetrahydropyrimidine, dihyrdopyridazine, pyridazine, dihydropyrimidine, dihydropyrazine, dihydrotriazine, dihydropyrazole, pyrrole, pyrimidine, pyrazine, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, thiadiazole, oxadiazole, azepane, azepine, dihydroazepine, tetrahydroazepine, diazepane, diazepine, dihydrodiazepine and tetrahydrodiazepine. </div>
</li> <li> <div class="description-line" id="h-0004" num="0000"> 5. The compound according to the above-described 1, wherein J is a bond. </div>
</li> <li> <div class="description-line" id="h-0005" num="0000"> 6. The compound according to the above-described 1, wherein R<sup>1 </sup>is C1-8 alkyl which may have a substituent(s). </div>
</li> <li> <para-num num="[0046]"> </para-num> <div class="description-line" id="p-0047" num="0046"> 7. The compound according to the above-described 1, wherein R<sup>2 </sup>is C1-8 alkyl which may have a substituent(s), C1-8 alkylcarbonyl which may have a substituent(s), C1-8 alkylsulfonyl which may have a substituent(s), carbamoyl which may have a substituent(s), a carbocyclic group which may have a substituent(s), a heterocyclic group which may have a substituent(s),  
<chemistry id="CHEM-US-00005" num="5"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/55/d1/61/996aa14b2a0f70/US20070232586A1-20071004-C00005.png"><img alt="Figure US20070232586A1-20071004-C00005" class="patent-full-image" file="US20070232586A1-20071004-C00005.TIF" he="9.74mm" height="39" id="EMI-C00005" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/55/d1/61/996aa14b2a0f70/US20070232586A1-20071004-C00005.png" wi="37.76mm" width="151"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00005.CDX" idref="CHEM-US-00005"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00005.MOL" idref="CHEM-US-00005"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0047]"> </para-num> <div class="description-line" id="p-0048" num="0047"> wherein T<sup>1 </sup>and T<sup>2 </sup>is each independently a bond or a spacer having from 1 to 3 atoms of the principle chain, and ring 1 and ring 2 is each independently a cyclic group which may have a substituent(s), or  
<chemistry id="CHEM-US-00006" num="6"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f8/35/f7/7fc3933c8266a4/US20070232586A1-20071004-C00006.png"><img alt="Figure US20070232586A1-20071004-C00006" class="patent-full-image" file="US20070232586A1-20071004-C00006.TIF" he="9.65mm" height="39" id="EMI-C00006" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/f8/35/f7/7fc3933c8266a4/US20070232586A1-20071004-C00006.png" wi="30.31mm" width="121"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00006.CDX" idref="CHEM-US-00006"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00006.MOL" idref="CHEM-US-00006"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0048]"> </para-num> <div class="description-line" id="p-0049" num="0048"> wherein E is a substituent containing a nitrogen atom having basicity, and other symbols have the same meanings as above, and </div>
</li> <li> <para-num num="[0049]"> </para-num> <div class="description-line" id="p-0050" num="0049"> R<sup>3 </sup>is hydrogen atom. 
<br/>
 8. The compound according to the above-described 1, which is represented by formula (I-4):  
<chemistry id="CHEM-US-00007" num="7"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/83/e0/37/95f5efebfa6724/US20070232586A1-20071004-C00007.png"><img alt="Figure US20070232586A1-20071004-C00007" class="patent-full-image" file="US20070232586A1-20071004-C00007.TIF" he="19.56mm" height="78" id="EMI-C00007" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/83/e0/37/95f5efebfa6724/US20070232586A1-20071004-C00007.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00007.CDX" idref="CHEM-US-00007"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00007.MOL" idref="CHEM-US-00007"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0050]"> </para-num> <div class="description-line" id="p-0051" num="0050"> wherein ring X<sup>P </sup>is a 5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring; R<sup>1P </sup>is C1-8 alkyl which may have a substituent(s); T<sup>1P </sup>is a bond or a spacer having 1 or 2 atoms of the principle chain; ring1<sup>P </sup>is a C5 to 7 monocyclic carbocyclic group which may have a substituent(s) or a 5- to 7-membered monocyclic heterocyclic group which may have a substituent(s); and other symbols have the same meanings as in the above-described 1 or 7. </div>
</li> <li> <div class="description-line" id="h-0006" num="0000"> 9. The compound according to the above-described 1, which is </div>
</li> <li> <div class="description-line" id="p-0052" num="0000">
</div> </li> <ul>
<li id="ul0001-0001" num="0051"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0002" num="0052"> N′-(2-cyano-5-methyl-4-pyrimidinyl)-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0003" num="0053"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-(dimethylamino)-N′-neopentylacetohydrazide, </li>
<li id="ul0001-0004" num="0054"> N′-(5-bromo-2-cyano-4-pyrimidinyl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0005" num="0055"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0006" num="0056"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-neopentylnicotinohydrazide, </li>
<li id="ul0001-0007" num="0057"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-(4-morpholinylmethyl)-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0008" num="0058"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(dimethylamino)methyl]-3-fluoro-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0009" num="0059"> N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0010" num="0060"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-methyl-2-[4-(1-methyl-4-piperidinyl)phenyl]-N′-neopentylpropanohydrazide, </li>
<li id="ul0001-0011" num="0061"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0012" num="0062"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-{4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide, </li>
<li id="ul0001-0013" num="0063"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[2-(dimethylamino)ethoxy]-N′-neopentylbenzohydrazide, </li>
<li id="ul0001-0014" num="0064"> N-(2-cyano-6-methyl-4-pyrimidinyl)-2-{(4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide, </li>
<li id="ul0001-0015" num="0065"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-neopentyl-2-(1-pyrrolidinyl)acetohydrazide, </li>
<li id="ul0001-0016" num="0066"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-6-4-methyl-1-piperazinyl)nicotinohydrazide, </li>
<li id="ul0001-0017" num="0067"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-4-{[(2-methoxyethyl)(methyl)amino]methyl}benzohydrazide, </li>
<li id="ul0001-0018" num="0068"> N-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)benzohydrazide, </li>
<li id="ul0001-0019" num="0069"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-3-(dimethylamino)-N′-(2,2-dimethylpropyl)propanohydrazide, </li>
<li id="ul0001-0020" num="0070"> N-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-{4-[(dimethylamino)methyl]phenyl}-N′-(2,2-dimethylpropyl)-2-methylpropanohydrazide, </li>
<li id="ul0001-0021" num="0071"> N-(2-cyano-6-methyl-4-pyrimidinyl)-N-(2,2-dimethylpropyl)-2-methyl-2-{4-[(4-methyl-1-pyrimidinyl)methyl]phenyl}propanohydrazide, </li>
<li id="ul0001-0022" num="0072"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4′-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-4-biphenylcarbohydrazide, </li>
<li id="ul0001-0023" num="0073"> N-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-3-methoxybenzohydrazide, </li>
<li id="ul0001-0024" num="0074"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-2-(methylamino)acetohydrazide, or </li>
<li id="ul0001-0025" num="0075"> tert-butyl 2-(2-cyano-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-2-(2,2-dimethylpropyl)hydrazinecarboxylate. 
<br/>
 10. A pharmaceutical composition comprising the compound of formula (I) according to the above-described 1, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof as an active ingredient. 
<br/>
 11. The pharmaceutical composition according to the above-described 10, which is an agent for prevention and/or treatment for a cysteine protease-related disease. 
<br/>
 12. The pharmaceutical composition according to the above-described 11, wherein a cysteine protease-related disease is a cathepsin K-related disease. 
<br/>
 13. The pharmaceutical composition according to the above-described 12, wherein a cathepsin K-related disease is a bone disease. 
<br/>
 14. The pharmaceutical composition according to the above-described 13, wherein a bone disease is at least one selected from osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcaemia, osteometastasis of cancer, osteosarcoma, periodontitis, and bone Paget's disease. 
<br/>
 15. The pharmaceutical composition according to the above-described 10, which is a bone resorption inhibitor. 
<br/>
 16. A drug comprising the compound of formula (I) according to the above-described 1, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof, combined with at least one selected from bisphosphonate formulations, vitamin D and its derivatives, vitamin K and its derivatives, calcitonin formulations, α-calcitonin gene-related peptide formulations, female hormone formulations, selective estrogen receptor modulators, ipriflavone formulations, calcium formulations, anabolic steroid formulations, parathyroid hormone formulations, PTHrP derivatives, caspase-1 inhibitors, farnesoid X receptor agonists, Bone Morphogenetic Protein formulations, anti-RANKL antibody, GSK inhibitor, metalloprotease inhibitors, prostaglandin derivatives, strontium formulations, anti TNF-α antibody, anti-IL-6 antibody, HMG-CoA reductase inhibitors, steroidal drugs, and antiinflammatory drugs. 
<br/>
 17. A method for the prophylaxis and/or treatment of a cysteine protease-related disease in a mammal characterized by administering to a mammal an effective amount of the compound of formula (I) according to the above-described 1, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. 
<br/>
 18. Use of the compound of formula (I) according to the above-described 1, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof, for the manufacture of a pharmaceutical preparation for the prophylaxis and/or treatment of a cysteine protease-related disease. 
</li>
</ul>
<li> <para-num num="[0076]"> </para-num> <div class="description-line" id="p-0053" num="0076"> Definition of the term in the present invention is described below. </div>
</li> <li> <para-num num="[0077]"> </para-num> <div class="description-line" id="p-0054" num="0077"> The “heterocyclic group which may contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring” represented by ring X is, for example, a monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized (S, S(O), SO<sub>2</sub>). Herein, the “monocyclic aromatic heterocyclic group” includes, for example, a 5- to 10-membered monocyclic aromatic heterocyclic group. </div>
</li> <li> <para-num num="[0078]"> </para-num> <div class="description-line" id="p-0055" num="0078"> The “5- to 10-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized” represented by ring X includes, for example, pyrimidine, pyridine, pyrazine, triazine, pyridazine, imidazole, pyrrole, thiazole, oxazole, triazole, pyrazole, thiadiazole, oxadiazole, isothiazole, isoxazole, piperidine, tetrahydropyridine, dihyrdopyridine, tetrahydropyrimidine, dihydropyrimidine, hexahydropyrimidine, azepane, tetrahydroazepine, dihydroazepine, diazepane, tetrahydroazepine, dihyrdodiazepine, triazepane, tetrahydrotriazepine and dihyrdotriazepine rings, etc. </div>
</li> <li> <para-num num="[0079]"> </para-num> <div class="description-line" id="p-0056" num="0079"> The “polycyclic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized” represented by ring X includes, for example,  
<chemistry id="CHEM-US-00008" num="8"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d2/9a/fe/05a23b7cf85606/US20070232586A1-20071004-C00008.png"><img alt="Figure US20070232586A1-20071004-C00008" class="patent-full-image" file="US20070232586A1-20071004-C00008.TIF" he="12.95mm" height="52" id="EMI-C00008" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d2/9a/fe/05a23b7cf85606/US20070232586A1-20071004-C00008.png" wi="18.71mm" width="75"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00008.CDX" idref="CHEM-US-00008"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00008.MOL" idref="CHEM-US-00008"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0080]"> </para-num> <div class="description-line" id="p-0057" num="0080"> (wherein ring A is a carbocyclic group or a heterocyclic group; ring B is a nitrogen-containing heterocyclic group; Y and Z is each independently a carbon atom or a nitrogen atom; and <div class="patent-image small-patent-image"><a href="https://patentimages.storage.googleapis.com/27/36/fd/dd5343f66ac704/US20070232586A1-20071004-P00001.png"><img alt="Figure US20070232586A1-20071004-P00001" class="patent-full-image" file="US20070232586A1-20071004-P00001.TIF" he="2.79mm" height="11" id="custom-character-00002" img-content="character" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/27/36/fd/dd5343f66ac704/US20070232586A1-20071004-P00001.png" wi="4.91mm" width="20"/></a></div>is a single bond or a double bond). </div>
</li> <li> <para-num num="[0081]"> </para-num> <div class="description-line" id="p-0058" num="0081"> The “carbocyclic group” represented by ring A includes, for example, C3-15 mono-, polycyclic aromatic cyclic group, the carbocyclic group which is partially or fully saturated, a polycyclic carbocyclic group having a spiro bond, a polycyclic bridged carbocyclic group, etc. The C3-15 mono-, polycyclic aromatic cyclic group, the carbocyclic group which is partially or fully saturated includes, for example, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclooctane, cyclononane, cyclodecane, cycloundecane, cyclododecane, cyclotridecane, cyclotetradecane, cyclopentadecane, cyclopentene, cyclohexene, cycloheptene, cyclooctene, cyclopentadiene, cyclohexadiene, cycloheptadiene, cyclooctadiene, benzene, pentalene, perhydropentalene, azulene, perhydroazulene, indene, perhydroindene, indan, naphthalene, dihydronaphthalene, teterahydronaphthalene, perhydronaphthalene, heptalene, perhydroheptalene, biphenylene, as-indacene, s-indacene, acenaphthylene, acenaphthene, fluorene, phenalene, phenanthrene and anthracene rings, etc. The polycyclic carbocyclic group having a spiro bond and the polycyclic bridged carbocyclic group include, for example, spiro[4,4]nonane, spiro[4,5]decane, spiro[5,5]undecane, bicyclo[2.2.1]heptane, bicyclo[2.2.1]hept-2-ene, bicyclo[3.1.1]heptane, bicyclo[3.1.1]hept-2-ene, bicyclo[2.2.2]octane, bicyclo[2.2.2]oct-2-ene, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, bicyclo[4.4.0]decane, adainantane and noradamantane rings, etc. </div>
</li> <li> <para-num num="[0082]"> </para-num> <div class="description-line" id="p-0059" num="0082"> The “heterocyclic group” represented by ring A includes, for example, a 3- to 15-membered monocyclic or polycyclic aromatic heterocyclic group which may be partially or full saturated and contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized (S, SO, SO<sub>2</sub>), a polycyclic heterocyclic group having a spiro bond, a polycyclic bridged heterocyclic group, etc. The 3- to 15-membered monocyclic or polycyclic aromatic heterocyclic group which may be partially or full saturated and contains 1 to 5 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized (S, SO, SO<sub>2</sub>), the polycyclic heterocyclic group having a spiro bond, and the polycyclic bridged heterocyclic group include, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, triazine, azepine, diazepine, furan, pyran, oxepine, thiophene, thiopyran, thiepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, indolizine, benzofuran, isobenzofuran, benzothiophene, isobenzothiophene, dithianaphthalene, indazole, quinoline, isoquinoline, quinolizine, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, pyrrolopyridine, benzoxazole, benzothiazole, thieno[3,2-c]pyridine, benzimidazole, chromene, benzoxepine, benzoxazepine, benzoxadiazepine, benzothiepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, benzofurazan, benzothiadiazole, benzotriazole, carbazole, β-carboline, acridine, phenazine, dibenzofuran, xanthene, dibenzothiophene, phenothiazine, phenoxazine, phenoxathiin, thianthrene, phenanthridine, phenanthroline, perimidine, pyridonaphthyridine, pyrazoloisoquinoline, pyrazolonaphthyridine, pyrimidoindole, aziridine, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyrazole (pyrazoline), tetrahydropyrazole (pyrazolidine), dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydrotriazine, tetrahydrotriazine, perhydrotriazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, oxirane, oxetane, dihydrofuran, tetrahydrofuran, dihydropyran, tetrahydropyran, dihydrooxepine, tetrahydrooxepine, perhydrooxepine, thiirane, thietane, dihydrothiophene, tetrahydrothiophene, dihydrothiopyran, tetrahydrothiopyran, dihydrothiepine, tetrahydrothiepine, perhydrothiepine, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, oxathiane, indoline, isoindoline, dihydrobenzofuran, perhydrobenzofuran, dihydroisobenzofuran, perhydroisobenzofuran, dihydrobenzothiophene, perhydrobenzothiophene, dihydroisobenzothiophene, perhydroisobenzothiophene, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, octahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, octahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, tetrahydropyrrolopyridine, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, benzoxathiane, dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, dihydrobenzimidazole, perhydrobenzimidazole, dihydrobenzazepine, tetrahydrobenzazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, benzodioxepane, dihydrobenzoxazepine, tetrahydrobenzoxazepine, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihydroacridine, tetrahydroacridine, perhydroacridine, dihydrodibenzofuran, dihydrodibenzothiophene, tetrahydrodibenzofuran, tetrahydrodibenzothiophene, perhydrodibenzofuran, perhydrodibenzothiophene, tetrahydronaphthyridine, tetrahydro-β-carboline, dihydroazepinoindole, hexahydroazepinoindole, tetrahydropyrazoloisoquinoline, tetrahydropyrazolonaphthyridine, dihydroazepinoindazole, hexahydroazepinoindazole, dihydropyrazolopyridoazepine, hexahydropyrazolopyridoazepine, tetrahydropyrimidoindole, dihydrothiazinoindole, tetrahydrothiazinoindole, dihydrooxazinoindole, tetrahydrooxazinoindole, 2,3-dihydro-1H-benzo[de]isoquinoline, dioxolane, dioxane, dithiolane, dithiane, benzodioxole, for example, 1,3-benzodioxole, etc., benzodioxane, chroman, benzodithiolane benzodithiane, azaspiro[4,4]nonane, oxaazaspiro[4,4]nonane, oxaazaspiro[2,5]octane, dioxaspiro[4,4]nonane, azaspiro[4.5]decane, thiaspiro[4.5]decane, dithiaspiro[4.5]decane, dioxaspiro[4.5]decane, oxaazaspiro[4.5]decane, azaspiro[5,5]undecane, oxaspiro[5.5]undecane, dioxaspiro[5,5]undecane, 1,4-dioxa-8-azaspiro[4.5]undecane, 1,3,8-triazaspiro[4.5]decane, azabicyclo[2.2.1]heptane, oxabicyclo[2.2.1]heptane, azabicyclo[3.1.1]heptane, azabicyclo[3.2.1]octane, oxabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[2.2.2]octane, 2,5-diazabicyclo[2.2.1]heptane, 1,3,8-triazaspiro[4.5]decane, 2,7-diazaspiro[4.5]decane, 1,4,9-triazaspiro[5.5]undecane, 2,4,6-trioxaspiro[bicyclo[3.3.0]octane-3,1′-cyclohexane], 1,3-dioxolano[4,5-g]chromene, 2-oxabicyclo[2.2.1]heptane, 2,3,4,9-tetrahydrospiro[β-carboline-1,1′-cyclopentane] and 3,9-diazaspiro [5,5]undecane rings, etc. </div>
</li> <li> <para-num num="[0083]"> </para-num> <div class="description-line" id="p-0060" num="0083"> The “nitrogen-containing heterocyclic group” represented by ring B includes, for example, a 3- to 15-membered monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and which may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized (S, S(O), SO<sub>2</sub>), a polycyclic heterocyclic group having a spiro bond, a polycyclic bridged heterocyclic group, etc. </div>
</li> <li> <para-num num="[0084]"> </para-num> <div class="description-line" id="p-0061" num="0084"> The “3- to 15-membered monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and which may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized (S, S(O), SO<sub>2</sub>), polycyclic heterocyclic group having a spiro bond, and polycyclic bridged heterocyclic group” include, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, pyridine, pyrazine, pyrimidine, triazine, pyridazine, azepine, diazepine, oxazole, isoxazole, thiazole, isothiazole, furazan, oxadiazole, oxazine, oxadiazine, oxazepine, oxadiazepine, thiadiazole, thiazine, thiadiazine, thiazepine, thiadiazepine, indole, isoindole, indazole, quinoline, isoquinoline, purine, phthalazine, pteridine, naphthyridine, quinoxaline, quinazoline, cinnoline, pyrrolopyridine, benzoxazole, benzothiazole, benzimidazole, benzoxazepine, benzoxadiazepine, benzothiazepine, benzothiadiazepine, benzazepine, benzodiazepine, β-carboline, phenanthridine, phenanthroline, pyridonaphthyridine, pyrazoloisoquinoline, pyrazolonaphthyridine, pyrimidoindole, azetidine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, pyrazoline, pyrazolidine, dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydrotriazine, tetrahydrotriazine, perhydrotriazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihydrothiadiazole, dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, indoline, isoindoline, dihydroindazole, perhydroindazole, dihydroquinoline, tetrahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, tetrahydronaphthyridine, perhydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, tetrahydropyrrolopyridine, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, dihydrobenzimidazole, perhydrobenzimidazole, dihydrobenzazepine, tetrahydrobenzazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, dihydrobenzoxazepine, tetrahydrobenzoxazepine, tetrahydronaphthyridine, tetrahydro-β-carboline, dihydroazepinoindole, hexahydroazepinoindole, tetrahydropyrazoloisoquinoline, tetrahydropyrazolonaphthyridine, dihydroazepinoindazole, hexahydroazepinoindazole, dihydropyrazolopyridoazepine, hexahydropyrazolopyridoazepine, tetrahydropyrimidoindole, dihydrothiazinoindole, tetrahydrothiazinoindole, azaspiro[4,4]nonane, oxaazaspiro[4,4]nonane, oxaazaspiro[2,5]octane, azaspiro[4,5]decane, oxaazaspiro[4,5]decane, azaspiro[5,5]undecane, 1,4-dioxa-8-azaspiro[4.5]undecane, 1,3,8-triazaspiro[4,5]decane, azabicyclo[2.2.1]heptane, azabicyclo[3.1.1]heptane, azabicyclo[3.2.1]octane, oxabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[2.2.2]octane, 2,5-diazabicyclo[2.2.1]heptane, 1,3,8-triazaspiro[4.5]decane, 2,7-diazaspiro[4.5]decane, 1,4,9-triazaspiro[5.5]undecane, 2,3,4,9-tetrahydrospiro[β-carboline-1,1′-cyclopentane] and 3,9-diazaspiro[5.5]undecane rings, etc. </div>
</li> <li> <para-num num="[0085]"> </para-num> <div class="description-line" id="p-0062" num="0085"> The substituent represented by R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>includes, for example, (1) hydrocarbon group which may have a substituent(s), (2) carbocyclic group which may have a substituent(s), (3) heterocyclic group which may have a substituent(s), (4) hydroxy which may have a substituent(s), (5) mercapto which may have a substituent(s), (6) amino which may have a substituent(s), (7) carbamoyl which may have a substituent(s), (8) sulfamoyl which may have a substituent(s), (9) carboxy, (10) alkoxycarbonyl (e.g., C1-6 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), (11) sulfo, (12) sulfino, (13) phosphono, (14) nitro, (15) cyano, (16) amidino, (17) imino, (18) dihydroxyboryl (—B(OH)<sub>2</sub>), (19) halogen (fluoro, chloro, bromo, iodo), (20) alkylsulfinyl (e.g., C1-6 alkylsulfinyl such as methylsulfinyl, ethylsulfinyl, etc.), (21) aromatic ring-sulfinyl (e.g., C6-10 aromatic ring-sulfinyl such as phenylsulfinyl, etc.), (22) alkylsulfonyl (e.g., C1-6 alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, etc.), (23) aromatic ring-sulfonyl (e.g., C6-10 aromatic ring-sulfonyl such as phenylsulfonyl, etc.), (24) (C1-6 alkoxyimino)methyl (e.g., (methoxyimino)methyl, etc.), (25) acyl, (26) formyl, (27) alkyl substituted by hydroxy which may have a substituent(s), (28) alkyl substituted by mercapto which may have a substituent(s), (29) alkyl substituted by amino which may have a substituent(s), (30) (alkyl which may have a substituent(s))oxycarbonyl, (31) HO—(CO-amino acid residue-NH)<sub>q</sub>—CO-T<sup>0</sup>- which may have a substituent(s), (32) H—(NH-amino acid residue-CO)<sub>q</sub>—O-T<sup>0</sup>- which may have a substituent(s), etc. </div>
</li> <li> <para-num num="[0086]"> </para-num> <div class="description-line" id="p-0063" num="0086"> R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>are each independently the same or different. </div>
</li> <li> <para-num num="[0087]"> </para-num> <div class="description-line" id="p-0064" num="0087"> The substituent represented by R includes, for example, (1) hydrocarbon group which may have a substituent(s), (2) carbocyclic group which may have a substituent(s), (3) heterocyclic group which may have a substituent(s), (4) hydroxy which may have a substituent(s), (5) mercapto which may have a substituent(s), (6) amino which may have a substituent(s), (7) carbamoyl which may have a substituent(s), (8) sulfamoyl which may have a substituent(s), (9) carboxy, (10) alkoxycarbonyl (e.g., C1-6 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), (11) sulfo, (12) sulfino, (13) phosphono, (14) nitro, (15) cyano, (16) amidino, (17) imino, (18) dihydroxyboryl (—B(OH)<sub>2</sub>), (19) halogen (fluoro, chloro, bromo, iodo), (20) alkylsulfinyl (e.g., C1-6 alkylsulfinyl such as methylsulfinyl, ethylsulfinyl, etc.), (21) aromatic ring-sulfinyl (e.g., C6-10 aromatic ring-sulfinyl such as phenylsulfinyl, etc.), (22) alkylsulfonyl (e.g., C1-6 alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, etc.), (23) aromatic ring-sulfonyl (e.g., C6-10 aromatic ring-sulfonyl such as phenylsulfonyl, etc.), (24) (C1-6 alkoxyimino)methyl (e.g., (methoxyimino)methyl, etc.), (25) acyl, (26) formyl, (27) alkyl substituted by hydroxy which may have a substituent(s), (28) alkyl substituted by mercapto which may have a substituent(s), (29) alkyl substituted by amino which may have a substituent(s), (30) (alkyl which may have a substituent(s))oxycarbonyl, (31) HO—(CO-amino acid residue-NH)<sub>q</sub>—CO-T<sup>0</sup>- which may have a substituent(s), (32) H—(NH-amino acid residue-CO)<sub>q</sub>—O-T<sup>0</sup>- which may have a substituent(s), (33) oxo, (34) thioxo, etc. </div>
</li> <li> <para-num num="[0088]"> </para-num> <div class="description-line" id="p-0065" num="0088"> A hydrocarbon group in “(1) hydrocarbon group which may have a substituent(s)” includes, for example, alkyl, alkenyl, alkynyl, alkylidene, alkenylidene, etc. </div>
</li> <li> <para-num num="[0089]"> </para-num> <div class="description-line" id="p-0066" num="0089"> The alkyl group includes, for example, straight chain or branched C1-8 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, hexyl, heptyl, octyl, etc. </div>
</li> <li> <para-num num="[0090]"> </para-num> <div class="description-line" id="p-0067" num="0090"> The alkenyl group includes, for example, straight chain or branched C2-8 alkenyl such as ethenyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, etc. </div>
</li> <li> <para-num num="[0091]"> </para-num> <div class="description-line" id="p-0068" num="0091"> The alkynyl group includes, for example, straight chain or branched C2-8 alkynyl such as ethynyl, propynyl, butynyl, pentynyl, hexynyl heptynyl, octynyl, etc. </div>
</li> <li> <para-num num="[0092]"> </para-num> <div class="description-line" id="p-0069" num="0092"> The alkylidene group includes, for example, straight chain or branched C1-8 alkylidene such as methylidene, ethylidene, propylidene, butylidene, pentylidene, hexylidene, heptylidene, octylidene, etc. </div>
</li> <li> <para-num num="[0093]"> </para-num> <div class="description-line" id="p-0070" num="0093"> The alkenylidene includes, for example, straight chain or branched C2-8 alkenylidene such as ethenylidene, propenylidene, butenylidene, pentenylidene, hexenylide, heptenylidene, octenylidene, etc. </div>
</li> <li> <para-num num="[0094]"> </para-num> <div class="description-line" id="p-0071" num="0094"> Herein, the substituent in “(1) hydrocarbon group which may have a substituent(s)” includes, for example, hydroxy, mercapto, amino, carboxy, nitro, cyano, mono- or di-C1-6 alkyl-substituted amino (e.g., methylamino, ethylamino, propylamino, dimethylamino, diethylamino, etc., herein, the C1-6 alkyl may be substituted with C1-6 alkoxy such as methoxy, ethoxy, etc.), N-aromatic ring amino (e.g., N-phenylamino, etc.), N-aromatic ring-N-alkylamino (e.g., N-phenyl-N-methylamino, N-phenyl-N-ethylamino, N-phenyl-N-propylamino, N-phenyl-N-butylamino, N-phenyl-N-pentylamino, N-phenyl-N-hexylamino, etc.), acylamino (e.g., acetylamino, etc.), N-acyl-N-alkylamino (e.g., N-acetyl-N-methylamino, etc.), N-alkyloxycarbonyl-N-alkylamino (e.g., N-tert-butoxycrbonyl-N-methylamino, etc.), etc.), C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, hexyloxy, etc.), C3-7 cycloalkyl-C1-6 alkoxy (e.g., cyclohexylmethyloxy, cyclopentylethyloxy, etc.), C3-7 cycloalkyloxy (e.g., cyclohexyloxy, etc.), C7-15 aralkyloxy (e.g., benzyloxy, phenethyloxy, phenylpropyloxy, naphthylmethyloxy, naphthylethyloxy, etc.), phenoxy, C1-6 alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), C1-6 alkylcarbonyloxy (e.g., acetoxy, ethylcarbonyloxy, etc.), C1-6 alkylthio (e.g., methylthio, ethylthio, propylthio, butylthio, etc.), halogen (fluoro, chloro, bromo, iodo), alkylsulfonyl (e.g., C1-4 alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, etc.), aromatic ring-sulfonyl (e.g., C6-10 aromatic ring-sulfonyl such as phenylsulfonyl, etc.), carbamoyl which may have a substituent(s) (e.g., non-substituted carbamoyl, N-mono-(C1-8 alkyl)carbamoyl (N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, etc.), N,N-di(C1-8 alkyl)carbamoyl (e.g., N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-dibutylcarbamoyl, etc.), piperidin-1-ylcarbonyl, etc.), acyl, carbocyclic group which may have a substituent(s), heterocyclic group which may have a substituent(s), etc. The 1 to 4 substituent(s) may exist wherever possible. Alkyl in the N-acyl-N-alkylamino and N-alkyloxycarbonyl-N-alkylamino includes, for example, straight chain or branched C1-6 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, etc. Acyl, acyl in the acylamino and N-acyl-N-alkylamino includes, for example, C1-8 alkylcarbonyl such as formyl, acetyl, propanoyl, butanoyl, pentanoyl, hexanoyl, heptanoy, octanoyl, pivaloyl, etc., C6-10 aromatic ring-carbonyl such as benzoyl, phenylmethylcarbonyl, 2-phenylethylcarbonyl, etc. Carbocyclic group which may have a substituent(s), heterocyclic group which may have a substituent(s) have the same meanings as the below-described “(2) carbocyclic group which may have a substituent(s)”, and “(3) heterocyclic group which may have a substituent(s)”, respectively. </div>
</li> <li> <para-num num="[0095]"> </para-num> <div class="description-line" id="p-0072" num="0095"> The carbocyclic group in the “(2) carbocyclic group which may have a substituent(s)” has the same meaning as the above-described carbocyclic group represented by ring A. Herein, substituent in the “(2) carbocyclic group which may have a substituent(s)” includes, for example, straight chain or branched C1-6 alkyl (e.g., methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, etc.), straight chain or branched C2-6 alkenyl (e.g., ethenyl, propenyl, butenyl, pentenyl, hexenyl, etc.), or straight chain or branched C2-6 alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, etc.) which may be substituted by hydroxy, C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, hexyloxy, etc.), carbocyclic group (which has the same meaning as the above-described carbocyclic group represented by ring A.), or heterocyclic group (which has the same meaning as the above-described heterocyclic group represented by ring A), hydroxy, straight chain or branched C1-6 alkoxy (e.g., methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutyloxy, tert-butoxy, pentyloxy, isopentyloxy, neopentyloxy, hexyloxy, isohexyloxy, etc.), mercapto, straight chain or branched C1-6 alkylthio (e.g., methylthio, ethylthio, propylthio, isopropylthio, butylthio, isobutylthio, tert-butylthio, pentylthio, isopentylthio, neopentylthio, hexylthio, isohexylthio, etc.), amino, mono- or di-C1-6 alkylamino (e.g., methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, tert-butylamino, pentylamino, isopentylamino, neopentylamino, hexylamino, dimethylamino, diethylamino, dipropylamino, N-methyl-N-ethylamino, etc.), halogen (fluoro, chloro, bromo, iodo), cyano, nitro, carboxy, straight chain or branched C1-6 alkoxycarbonyl (e.g., methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, isopropyloxycarbonyl, butoxycarbonyl, isobutyloxycarbonyl, tert-butoxycarbonyl, etc.), trihalomethyl (e.g., trifluoromethyl, trichloromethyl, etc.), trihalomethoxy (e.g., trifluoromethoxy, trichloromethyloxy, etc.), trihalomethylthio (trifluoromethylthio, trichloromethylthio, etc.), dihalomethylthio (difluoromethylthio, dichloromethylthio, etc.), oxo, carbocyclic group (which has the same meaning as the above-described carbocyclic group represented by ring A.), heterocyclic group (which has the same meaning as the above-described heterocyclic group represented by ring A), etc. And the 1 to 4 substituent(s) may exist wherever possible. </div>
</li> <li> <para-num num="[0096]"> </para-num> <div class="description-line" id="p-0073" num="0096"> Heterocyclic group in the “(3) heterocyclic group which may have a substituent(s)” has the same meaning as the above-described heterocyclic group represented by ring A. Herein, substituent in the heterocyclic group has the same meaning as the above-described substituent(s) in the “(2) carbocyclic group which may have a substituent(s)”. </div>
</li> <li> <para-num num="[0097]"> </para-num> <div class="description-line" id="p-0074" num="0097"> Substituent in the “(4) hydroxy which may have a substituent(s)”, “(5) mercapto which may have a substituent(s)”, “(6) amino which may have a substituent(s)”, “(31) HO—(CO-amino acid residue-NH)<sub>q</sub>—CO-T<sup>0</sup>- which may have a substituent(s)”, and “(32) H—(NH-amino acid residue-CO)<sub>q</sub>—O-T<sup>0</sup>- which may have a substituent(s)” includes, for example, hydrocarbon group which may have a substituent(s) (which has the same meaning as the above-described “(1) hydrocarbon group which may have a substituent(s)”), carbocyclic group which may have a substituent(s) (which has the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s)”), heterocyclic group which may have a substituent(s) (which has the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”), alkylsulfonyl (e.g., C1-4 alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, etc.), aromatic ring-sulfonyl (e.g., C6-10 aromatic ring-sulfonyl such as phenylsulfonyl, etc.), acyl (which has the same meaning as the below-described “(25) acyl”), (alkyl which may have a substituent(s))oxycarbonyl (which has the same meaning as the below-described “(30) (alkyl which may have a substituent(s))oxycarbonyl”), etc. </div>
</li> <li> <para-num num="[0098]"> </para-num> <div class="description-line" id="p-0075" num="0098"> “(7) Carbamoyl which may have a substituent(s)” includes, for example, non-substituted carbamoyl, N-mono-C1-6 alkylcarbamoyl (e.g., N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N-isopropylcarbamoyl, N-butylcarbamoyl, etc.), N,N-di(C1-6 alkyl)carbamoyl (e.g., N,N-dimethylcarbamoyl, N,N-diethylcarbamoyl, N,N-dipropylcarbamoyl, N,N-dibutylcarbamoyl, N-ethyl-N-methylcarbamoyl, etc.), piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, etc. </div>
</li> <li> <para-num num="[0099]"> </para-num> <div class="description-line" id="p-0076" num="0099"> “(8) Sulfamoyl which may have a substituent(s)” includes, for example, non-substituted sulfamoyl, N-mono-C1-6 alkylsulfamoyl (e.g., N-methylsulfamoyl, N-ethylsulfamoyl, N-propylsulfamoyl, N-isopropylsulfamoyl, N-butylsulfamoyl, etc.), N,N-di(C1-6 alkyl)sulfamoyl (e.g., N,N-dimethylsulfamoyl, N,N-diethylsulfamoyl, N,N-dipropylsulfamoyl, N,N-dibutylsulfamoyl, N-ethyl-N-methylsulfamoyl, etc.), etc. </div>
</li> <li> <para-num num="[0100]"> </para-num> <div class="description-line" id="p-0077" num="0100"> “(25) Acyl” includes, for example, alkylcarbonyl which may have a substituent(s) (wherein alkyl which may have a substituent(s) has the same meaning as the above-described “alkyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), alkenylcarbonyl which may have a substituent(s) (wherein alkenyl which may have a substituent(s) has the same meaning as the above-described “alkenyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), alkynylcarbonyl which may have a substituent(s) (wherein alkynyl which may has a substituent(s) have the same meaning as the above-described “alkynyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), (carbocyclic group which may have a substituent(s))carbonyl (wherein carbocyclic group which may have a substituent(s) has the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s)”), (heterocyclic group which may have a substituent(s))carbonyl (wherein heterocyclic group which may have a substituent(s) has the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”, alkylsulfonyl which may have a substituent(s) (wherein alkyl which may have a substituent(s) has the same meaning as the above-described “alkyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), alkenylsulfonyl which may have a substituent(s) (wherein alkenyl which may have a substituent(s) has the same meaning as the above-described “alkenyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), alkynylsulfonyl which may have a substituent(s) (wherein alkynyl which may has a substituent(s) have the same meaning as the above-described “alkynyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”), (carbocyclic group which may have a substituent(s))sulfonyl (wherein carbocyclic group which may have a substituent(s) has the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s)”), (heterocyclic group which may have a substituent(s))sulfonyl (wherein heterocyclic group which may have a substituent(s) has the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”, etc. </div>
</li> <li> <para-num num="[0101]"> </para-num> <div class="description-line" id="p-0078" num="0101"> Hydroxy which may have a substituent(s) in the “(27) alkyl substituted by hydroxy which may have a substituent(s)” has the same meaning as the above-described “(4) hydroxy which may have a substituent(s)”, mercapto which may have a substituent(s) in the “(28) alkyl substituted by mercapto which may have a substituent(s)” has the same meaning as the above-described “(5) mercapto which may have a substituent(s)”, amino which may have a substituent(s) in the “(29) alkyl substituted by amino which may have a substituent(s)” has the same meaning as the above-described “(6) amino which may have a substituent(s)”. Alkyl in the “(27) alkyl substituted by hydroxy which may have a substituent(s)”, “(28) alkyl substituted by mercapto which may have a substituent(s)” and “(29) alkyl substituted by amino which may have a substituent(s) includes, for example, straight chain or branched C1-6 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, hexyl, isohexyl, etc. </div>
</li> <li> <para-num num="[0102]"> </para-num> <div class="description-line" id="p-0079" num="0102"> Alkyl which may have a substituent(s) in the “(30) (alkyl which may have a substituent(s))oxycarbonyl” has the same meaning as the above-described “alkyl which may have a substituent(s)” in the “(1) hydrocarbon group which may have a substituent(s)”. </div>
</li> <li> <para-num num="[0103]"> </para-num> <div class="description-line" id="p-0080" num="0103"> “q” in the “(31) HO—(CO-amino acid residue-NH)<sub>q</sub>—CO-T<sup>0</sup>- which may have a substituent(s)”, and “(32) H—(NH-amino acid residue-CO)<sub>q</sub>—O-T<sup>0</sup>- which may have a substituent(s)” is an integer of 1 to 3. “Amino acid” means natural amino acid or unusual amino acid, and includes, for example, glycine, alanine, valine, leucine, isoleucine, serine, threonine, cystein, methionine, proline, asparagine, glutamine, phenylalanine, tyrosine, tryotophan, aspartic acid, glutamic acid, lysine, arginine, histidine, β-alanine, cystathionine, cystine, homoserine, isoleucine, lanthionine, norleucine, norvaline, ornithine, sarcosine, thyronine, etc. T<sup>0 </sup>in the group has the same meaning as the below-described T<sup>1</sup>, T<sup>2 </sup>and T<sup>3</sup>. </div>
</li> <li> <para-num num="[0104]"> </para-num> <div class="description-line" id="p-0081" num="0104"> Also, the substituent represented by R, R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>includes the following group:  
<chemistry id="CHEM-US-00009" num="9"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/b4/f2/c515d863f45ef7/US20070232586A1-20071004-C00009.png"><img alt="Figure US20070232586A1-20071004-C00009" class="patent-full-image" file="US20070232586A1-20071004-C00009.TIF" he="38.95mm" height="156" id="EMI-C00009" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/95/b4/f2/c515d863f45ef7/US20070232586A1-20071004-C00009.png" wi="61.04mm" width="244"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00009.CDX" idref="CHEM-US-00009"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00009.MOL" idref="CHEM-US-00009"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0105]"> </para-num> <div class="description-line" id="p-0082" num="0105"> The nitrogen-containing substituent includes, for example, amino which may have a substituent(s) or a nitrogen-containing heterocyclic group which may have a substituent(s). The “amino which may have a substituent(s)” has the same meaning as the above-described “(6) amino which may have a substituent(s)”. The “nitrogen-containing heterocyclic group” has the same meaning as the above-described “nitrogen-containing heterocyclic group” represented by ring B. The “nitrogen-containing heterocyclic group” may have 1 to 5 substituents. The substituent(s) in the nitrogen-containing heterocyclic group” has the same meaning as the above-described substituent(s) in the “(2) carbocyclic group which may have a substituent(s)”. When the nitrogen-containing heterocyclic group has plural substituents, the substituents are the same or different. </div>
</li> <li> <para-num num="[0106]"> </para-num> <div class="description-line" id="p-0083" num="0106"> T<sup>1</sup>, T<sup>2 </sup>and T<sup>3 </sup>is each independently a bond or a spacer having from 1 to 3 atoms of the principle chain, and ring 1, ring 2 and ring 3 is each independently a cyclic group which may have a substituent(s). </div>
</li> <li> <para-num num="[0107]"> </para-num> <div class="description-line" id="p-0084" num="0107"> A spacer having from 1 to 3 atoms of the principle chain represented by T<sup>1</sup>, T<sup>2 </sup>and T<sup>3 </sup>means a space formed by 1 to 3 continued atoms of a main chain. In this case, the “number of atoms as a principle chain” should be counted such that atoms as a main chain become minimum. The “spacer having from 1 to 3 atoms of the principle chain” includes, for example, a bivalent group formed by 1 to 3 continued atoms of a main chain comprising 1 to 3 selected from —O—, —S—, —S(O)—, —SO<sub>2</sub>—, —CO—, a nitrogen atom which may have a substituent(s), and a bivalent C1-3 aliphatic hydrocarbon group which may have a substituent(s), etc. “A nitrogen atom which may have a substituent(s)” includes, an —NH— in which hydrogen atom is replaced by hydrocarbon group which may have a substituent(s) (which has the same meaning as the above-described “(1) hydrocarbon group which may have a substituent(s)”) besides —NH— and ═N—. </div>
</li> <li> <para-num num="[0108]"> </para-num> <div class="description-line" id="p-0085" num="0108"> “A divalent C1-3 aliphatic hydrocarbon group” in the “a divalent C1-3 aliphatic hydrocarbon group which may have a substituent(s)” includes, for example, C1-3 alkylene (e.g., —CH<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>3</sub>—, etc.), C2-3 alkenylene (e.g., —CH═CH—, —CH<sub>2</sub>—CH═CH—, —CH═CH—CH<sub>2</sub>—, etc.), C2-3 alkynylene (e.g., —C≡C—, —CH<sub>2</sub>—C≡C—, —C≡C—CH<sub>2</sub>—, etc.). “Substituent” in “a divalent C1-3 aliphatic hydrocarbon group which may have a substituent(s)” has the same meaning as the above-described “substituent” in “(1) hydrocarbon group which may have a substituent(s)”. When the substituents is plural, these substituents may be taken together with carbon atom(s) which they bind to form carbocyclic group or heterocyclic group. The “carbocyclic group” and the “heterocyclic group” have the same meanings as the “carbocyclic group” and the “heterocyclic group”, respectively, described above in ring A. The “carbocyclic group” is preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane, etc., and the “heterocyclic group” is preferably piperidine, etc. </div>
</li> <li> <para-num num="[0109]"> </para-num> <div class="description-line" id="p-0086" num="0109"> The cyclic ring in the “cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3 includes, for example, a carbocyclic group, a heterocyclic group, etc. This carbocyclic group and heterocyclic group have the same meanings as the above-described carbocyclic group and heterocyclic group represented by ring A. </div>
</li> <li> <para-num num="[0110]"> </para-num> <div class="description-line" id="p-0087" num="0110"> Substituent in the “cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3 includes, for example, hydrocarbon group which may have a substituent(s) (which has the same meaning as above-described “(1) hydrocarbon group which may have a substituent(s)”), carbocyclic group which may have a substituent(s) (which has the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s)”), heterocyclic group which may have a substituent(s) (which has the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”), hydroxy which may have a substituent(s) (which has the same meaning as the above-described “(4) hydroxy which may have a substituent(s)”), mercapto which may have a substituent(s) (which has the same meaning as the above-described “(5) mercapto which may have a substituent(s)”), amino which may have a substituent(s) (which has the same meaning as the above-described “(6) amino which may have a substituent(s)”), carbamoyl which may have a substituent(s) (which has the same meaning as the above-described “(7) carbamoyl which may have a substituent(s)”), sulfamoyl which may have a substituent(s) (which has the same meaning as the above-described “(8) sulfamoyl which may have a substituent(s)”), carboxy, alkoxycarbonyl (e.g., C1-6 alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, etc.), sulfo, sulfino, phosphono, nitro, cyano, amidino, imino, dihydroboryl (—B(OH)<sub>2</sub>), halogen (fluoro, chloro, bromo, iodo), alkylsulfinyl (e.g., C1-6 alkylsulfinyl such as methylsulfinyl, ethylsulfinyl, etc.), aromatic ring-sulfinyl (e.g., C6-10 aromatic ring-sulfinyl such as phenylsulfinyl, etc.), alkylsulfonyl (e.g., C1-8 alkylsulfonyl such as methylsulfonyl, ethylsulfonyl, etc.), aromatic ring-sulfonyl (e.g., C6-10 aromatic ring-sulfonyl such as phenylsulfonyl, etc.), oxo, thioxo, (C1-6 alkoxyimino)methyl (e.g., (methoxyimino)methyl, etc.), acyl (which has the same meaning as the above-described “(25) acyl”), formyl, alkyl substituted by hydroxy which may have a substituent(s) (which has the same meaning as the above-described “(27) alkyl substituted by hydroxy which may have a substituent(s)”), alkyl substituted by mercapto which may have a substituent(s) (which has the same meaning the above-described “(28) alkyl substituted by mercapto which may have a substituent(s)”), alkyl substituted by amino which may have a substituent(s) (which has the same meaning as the above-described “(29) alkyl substituted by amino which may have a substituent(s)”.), (alkyl which may have a substituent(s))oxycarbonyl (which has the same meaning as the above-described “(30) (alkyl which may have a substituent(s))oxycarbonyl”), and the 1 to 5 substituent(s) may exist wherever possible. </div>
</li> <li> <para-num num="[0111]"> </para-num> <div class="description-line" id="p-0088" num="0111"> “A cyclic group which may have a substituent(s)” formed by two Rs together with an atom on ring X to which they bind has the same meaning as the above-described “a cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3. </div>
</li> <li> <para-num num="[0112]"> </para-num> <div class="description-line" id="p-0089" num="0112"> The “cyclic group” in the “cyclic group which may have a substituent(s)” formed by R<sup>1 </sup>and R<sup>2 </sup>together with a nitrogen atom to which they bind includes, for example, a monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains two adjoining nitrogen atoms, and may contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, etc. </div>
</li> <li> <para-num num="[0113]"> </para-num> <div class="description-line" id="p-0090" num="0113"> The “monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains two adjoining nitrogen atoms, and may contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized” includes, for example, triazoline, triazolidine, tetraazoline, tetrazolidine, dihyrdopyrazole (pyrazoline), tetrahydropyrazole (pyrazolidine), dihyrdopyridazine, tetrahydropyridazine, perhydropyridazine, dihydrotriazine, tetrahydrotriazine, perhydrotriazine, dihyrdooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihyrdooxadiadine, tetrahydrooxadiadine, dihyrdooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihyrdothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihyrdothiadiadine, tetrahydrothiadiadine, dihyrdothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, dihyrdoindazole, perhydroindazole, dihyrdophthalazine, tetrahydrophthalazine, perhydrophthalazine, tetrahydropyrrolopyridine, dihyrdocinnoline, tetrahydrocinnoline, perhydrocinnoline rings, etc. The cyclic group may have 1 to 5 substituent(s) at substitutable positions, and the substituent(s) have the same meanings as the substituent(s) in the “cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3. </div>
</li> <li> <para-num num="[0114]"> </para-num> <div class="description-line" id="p-0091" num="0114"> The cyclic group in the “cyclic group which may have a substituent(s)” formed by R<sup>2 </sup>and R<sup>3 </sup>together with a nitrogen atom to which they bind includes, for example, a monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, etc. </div>
</li> <li> <para-num num="[0115]"> </para-num> <div class="description-line" id="p-0092" num="0115"> The “monocyclic or polycyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized” includes, for example, pyrrole, imidazole, triazole, tetrazole, pyrazole, azepine, diazepine, oxazine, oxadiazine, thiazine, thiadiazine, indole, isoindole, indazole, purine, pyrrolopyridine, benzazepine, benzodiazepine, benzotriazole, carbazole, β-carboline, phenothiazine, phenoxazine, perimidine, pyrazoloisoquinoline, pyrazolonaphthyridine, pyrroline, pyrrolidine, imidazoline, imidazolidine, triazoline, triazolidine, tetrazoline, tetrazolidine, dihydropyrazole (pyrazoline), tetrahydropyrazole (pyrazolidine), dihydropyridine, tetrahydropyridine, piperidine, dihydropyrazine, tetrahydropyrazine, piperazine, dihydropyrimidine, tetrahydropyrimidine, perhydropyrimidine, dihydropyridazine, tetrahydropyridazine, perhydropyridazine, dihydrotriazine, tetrahydrotriazine, perhydrotriazine, dihydroazepine, tetrahydroazepine, perhydroazepine, dihydrodiazepine, tetrahydrodiazepine, perhydrodiazepine, dihydrooxazole, tetrahydrooxazole (oxazolidine), dihydroisoxazole, tetrahydroisoxazole (isoxazolidine), dihydrothiazole, tetrahydrothiazole (thiazolidine), dihydroisothiazole, tetrahydroisothiazole (isothiazolidine), dihydrofurazan, tetrahydrofurazan, dihydrooxadiazole, tetrahydrooxadiazole (oxadiazolidine), dihydrooxazine, tetrahydrooxazine, dihydrooxadiazine, tetrahydrooxadiazine, dihydrooxazepine, tetrahydrooxazepine, perhydrooxazepine, dihydrooxadiazepine, tetrahydrooxadiazepine, perhydrooxadiazepine, dihydrothiadiazole, tetrahydrothiadiazole (thiadiazolidine), dihydrothiazine, tetrahydrothiazine, dihydrothiadiazine, tetrahydrothiadiazine, dihydrothiazepine, tetrahydrothiazepine, perhydrothiazepine, dihydrothiadiazepine, tetrahydrothiadiazepine, perhydrothiadiazepine, morpholine, thiomorpholine, indoline, isoindoline, dihydroquinoline, tetrahydroquinoline, octahydroquinoline, perhydroquinoline, dihydroisoquinoline, tetrahydroisoquinoline, octahydroisoquinoline, perhydroisoquinoline, dihydrophthalazine, tetrahydrophthalazine, perhydrophthalazine, dihydronaphthyridine, dihydroquinoxaline, tetrahydroquinoxaline, perhydroquinoxaline, dihydroquinazoline, tetrahydroquinazoline, perhydroquinazoline, tetrahydropyrrolopyridine, dihydrocinnoline, tetrahydrocinnoline, perhydrocinnoline, dihydrobenzoxazine, dihydrobenzothiazine, pyrazinomorpholine, dihydrobenzoxazole, perhydrobenzoxazole, dihydrobenzothiazole, perhydrobenzothiazole, 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, dihydrobenzimidazole, perhydrobenzimidazole, dihydrobenzazepine, tetrahydrobenzazepine, dihydrobenzodiazepine, tetrahydrobenzodiazepine, benzodioxepane, dihydrobenzoxazepine, tetrahydrobenzoxazepine, dihydrocarbazole, tetrahydrocarbazole, perhydrocarbazole, dihydroacridine, tetrahydroacridine, perhydroacridine, tetrahydrodibenzothiophene, tetrahydronaphthyridine, tetrahydro-β-carboline, dihydroazepinoindole, hexahydroazepinoindole, tetrahydropyrazoloisoquinoline, tetrahydropyrazolonaphthyridine, dihydroazepinoindazole, hexahydroazepinoindazole, dihydropyrazolopyridoazepine, hexahydropyrazolopyridoazepine, tetrahydropyrimidoindole, dihydrothiazinoindole, tetrahydrothiazinoindole, dihydrooxazinoindole, tetrahydrooxazinoindole, 2,3-dihydro-1H-benzo[de]isoquinoline, azaspiro[4,4]nonane, oxaazaspiro[4,4]nonane, oxaazaspiro[2,5]octane, dioxaspiro[4,4]nonane, azaspiro[4,5]decane, oxaazaspiro[4,5]decane, azaspiro[5.5]undecane, 1,4-dioxa-8-azaspiro[4.5]undecane, 1,3,8-triazaspiro[4.5]decane, azabicyclo[2.2.1]heptane, azabicyclo[3.1.1]heptane, azabicyclo[3.2.1]octane, azabicyclo[2.2.2]octane, diazabicyclo[2.2.2]octane, 2,5-diazabicyclo[2.2.1]heptane, 1,3,8-triazaspiro[4.5]decane, 2,7-diazaspiro[4.5]decane, 2,8-diazaspiro[4,5]decane, 1,4,9-triazaspiro[5,5]undecane, 2,3,4,9-tetrahydrospiro[β-carboline-1,1′-cyclopentane], 3,9-diazaspiro[5,5]undecane rings, etc. The cyclic group may have 1 to 5 substituent(s) at substitutable positions, and the substituent(s) have the same meanings as the substituent(s) in the “cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3. </div>
</li> <li> <para-num num="[0116]"> </para-num> <div class="description-line" id="p-0093" num="0116"> Also, the group represented by  
<chemistry id="CHEM-US-00010" num="10"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/ad/b0/5b2333bd46546a/US20070232586A1-20071004-C00010.png"><img alt="Figure US20070232586A1-20071004-C00010" class="patent-full-image" file="US20070232586A1-20071004-C00010.TIF" he="10.92mm" height="44" id="EMI-C00010" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/3f/ad/b0/5b2333bd46546a/US20070232586A1-20071004-C00010.png" wi="11.18mm" width="45"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00010.CDX" idref="CHEM-US-00010"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00010.MOL" idref="CHEM-US-00010"> </attachment> </attachments> </chemistry>
<br/>
 may represent  
<chemistry id="CHEM-US-00011" num="11"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/c8/ea/841cb48275e0f2/US20070232586A1-20071004-C00011.png"><img alt="Figure US20070232586A1-20071004-C00011" class="patent-full-image" file="US20070232586A1-20071004-C00011.TIF" he="12.19mm" height="49" id="EMI-C00011" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d0/c8/ea/841cb48275e0f2/US20070232586A1-20071004-C00011.png" wi="47.58mm" width="190"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00011.CDX" idref="CHEM-US-00011"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00011.MOL" idref="CHEM-US-00011"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0117]"> </para-num> <div class="description-line" id="p-0094" num="0117"> (wherein R<sup>2X </sup>and R<sup>3X </sup>is each independently hydrogen atom, a hydrocarbon group which may have a substituent(s) (having the same meaning as the above-described “(1) hydrocarbon group which may have a substituent(s)), a carbocyclic group which may have a substituent(s) (having the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s)) or a heterocyclic group which may have a substituent(s) (having the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”) by combining R<sup>2 </sup>and R<sup>3</sup>, or R<sup>2X </sup>and R<sup>3X</sup>, together with a nitrogen atom to which they bind, may form a carbocyclic group which may have a substituent(s) (having the same meaning as the above-described “(2) carbocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s) (having the same meaning as the above-described “(3) heterocyclic group which may have a substituent(s)”)). </div>
</li> <li> <para-num num="[0118]"> </para-num> <div class="description-line" id="p-0095" num="0118"> The “spacer having from 1 to 8 atoms of the principle chain” represented by J means a space formed by 1 to 8 continued atoms of a main chain. In this case, the “number of atoms as a principle chain” should be counted such that atoms as a main chain become minimum. The “spacer having from 1 to 8 atoms of the principle chain” includes, for example, a bivalent group formed by 1 to 8 continued atoms of a main chain comprising 1 to 8 selected from —O—, —S—, —S(O)—, —SO<sub>2</sub>—, —CO—, a nitrogen atom which may have a substituent(s), and a bivalent C1-8 aliphatic hydrocarbon group which may have a substituent(s). Herein, the “nitrogen atom which may have a substituent(s)” is —NH—, ═N— or one in which a hydrogen atom in “—NH—” is replaced with a hydrocarbon group which may have a substituent(s) (having the same meaning as the above-described (1) hydrocarbon group which may have a substituent(s)). </div>
</li> <li> <para-num num="[0119]"> </para-num> <div class="description-line" id="p-0096" num="0119"> The “bivalent C1-8 aliphatic hydrocarbon group” in the “bivalent C1-8 aliphatic hydrocarbon group which may have a substituent(s)” includes, for example, C1-8 alkylene (e.g., —CH<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>3</sub>—, —(CH<sub>2</sub>)<sub>8</sub>—, etc.), C2-8 alkenylene (e.g., —CH═CH—, —CH<sub>2</sub>—CH═CH—, —CH═CH—CH<sub>2</sub>—, —CH═CH—(CH<sub>2</sub>)<sub>6</sub>—, etc.), C2-8 alkynylene (e.g., —C≡C—, —CH<sub>2</sub>—C≡C—, —C≡C—CH<sub>2</sub>—, —CH≡CH—(CH<sub>2</sub>)<sub>6</sub>—, etc.), and the like. Also, the “substituent(s)” in the “bivalent C1-8 aliphatic hydrocarbon group which may have a substituent(s)” has the same meaning as the substituent(s) in the above-described “(1) hydrocarbon group which may have a substituent(s)”</div>
</li> <li> <para-num num="[0120]"> </para-num> <div class="description-line" id="p-0097" num="0120"> The monocyclic group represented by ring X is preferably a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized. </div>
</li> <li> <para-num num="[0121]"> </para-num> <div class="description-line" id="p-0098" num="0121"> Specifically, preferred as  
<chemistry id="CHEM-US-00012" num="12"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/be/9a/40583dc3629548/US20070232586A1-20071004-C00012.png"><img alt="Figure US20070232586A1-20071004-C00012" class="patent-full-image" file="US20070232586A1-20071004-C00012.TIF" he="12.28mm" height="49" id="EMI-C00012" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d1/be/9a/40583dc3629548/US20070232586A1-20071004-C00012.png" wi="17.19mm" width="69"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00012.CDX" idref="CHEM-US-00012"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00012.MOL" idref="CHEM-US-00012"> </attachment> </attachments> </chemistry>
<br/>
 is  
<chemistry id="CHEM-US-00013" num="13"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bd/7b/a0/ea0d911283b676/US20070232586A1-20071004-C00013.png"><img alt="Figure US20070232586A1-20071004-C00013" class="patent-full-image" file="US20070232586A1-20071004-C00013.TIF" he="235.80mm" height="943" id="EMI-C00013" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/bd/7b/a0/ea0d911283b676/US20070232586A1-20071004-C00013.png" wi="68.83mm" width="275"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00013.CDX" idref="CHEM-US-00013"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00013.MOL" idref="CHEM-US-00013"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00014" num="14"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/f1/37/e2755b315df51b/US20070232586A1-20071004-C00014.png"><img alt="Figure US20070232586A1-20071004-C00014" class="patent-full-image" file="US20070232586A1-20071004-C00014.TIF" he="234.53mm" height="938" id="EMI-C00014" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/3c/f1/37/e2755b315df51b/US20070232586A1-20071004-C00014.png" wi="68.83mm" width="275"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00014.CDX" idref="CHEM-US-00014"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00014.MOL" idref="CHEM-US-00014"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00015" num="15"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/af/04/e3/edcc1c8d0f4d64/US20070232586A1-20071004-C00015.png"><img alt="Figure US20070232586A1-20071004-C00015" class="patent-full-image" file="US20070232586A1-20071004-C00015.TIF" he="39.54mm" height="158" id="EMI-C00015" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/af/04/e3/edcc1c8d0f4d64/US20070232586A1-20071004-C00015.png" wi="68.83mm" width="275"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00015.CDX" idref="CHEM-US-00015"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00015.MOL" idref="CHEM-US-00015"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0122]"> </para-num> <div class="description-line" id="p-0099" num="0122"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0123]"> </para-num> <div class="description-line" id="p-0100" num="0123"> The carbocyclic group represented by ring A is preferably a C3-10 monocyclic or bicyclic aromatic carbocyclic group which may be partially or fully saturated, more preferably a C5-7 monocyclic aromatic carbocyclic ring which may be partially or fully saturated, and most preferably cyclopropane, cyclobutane, cyclopentane, cyclohexane, cycloheptane, cyclopentene, cyclohexene, cycloheptene, cyclopentadiene, cyclohexadiene, cycloheptadiene or benzene ring. </div>
</li> <li> <para-num num="[0124]"> </para-num> <div class="description-line" id="p-0101" num="0124"> The heterocyclic group represented by ring A is preferably a 3- to 10-membered monocyclic or bicyclic aromatic heterocyclic group which may be partially or fully saturated and contains 1 to 3 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized, more preferably a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated and contains an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized, and most preferably pyridine, pyrimidine, pyrazine, tetrahydropyrimidine, dihyrdopyridazine, pyridazine, dihydropyrimidine, dihydropyrazine, dihydrotriazine, pyrazole, dihydropyrazole, pyrrole, imidazole, triazole, thiophene or furan ring. </div>
</li> <li> <para-num num="[0125]"> </para-num> <div class="description-line" id="p-0102" num="0125"> Preferred as  
<chemistry id="CHEM-US-00016" num="16"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/c9/b4/4867559ed63ddf/US20070232586A1-20071004-C00016.png"><img alt="Figure US20070232586A1-20071004-C00016" class="patent-full-image" file="US20070232586A1-20071004-C00016.TIF" he="11.35mm" height="45" id="EMI-C00016" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/88/c9/b4/4867559ed63ddf/US20070232586A1-20071004-C00016.png" wi="14.56mm" width="58"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00016.CDX" idref="CHEM-US-00016"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00016.MOL" idref="CHEM-US-00016"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0126]"> </para-num> <div class="description-line" id="p-0103" num="0126"> (wherein the rightward arrow represents a binding position to ring B) is  
<chemistry id="CHEM-US-00017" num="17"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/a2/6d/e79a363b481345/US20070232586A1-20071004-C00017.png"><img alt="Figure US20070232586A1-20071004-C00017" class="patent-full-image" file="US20070232586A1-20071004-C00017.TIF" he="203.03mm" height="812" id="EMI-C00017" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/cc/a2/6d/e79a363b481345/US20070232586A1-20071004-C00017.png" wi="56.05mm" width="224"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00017.CDX" idref="CHEM-US-00017"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00017.MOL" idref="CHEM-US-00017"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0127]"> </para-num> <div class="description-line" id="p-0104" num="0127"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0128]"> </para-num> <div class="description-line" id="p-0105" num="0128"> The nitrogen-containing heterocyclic group represented by ring B is preferable a 3- to 10-membered monocyclic or bicyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and further contains 1 or 2 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized, more preferably a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and further contains an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized, and most preferably pyrrole, imidazole, triazole, pyrazole, pyridine, pyrimidine, dihydrotriazine, pyrazine or dihyrdopyrimidine ring. </div>
</li> <li> <para-num num="[0129]"> </para-num> <div class="description-line" id="p-0106" num="0129"> Preferred as  
<chemistry id="CHEM-US-00018" num="18"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/ca/58/5e218f06f86142/US20070232586A1-20071004-C00018.png"><img alt="Figure US20070232586A1-20071004-C00018" class="patent-full-image" file="US20070232586A1-20071004-C00018.TIF" he="12.95mm" height="52" id="EMI-C00018" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d9/ca/58/5e218f06f86142/US20070232586A1-20071004-C00018.png" wi="20.32mm" width="81"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00018.CDX" idref="CHEM-US-00018"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00018.MOL" idref="CHEM-US-00018"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0130]"> </para-num> <div class="description-line" id="p-0107" num="0130"> (wherein the leftward arrow represents a binding position to ring A) is  
<chemistry id="CHEM-US-00019" num="19"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/6d/f5/3d9eb6c8ff0ca3/US20070232586A1-20071004-C00019.png"><img alt="Figure US20070232586A1-20071004-C00019" class="patent-full-image" file="US20070232586A1-20071004-C00019.TIF" he="79.84mm" height="319" id="EMI-C00019" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/84/6d/f5/3d9eb6c8ff0ca3/US20070232586A1-20071004-C00019.png" wi="72.64mm" width="291"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00019.CDX" idref="CHEM-US-00019"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00019.MOL" idref="CHEM-US-00019"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0131]"> </para-num> <div class="description-line" id="p-0108" num="0131"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0132]"> </para-num> <div class="description-line" id="p-0109" num="0132"> When ring X is a bicyclic heterocyclic group, a preferred ring is, for example, pyrazolo[1,5-a]pyrimidine, imidazole, 1,3-thiazole, pyrazolo[1,5-a]pyrimidine, pyrazolo[1,5-a][1,3,5]triazine, imidazo[1,2-a]pyrimidine, imidazo[1,5-a]pyrazine, pyrazolo[1,5-a]pyrimidine, 6,7-dihydro-5H-cyclopenta[d]pyrimidine, imidazo[1,5-a]pyrazine, thieno[3,2-d]pyrimidine, quinazoline, indole, isoindole, quinoxaline, indazole, quinolidine, quinoline, isoquinoline, phthalazine, naphthylidine, cinnoline or pteridine ring, etc. </div>
</li> <li> <para-num num="[0133]"> </para-num> <div class="description-line" id="p-0110" num="0133"> Preferred as  
<chemistry id="CHEM-US-00020" num="20"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/d4/26/b19432e04d0525/US20070232586A1-20071004-C00020.png"><img alt="Figure US20070232586A1-20071004-C00020" class="patent-full-image" file="US20070232586A1-20071004-C00020.TIF" he="12.95mm" height="52" id="EMI-C00020" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/5d/d4/26/b19432e04d0525/US20070232586A1-20071004-C00020.png" wi="26.33mm" width="105"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00020.CDX" idref="CHEM-US-00020"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00020.MOL" idref="CHEM-US-00020"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0134]"> </para-num> <div class="description-line" id="p-0111" num="0134"> is concretely, for example,  
<chemistry id="CHEM-US-00021" num="21"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/4b/f8/a2b090e32f855d/US20070232586A1-20071004-C00021.png"><img alt="Figure US20070232586A1-20071004-C00021" class="patent-full-image" file="US20070232586A1-20071004-C00021.TIF" he="245.36mm" height="981" id="EMI-C00021" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/66/4b/f8/a2b090e32f855d/US20070232586A1-20071004-C00021.png" wi="66.46mm" width="266"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00021.CDX" idref="CHEM-US-00021"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00021.MOL" idref="CHEM-US-00021"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00022" num="22"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/08/19/75/cfd8f42dd87c56/US20070232586A1-20071004-C00022.png"><img alt="Figure US20070232586A1-20071004-C00022" class="patent-full-image" file="US20070232586A1-20071004-C00022.TIF" he="246.63mm" height="987" id="EMI-C00022" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/08/19/75/cfd8f42dd87c56/US20070232586A1-20071004-C00022.png" wi="64.43mm" width="258"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00022.CDX" idref="CHEM-US-00022"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00022.MOL" idref="CHEM-US-00022"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00023" num="23"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/be/12/b4/cf5432e407d94c/US20070232586A1-20071004-C00023.png"><img alt="Figure US20070232586A1-20071004-C00023" class="patent-full-image" file="US20070232586A1-20071004-C00023.TIF" he="243.76mm" height="975" id="EMI-C00023" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/be/12/b4/cf5432e407d94c/US20070232586A1-20071004-C00023.png" wi="66.29mm" width="265"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00023.CDX" idref="CHEM-US-00023"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00023.MOL" idref="CHEM-US-00023"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0135]"> </para-num> <div class="description-line" id="p-0112" num="0135"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0136]"> </para-num> <div class="description-line" id="p-0113" num="0136"> Also, other preferred embodiments as include, for example,  
<chemistry id="CHEM-US-00024" num="24"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/18/80/fad1bd52b6313f/US20070232586A1-20071004-C00024.png"><img alt="Figure US20070232586A1-20071004-C00024" class="patent-full-image" file="US20070232586A1-20071004-C00024.TIF" he="12.70mm" height="51" id="EMI-C00024" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/c6/18/80/fad1bd52b6313f/US20070232586A1-20071004-C00024.png" wi="26.33mm" width="105"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00024.CDX" idref="CHEM-US-00024"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00024.MOL" idref="CHEM-US-00024"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00025" num="25"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/fb/6a/f2807822afc064/US20070232586A1-20071004-C00025.png"><img alt="Figure US20070232586A1-20071004-C00025" class="patent-full-image" file="US20070232586A1-20071004-C00025.TIF" he="12.87mm" height="51" id="EMI-C00025" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/06/fb/6a/f2807822afc064/US20070232586A1-20071004-C00025.png" wi="33.02mm" width="132"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00025.CDX" idref="CHEM-US-00025"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00025.MOL" idref="CHEM-US-00025"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0137]"> </para-num> <div class="description-line" id="p-0114" num="0137"> (wherein Y<sup>1 </sup>and Z<sup>1 </sup>is each independently a carbon atom or a nitrogen atom, ring G is a ring formed by two Rs),  
<chemistry id="CHEM-US-00026" num="26"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/0c/42/888d9d98911c25/US20070232586A1-20071004-C00026.png"><img alt="Figure US20070232586A1-20071004-C00026" class="patent-full-image" file="US20070232586A1-20071004-C00026.TIF" he="22.44mm" height="90" id="EMI-C00026" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/cc/0c/42/888d9d98911c25/US20070232586A1-20071004-C00026.png" wi="31.24mm" width="125"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00026.CDX" idref="CHEM-US-00026"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00026.MOL" idref="CHEM-US-00026"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0138]"> </para-num> <div class="description-line" id="p-0115" num="0138"> (wherein all symbols have the same meanings as described above),  
<chemistry id="CHEM-US-00027" num="27"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/82/aa/b0b320ea9cbba9/US20070232586A1-20071004-C00027.png"><img alt="Figure US20070232586A1-20071004-C00027" class="patent-full-image" file="US20070232586A1-20071004-C00027.TIF" he="23.20mm" height="93" id="EMI-C00027" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/aa/82/aa/b0b320ea9cbba9/US20070232586A1-20071004-C00027.png" wi="24.47mm" width="98"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00027.CDX" idref="CHEM-US-00027"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00027.MOL" idref="CHEM-US-00027"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0139]"> </para-num> <div class="description-line" id="p-0116" num="0139"> (wherein all symbols have the same meanings as described above),  
<chemistry id="CHEM-US-00028" num="28"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/50/18/624ef59a2bc1c0/US20070232586A1-20071004-C00028.png"><img alt="Figure US20070232586A1-20071004-C00028" class="patent-full-image" file="US20070232586A1-20071004-C00028.TIF" he="18.03mm" height="72" id="EMI-C00028" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/a5/50/18/624ef59a2bc1c0/US20070232586A1-20071004-C00028.png" wi="24.47mm" width="98"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00028.CDX" idref="CHEM-US-00028"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00028.MOL" idref="CHEM-US-00028"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0140]"> </para-num> <div class="description-line" id="p-0117" num="0140"> (wherein all symbols have the same meanings as described above), etc. </div>
</li> <li> <para-num num="[0141]"> </para-num> <div class="description-line" id="p-0118" num="0141"> Preferred as  
<chemistry id="CHEM-US-00029" num="29"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/7e/3c/a41a8b1afc3f2b/US20070232586A1-20071004-C00029.png"><img alt="Figure US20070232586A1-20071004-C00029" class="patent-full-image" file="US20070232586A1-20071004-C00029.TIF" he="12.87mm" height="51" id="EMI-C00029" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/fc/7e/3c/a41a8b1afc3f2b/US20070232586A1-20071004-C00029.png" wi="33.02mm" width="132"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00029.CDX" idref="CHEM-US-00029"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00029.MOL" idref="CHEM-US-00029"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0142]"> </para-num> <div class="description-line" id="p-0119" num="0142"> is concretely, for example,  
<chemistry id="CHEM-US-00030" num="30"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b3/ea/7e/ec68eabf29edeb/US20070232586A1-20071004-C00030.png"><img alt="Figure US20070232586A1-20071004-C00030" class="patent-full-image" file="US20070232586A1-20071004-C00030.TIF" he="215.73mm" height="863" id="EMI-C00030" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/b3/ea/7e/ec68eabf29edeb/US20070232586A1-20071004-C00030.png" wi="37.68mm" width="151"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00030.CDX" idref="CHEM-US-00030"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00030.MOL" idref="CHEM-US-00030"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00031" num="31"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/d1/94/d40307dc1e0731/US20070232586A1-20071004-C00031.png"><img alt="Figure US20070232586A1-20071004-C00031" class="patent-full-image" file="US20070232586A1-20071004-C00031.TIF" he="234.36mm" height="937" id="EMI-C00031" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/eb/d1/94/d40307dc1e0731/US20070232586A1-20071004-C00031.png" wi="68.33mm" width="273"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00031.CDX" idref="CHEM-US-00031"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00031.MOL" idref="CHEM-US-00031"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00032" num="32"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/e5/a2/d80c5c0985f6f9/US20070232586A1-20071004-C00032.png"><img alt="Figure US20070232586A1-20071004-C00032" class="patent-full-image" file="US20070232586A1-20071004-C00032.TIF" he="234.87mm" height="939" id="EMI-C00032" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/f1/e5/a2/d80c5c0985f6f9/US20070232586A1-20071004-C00032.png" wi="69.34mm" width="277"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00032.CDX" idref="CHEM-US-00032"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00032.MOL" idref="CHEM-US-00032"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00033" num="33"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b2/0a/ba/bbe72bbd04948f/US20070232586A1-20071004-C00033.png"><img alt="Figure US20070232586A1-20071004-C00033" class="patent-full-image" file="US20070232586A1-20071004-C00033.TIF" he="127.59mm" height="510" id="EMI-C00033" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/b2/0a/ba/bbe72bbd04948f/US20070232586A1-20071004-C00033.png" wi="34.71mm" width="139"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00033.CDX" idref="CHEM-US-00033"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00033.MOL" idref="CHEM-US-00033"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0143]"> </para-num> <div class="description-line" id="p-0120" num="0143"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R), etc. </div>
</li> <li> <para-num num="[0144]"> </para-num> <div class="description-line" id="p-0121" num="0144"> Preferred as  
<chemistry id="CHEM-US-00034" num="34"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e3/32/b9/27224708698f92/US20070232586A1-20071004-C00034.png"><img alt="Figure US20070232586A1-20071004-C00034" class="patent-full-image" file="US20070232586A1-20071004-C00034.TIF" he="22.44mm" height="90" id="EMI-C00034" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/e3/32/b9/27224708698f92/US20070232586A1-20071004-C00034.png" wi="31.24mm" width="125"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00034.CDX" idref="CHEM-US-00034"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00034.MOL" idref="CHEM-US-00034"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0145]"> </para-num> <div class="description-line" id="p-0122" num="0145"> is concretely, for example,  
<chemistry id="CHEM-US-00035" num="35"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c9/9a/ff/0ca548ae7e10a2/US20070232586A1-20071004-C00035.png"><img alt="Figure US20070232586A1-20071004-C00035" class="patent-full-image" file="US20070232586A1-20071004-C00035.TIF" he="222.08mm" height="888" id="EMI-C00035" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/c9/9a/ff/0ca548ae7e10a2/US20070232586A1-20071004-C00035.png" wi="60.20mm" width="241"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00035.CDX" idref="CHEM-US-00035"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00035.MOL" idref="CHEM-US-00035"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00036" num="36"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/bb/56/2b9e0c212d2ad8/US20070232586A1-20071004-C00036.png"><img alt="Figure US20070232586A1-20071004-C00036" class="patent-full-image" file="US20070232586A1-20071004-C00036.TIF" he="211.50mm" height="846" id="EMI-C00036" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/31/bb/56/2b9e0c212d2ad8/US20070232586A1-20071004-C00036.png" wi="62.91mm" width="252"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00036.CDX" idref="CHEM-US-00036"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00036.MOL" idref="CHEM-US-00036"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00037" num="37"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7e/62/38/03bd2350080780/US20070232586A1-20071004-C00037.png"><img alt="Figure US20070232586A1-20071004-C00037" class="patent-full-image" file="US20070232586A1-20071004-C00037.TIF" he="136.65mm" height="547" id="EMI-C00037" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/7e/62/38/03bd2350080780/US20070232586A1-20071004-C00037.png" wi="62.74mm" width="251"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00037.CDX" idref="CHEM-US-00037"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00037.MOL" idref="CHEM-US-00037"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0146]"> </para-num> <div class="description-line" id="p-0123" num="0146"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R), etc. </div>
</li> <li> <para-num num="[0147]"> </para-num> <div class="description-line" id="p-0124" num="0147"> Preferred as  
<chemistry id="CHEM-US-00038" num="38"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7c/12/1c/e1ad03d7a2370b/US20070232586A1-20071004-C00038.png"><img alt="Figure US20070232586A1-20071004-C00038" class="patent-full-image" file="US20070232586A1-20071004-C00038.TIF" he="33.95mm" height="136" id="EMI-C00038" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/7c/12/1c/e1ad03d7a2370b/US20070232586A1-20071004-C00038.png" wi="57.15mm" width="229"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00038.CDX" idref="CHEM-US-00038"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00038.MOL" idref="CHEM-US-00038"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0148]"> </para-num> <div class="description-line" id="p-0125" num="0148"> is concretely, for example,  
<chemistry id="CHEM-US-00039" num="39"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/1c/19/937487e4f0ecaf/US20070232586A1-20071004-C00039.png"><img alt="Figure US20070232586A1-20071004-C00039" class="patent-full-image" file="US20070232586A1-20071004-C00039.TIF" he="209.63mm" height="839" id="EMI-C00039" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/2a/1c/19/937487e4f0ecaf/US20070232586A1-20071004-C00039.png" wi="58.76mm" width="235"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00039.CDX" idref="CHEM-US-00039"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00039.MOL" idref="CHEM-US-00039"> </attachment> </attachments> </chemistry>
<chemistry id="CHEM-US-00040" num="40"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f6/cb/12/a4a499cfc8c4ab/US20070232586A1-20071004-C00040.png"><img alt="Figure US20070232586A1-20071004-C00040" class="patent-full-image" file="US20070232586A1-20071004-C00040.TIF" he="130.73mm" height="523" id="EMI-C00040" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/f6/cb/12/a4a499cfc8c4ab/US20070232586A1-20071004-C00040.png" wi="61.89mm" width="248"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00040.CDX" idref="CHEM-US-00040"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00040.MOL" idref="CHEM-US-00040"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0149]"> </para-num> <div class="description-line" id="p-0126" num="0149"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R), etc. </div>
</li> <li> <para-num num="[0150]"> </para-num> <div class="description-line" id="p-0127" num="0150"> Ring X is preferably, for example, a 5- to 7-membered monocyclic aromatic heterocyclic ring which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, etc., such as tetrahydropyrimidine, dihyrdopyridazine, pyridazine, dihydropyrimidine, dihydropyrazine, dihydrotriazine, dihydropyrazole, diazepane, pyrrole, pyrimidine, pyrazine, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, thiadiazole, oxadiazole, azepane, azepine, dihydroazepine, tetrahydroazepine, diazepane, diazepine, dihydroazepine or tetrahydroazepine ring, and more preferably pyrimidine, pyrazine, pyridazine, thiazole or oxazole ring, etc. </div>
</li> <li> <para-num num="[0151]"> </para-num> <div class="description-line" id="p-0128" num="0151"> R is preferably, for example, a hydrogen atom, C1-8 alkyl which may have a substituent(s), trifluoromethyl, hydroxy which may have a substituent(s) (e.g., hydroxy, C1-8 alkoxy which may have a substituent(s) (C1-8 alkoxy including, for example, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, heptyloxy, octyloxy, etc.), C1-6 alkoxycarbonyl, cyano, a halogen atom, etc., more preferably C1-6 alkyl which may have a substituent(s), trifluoromethyl, C1-6 alkoxy which may have a substituent(s), a halogen atom, etc., and more preferably methyl, ethyl, propyl, butyl, isopropyl, isobutyl, neopentyl, methoxy, ethoxy, propoxy, butoxy, chloro, fluoro, bromo, trifluoromethyl, etc. </div>
</li> <li> <para-num num="[0152]"> </para-num> <div class="description-line" id="p-0129" num="0152"> R<sup>1 </sup>is preferably, for example, a hydrogen atom, C1-8 alkyl which may have a substituent(s), etc., more preferably straight chain or branched C1-8 alkyl, etc., and most preferably branched C3-8 alkyl such as isopropyl, isobutyl, sec-butyl, neopentyl and isopentyl, etc. </div>
</li> <li> <para-num num="[0153]"> </para-num> <div class="description-line" id="p-0130" num="0153"> R<sup>2 </sup>is preferably C1-8 alkyl which may have a substituent(s), C1-8 alkylcarbonyl which may have a substituent(s), C1-8 alkylsulfonyl which may have a substituent(s), carbamoyl which may have a substituent(s), a carbocyclic group which may have a substituent(s), a heterocyclic group which may have a substituent(s),  
<chemistry id="CHEM-US-00041" num="41"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/e6/a9/c15ede99de5291/US20070232586A1-20071004-C00041.png"><img alt="Figure US20070232586A1-20071004-C00041" class="patent-full-image" file="US20070232586A1-20071004-C00041.TIF" he="9.74mm" height="39" id="EMI-C00041" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/e4/e6/a9/c15ede99de5291/US20070232586A1-20071004-C00041.png" wi="19.47mm" width="78"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00041.CDX" idref="CHEM-US-00041"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00041.MOL" idref="CHEM-US-00041"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0154]"> </para-num> <div class="description-line" id="p-0131" num="0154"> (wherein all symbols have the same meanings as described above),  
<chemistry id="CHEM-US-00042" num="42"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/49/e3/cee3c147dc18ba/US20070232586A1-20071004-C00042.png"><img alt="Figure US20070232586A1-20071004-C00042" class="patent-full-image" file="US20070232586A1-20071004-C00042.TIF" he="9.65mm" height="39" id="EMI-C00042" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/5b/49/e3/cee3c147dc18ba/US20070232586A1-20071004-C00042.png" wi="37.76mm" width="151"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00042.CDX" idref="CHEM-US-00042"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00042.MOL" idref="CHEM-US-00042"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0155]"> </para-num> <div class="description-line" id="p-0132" num="0155"> (wherein all symbols have the same meanings as described above), or  
<chemistry id="CHEM-US-00043" num="43"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/a3/b8/b0b18ab5c64085/US20070232586A1-20071004-C00043.png"><img alt="Figure US20070232586A1-20071004-C00043" class="patent-full-image" file="US20070232586A1-20071004-C00043.TIF" he="9.74mm" height="39" id="EMI-C00043" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/4d/a3/b8/b0b18ab5c64085/US20070232586A1-20071004-C00043.png" wi="30.31mm" width="121"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00043.CDX" idref="CHEM-US-00043"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00043.MOL" idref="CHEM-US-00043"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0156]"> </para-num> <div class="description-line" id="p-0133" num="0156"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0157]"> </para-num> <div class="description-line" id="p-0134" num="0157"> and R<sup>3 </sup>is preferably a hydrogen atom. </div>
</li> <li> <para-num num="[0158]"> </para-num> <div class="description-line" id="p-0135" num="0158"> The ring represented by ring 1, ring 2 or ring 3 is preferably a C5-7 monocyclic aromatic carbocyclic group which may be partially or fully saturated, or a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated and contains 1 to 3 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized. </div>
</li> <li> <para-num num="[0159]"> </para-num> <div class="description-line" id="p-0136" num="0159"> Ring 1 is more preferably, for example, a C5 or C6 monocyclic carbocyclic ring such as benzene, cyclohexane, cyclopentane, cyclohexene or cyclopentene ring, or a 5- or 6-membered monocyclic heterocyclic group such as pyridine, thiazole, pyrrolidine, imidazolidine, dihyrdopyridine, piperidine, piperazine, tetrahydropyran, tetrahydrothiazole (thiazolidine), morpholine or thiomorpholine ring, and most preferably benzene. </div>
</li> <li> <para-num num="[0160]"> </para-num> <div class="description-line" id="p-0137" num="0160"> Ring 2 is more preferably, for example, a benzene ring or a 5- to 7-membered monocyclic aromatic heterocyclic ring which may be partially or fully saturated and contains 1 to 3 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) or a sulfur atom(s) which may be oxidized, and most preferably benzene, pyridine, pyrrolidine, imidazolidine, piperidine, piperazine, tetrahydropyran, morpholine or thiomorpholine ring. </div>
</li> <li> <para-num num="[0161]"> </para-num> <div class="description-line" id="p-0138" num="0161"> T<sup>1</sup>, T<sup>2</sup>, T<sup>3 </sup>is preferably a bond or a spacer having 1 or 2 atoms of the principle chain of a combination of one or two selected from C1-3 alkylene (e.g., —CH<sub>2</sub>—, —(CH<sub>2</sub>)<sub>2</sub>—, —(CH<sub>2</sub>)<sub>3</sub>—, etc.) which may have 1 or 2 substituent(s) (e.g., C1-4 alkyl such as methyl, ethyl, propyl and butyl, etc.), —O—, —SO<sub>2</sub>—, —CO— and a nitrogen atom which may have a substituent(s) (specifically, e.g., —CO—, —CH<sub>2</sub>—CO—, —C(CH<sub>3</sub>)<sub>2</sub>—CO—, —NH—CO—, —N(CH<sub>3</sub>)—CO—, —CH<sub>2</sub>—O—, etc.). </div>
</li> <li> <para-num num="[0162]"> </para-num> <div class="description-line" id="p-0139" num="0162"> T<sup>1 </sup>is preferably —SO<sub>2</sub>—, —CO—, and more preferably —CO—. </div>
</li> <li> <para-num num="[0163]"> </para-num> <div class="description-line" id="p-0140" num="0163"> T<sup>2 </sup>is preferably a bond, C1-3 alkylene which may have a substituent(s) (e.g., C1-4 alkyl such as methyl, ethyl, propyl and butyl, etc.) or —CH<sub>2</sub>—O—, and more preferably —CH<sub>2</sub>—. </div>
</li> <li> <para-num num="[0164]"> </para-num> <div class="description-line" id="p-0141" num="0164"> E is preferably, for example, amino, amino which may have a substituent(s) (e.g., C1-4 alkyl, methoxyethyl, tetrahydropyranyl, etc.) such as dimethylamino, di(methoxyethyl)amino, N-methoxyethyl-N-methylamino and N-methyl-N-(tetrahydro-2H-pyran-4-yl)amino, or a 5- or 6-membered nitrogen-containing heterocyclic group (e.g., pyrrolidine, pyridine, piperidine, piperazine, morpholine ring, etc.) which may have a substituent(s) (e.g., C1-4 alkyl, methoxyethyl, tetrahydropyranyl, etc.). </div>
</li> <li> <para-num num="[0165]"> </para-num> <div class="description-line" id="p-0142" num="0165"> Among the groups represented by  
<chemistry id="CHEM-US-00044" num="44"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/8a/25/34b0a482c8d6a6/US20070232586A1-20071004-C00044.png"><img alt="Figure US20070232586A1-20071004-C00044" class="patent-full-image" file="US20070232586A1-20071004-C00044.TIF" he="12.19mm" height="49" id="EMI-C00044" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/7a/8a/25/34b0a482c8d6a6/US20070232586A1-20071004-C00044.png" wi="16.09mm" width="64"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00044.CDX" idref="CHEM-US-00044"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00044.MOL" idref="CHEM-US-00044"> </attachment> </attachments> </chemistry>
<br/>
 when R<sup>2X </sup>and R<sup>3X </sup>forms a ring together with a nitrogen atom to which they bind,  
<chemistry id="CHEM-US-00045" num="45"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a8/16/a7/c2fe278ba4c607/US20070232586A1-20071004-C00045.png"><img alt="Figure US20070232586A1-20071004-C00045" class="patent-full-image" file="US20070232586A1-20071004-C00045.TIF" he="12.19mm" height="49" id="EMI-C00045" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/a8/16/a7/c2fe278ba4c607/US20070232586A1-20071004-C00045.png" wi="9.48mm" width="38"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00045.CDX" idref="CHEM-US-00045"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00045.MOL" idref="CHEM-US-00045"> </attachment> </attachments> </chemistry>
<br/>
 is preferably  
<chemistry id="CHEM-US-00046" num="46"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/f6/f4/ec07a37e552dd0/US20070232586A1-20071004-C00046.png"><img alt="Figure US20070232586A1-20071004-C00046" class="patent-full-image" file="US20070232586A1-20071004-C00046.TIF" he="76.71mm" height="307" id="EMI-C00046" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/52/f6/f4/ec07a37e552dd0/US20070232586A1-20071004-C00046.png" wi="74.93mm" width="300"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00046.CDX" idref="CHEM-US-00046"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00046.MOL" idref="CHEM-US-00046"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0166]"> </para-num> <div class="description-line" id="p-0143" num="0166"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0167]"> </para-num> <div class="description-line" id="p-0144" num="0167"> Among the groups represented by  
<chemistry id="CHEM-US-00047" num="47"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/89/d7/61201382a42b13/US20070232586A1-20071004-C00047.png"><img alt="Figure US20070232586A1-20071004-C00047" class="patent-full-image" file="US20070232586A1-20071004-C00047.TIF" he="12.95mm" height="52" id="EMI-C00047" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/39/89/d7/61201382a42b13/US20070232586A1-20071004-C00047.png" wi="16.09mm" width="64"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00047.CDX" idref="CHEM-US-00047"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00047.MOL" idref="CHEM-US-00047"> </attachment> </attachments> </chemistry>
<br/>
 when R<sup>1 </sup>and R<sup>2 </sup>form a cyclic group together with a nitrogen atom to which they bind, that is,  
<chemistry id="CHEM-US-00048" num="48"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/72/2d/2c03c65e633f24/US20070232586A1-20071004-C00048.png"><img alt="Figure US20070232586A1-20071004-C00048" class="patent-full-image" file="US20070232586A1-20071004-C00048.TIF" he="18.12mm" height="72" id="EMI-C00048" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/1f/72/2d/2c03c65e633f24/US20070232586A1-20071004-C00048.png" wi="15.32mm" width="61"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00048.CDX" idref="CHEM-US-00048"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00048.MOL" idref="CHEM-US-00048"> </attachment> </attachments> </chemistry>
<br/>
 is preferably  
<chemistry id="CHEM-US-00049" num="49"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8f/14/73/9d8492d3ffdd4b/US20070232586A1-20071004-C00049.png"><img alt="Figure US20070232586A1-20071004-C00049" class="patent-full-image" file="US20070232586A1-20071004-C00049.TIF" he="45.38mm" height="182" id="EMI-C00049" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/8f/14/73/9d8492d3ffdd4b/US20070232586A1-20071004-C00049.png" wi="69.51mm" width="278"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00049.CDX" idref="CHEM-US-00049"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00049.MOL" idref="CHEM-US-00049"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0168]"> </para-num> <div class="description-line" id="p-0145" num="0168"> The cyclic group formed by R<sup>2 </sup>and R<sup>3 </sup>together with a nitrogen atom to which they bind, that is,  
<chemistry id="CHEM-US-00050" num="50"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/57/fc/f1c28fbcbf93a5/US20070232586A1-20071004-C00050.png"><img alt="Figure US20070232586A1-20071004-C00050" class="patent-full-image" file="US20070232586A1-20071004-C00050.TIF" he="10.41mm" height="42" id="EMI-C00050" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/8d/57/fc/f1c28fbcbf93a5/US20070232586A1-20071004-C00050.png" wi="13.46mm" width="54"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00050.CDX" idref="CHEM-US-00050"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00050.MOL" idref="CHEM-US-00050"> </attachment> </attachments> </chemistry>
<br/>
 is preferably  
<chemistry id="CHEM-US-00051" num="51"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/20/37/d7/4eb8fe700ee712/US20070232586A1-20071004-C00051.png"><img alt="Figure US20070232586A1-20071004-C00051" class="patent-full-image" file="US20070232586A1-20071004-C00051.TIF" he="118.79mm" height="475" id="EMI-C00051" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/20/37/d7/4eb8fe700ee712/US20070232586A1-20071004-C00051.png" wi="68.33mm" width="273"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00051.CDX" idref="CHEM-US-00051"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00051.MOL" idref="CHEM-US-00051"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0169]"> </para-num> <div class="description-line" id="p-0146" num="0169"> (wherein a hydrogen atom bound to a nitrogen atom may be replaced with J or R). </div>
</li> <li> <para-num num="[0170]"> </para-num> <div class="description-line" id="p-0147" num="0170"> The substituents in the cyclic group which is formed by R<sup>1 </sup>and R<sup>2 </sup>together with a nitrogen atom to which they bind and the cyclic group formed by R<sup>2 </sup>and R<sup>3 </sup>together with a nitrogen atom to which they bind are preferably 1 to 5 substituents selected from C1-8 alkyl, acyl, hydroxy which may have a substituent(s). </div>
</li> <li> <para-num num="[0171]"> </para-num> <div class="description-line" id="p-0148" num="0171"> J is preferably a bond, C1-4 alkylene which may have 1 or 2 substituents, carbonyl or sulfonyl, more preferably a bond, methylene or carbonyl, and most preferably a bond. </div>
</li> <li> <para-num num="[0172]"> </para-num> <div class="description-line" id="p-0149" num="0172"> Among the compounds represented by formula (I), preferred compounds are a compound represented by formula (I-1A):  
<chemistry id="CHEM-US-00052" num="52"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/48/42/de/b870b4c59e37c1/US20070232586A1-20071004-C00052.png"><img alt="Figure US20070232586A1-20071004-C00052" class="patent-full-image" file="US20070232586A1-20071004-C00052.TIF" he="20.32mm" height="81" id="EMI-C00052" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/48/42/de/b870b4c59e37c1/US20070232586A1-20071004-C00052.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00052.CDX" idref="CHEM-US-00052"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00052.MOL" idref="CHEM-US-00052"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0173]"> </para-num> <div class="description-line" id="p-0150" num="0173"> (wherein X<sup>1 </sup>and X<sup>2 </sup>is each independently a carbon atom or a nitrogen atom; R<sup>1P </sup>is C1-8 alkyl which may have a substituent(s); and n1 is 0 or an integer of 1-3), </div>
</li> <li> <para-num num="[0174]"> </para-num> <div class="description-line" id="p-0151" num="0174"> a compound represented by formula (I-1B):  
<chemistry id="CHEM-US-00053" num="53"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/3a/18/289084f2329c71/US20070232586A1-20071004-C00053.png"><img alt="Figure US20070232586A1-20071004-C00053" class="patent-full-image" file="US20070232586A1-20071004-C00053.TIF" he="21.67mm" height="87" id="EMI-C00053" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d1/3a/18/289084f2329c71/US20070232586A1-20071004-C00053.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00053.CDX" idref="CHEM-US-00053"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00053.MOL" idref="CHEM-US-00053"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0175]"> </para-num> <div class="description-line" id="p-0152" num="0175"> (wherein ring L<sup>1 </sup>is a cyclic group which may have a substituent(s) formed by R<sup>1 </sup>and R<sup>2 </sup>together with a nitrogen atom to which they bind; and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0176]"> </para-num> <div class="description-line" id="p-0153" num="0176"> a compound represented by formula (I-1C):  
<chemistry id="CHEM-US-00054" num="54"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/9e/3a/49475269119184/US20070232586A1-20071004-C00054.png"><img alt="Figure US20070232586A1-20071004-C00054" class="patent-full-image" file="US20070232586A1-20071004-C00054.TIF" he="20.24mm" height="81" id="EMI-C00054" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/87/9e/3a/49475269119184/US20070232586A1-20071004-C00054.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00054.CDX" idref="CHEM-US-00054"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00054.MOL" idref="CHEM-US-00054"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0177]"> </para-num> <div class="description-line" id="p-0154" num="0177"> (wherein ring L<sup>2 </sup>is a carbocyclic group which may have a substituent(s) or a heterocyclic group which may have a substituent(s) formed by R<sup>2X </sup>and R<sup>3X </sup>together with a carbon atom to which they bind; and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0178]"> </para-num> <div class="description-line" id="p-0155" num="0178"> a compound represented by formula (I-1D):  
<chemistry id="CHEM-US-00055" num="55"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/ab/1b/e53173d9405f1e/US20070232586A1-20071004-C00055.png"><img alt="Figure US20070232586A1-20071004-C00055" class="patent-full-image" file="US20070232586A1-20071004-C00055.TIF" he="20.32mm" height="81" id="EMI-C00055" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/5d/ab/1b/e53173d9405f1e/US20070232586A1-20071004-C00055.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00055.CDX" idref="CHEM-US-00055"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00055.MOL" idref="CHEM-US-00055"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0179]"> </para-num> <div class="description-line" id="p-0156" num="0179"> (wherein ring L<sup>3 </sup>is a cyclic group which may have a substituent(s) formed by R<sup>2 </sup>and R<sup>3 </sup>together with a nitrogen atom to which they bind; and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0180]"> </para-num> <div class="description-line" id="p-0157" num="0180"> a compound represented by formula (1-2A):  
<chemistry id="CHEM-US-00056" num="56"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/5e/3d/13830c978f4462/US20070232586A1-20071004-C00056.png"><img alt="Figure US20070232586A1-20071004-C00056" class="patent-full-image" file="US20070232586A1-20071004-C00056.TIF" he="16.17mm" height="65" id="EMI-C00056" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/9b/5e/3d/13830c978f4462/US20070232586A1-20071004-C00056.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00056.CDX" idref="CHEM-US-00056"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00056.MOL" idref="CHEM-US-00056"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0181]"> </para-num> <div class="description-line" id="p-0158" num="0181"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0182]"> </para-num> <div class="description-line" id="p-0159" num="0182"> a compound represented by formula (1-2B):  
<chemistry id="CHEM-US-00057" num="57"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/30/6f/289bd062c58bf5/US20070232586A1-20071004-C00057.png"><img alt="Figure US20070232586A1-20071004-C00057" class="patent-full-image" file="US20070232586A1-20071004-C00057.TIF" he="17.44mm" height="70" id="EMI-C00057" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/23/30/6f/289bd062c58bf5/US20070232586A1-20071004-C00057.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00057.CDX" idref="CHEM-US-00057"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00057.MOL" idref="CHEM-US-00057"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0183]"> </para-num> <div class="description-line" id="p-0160" num="0183"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0184]"> </para-num> <div class="description-line" id="p-0161" num="0184"> a compound represented by formula (I-2C):  
<chemistry id="CHEM-US-00058" num="58"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d9/7d/2b/6a440253ecfefe/US20070232586A1-20071004-C00058.png"><img alt="Figure US20070232586A1-20071004-C00058" class="patent-full-image" file="US20070232586A1-20071004-C00058.TIF" he="16.09mm" height="64" id="EMI-C00058" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d9/7d/2b/6a440253ecfefe/US20070232586A1-20071004-C00058.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00058.CDX" idref="CHEM-US-00058"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00058.MOL" idref="CHEM-US-00058"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0185]"> </para-num> <div class="description-line" id="p-0162" num="0185"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0186]"> </para-num> <div class="description-line" id="p-0163" num="0186"> a compound represented by formula (I-2D):  
<chemistry id="CHEM-US-00059" num="59"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/1f/09/cb98e83ea402f6/US20070232586A1-20071004-C00059.png"><img alt="Figure US20070232586A1-20071004-C00059" class="patent-full-image" file="US20070232586A1-20071004-C00059.TIF" he="16.09mm" height="64" id="EMI-C00059" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/1d/1f/09/cb98e83ea402f6/US20070232586A1-20071004-C00059.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00059.CDX" idref="CHEM-US-00059"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00059.MOL" idref="CHEM-US-00059"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0187]"> </para-num> <div class="description-line" id="p-0164" num="0187"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0188]"> </para-num> <div class="description-line" id="p-0165" num="0188"> a compound represented by formula (I-3A):  
<chemistry id="CHEM-US-00060" num="60"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/16/b6/53aecaf21f5b9c/US20070232586A1-20071004-C00060.png"><img alt="Figure US20070232586A1-20071004-C00060" class="patent-full-image" file="US20070232586A1-20071004-C00060.TIF" he="22.78mm" height="91" id="EMI-C00060" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/84/16/b6/53aecaf21f5b9c/US20070232586A1-20071004-C00060.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00060.CDX" idref="CHEM-US-00060"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00060.MOL" idref="CHEM-US-00060"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0189]"> </para-num> <div class="description-line" id="p-0166" num="0189"> (wherein R<sup>w </sup>is hydrogen atom or a substituent (having the same meaning as the substituent in the above-described “(2)carbocyclic group which may have a substituent(s)”; m is 0 or an integer of 1-5; and other symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0190]"> </para-num> <div class="description-line" id="p-0167" num="0190"> a compound represented by formula (I-3B):  
<chemistry id="CHEM-US-00061" num="61"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/a1/7c/3e664867ec10aa/US20070232586A1-20071004-C00061.png"><img alt="Figure US20070232586A1-20071004-C00061" class="patent-full-image" file="US20070232586A1-20071004-C00061.TIF" he="26.25mm" height="105" id="EMI-C00061" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/5f/a1/7c/3e664867ec10aa/US20070232586A1-20071004-C00061.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00061.CDX" idref="CHEM-US-00061"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00061.MOL" idref="CHEM-US-00061"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0191]"> </para-num> <div class="description-line" id="p-0168" num="0191"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0192]"> </para-num> <div class="description-line" id="p-0169" num="0192"> a compound represented by formula (I-3C):  
<chemistry id="CHEM-US-00062" num="62"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/e7/88/e329d69746da5b/US20070232586A1-20071004-C00062.png"><img alt="Figure US20070232586A1-20071004-C00062" class="patent-full-image" file="US20070232586A1-20071004-C00062.TIF" he="24.89mm" height="100" id="EMI-C00062" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/1f/e7/88/e329d69746da5b/US20070232586A1-20071004-C00062.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00062.CDX" idref="CHEM-US-00062"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00062.MOL" idref="CHEM-US-00062"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0193]"> </para-num> <div class="description-line" id="p-0170" num="0193"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0194]"> </para-num> <div class="description-line" id="p-0171" num="0194"> a compound represented by formula (I-3D):  
<chemistry id="CHEM-US-00063" num="63"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/48/71/3e79ccbfe4cc70/US20070232586A1-20071004-C00063.png"><img alt="Figure US20070232586A1-20071004-C00063" class="patent-full-image" file="US20070232586A1-20071004-C00063.TIF" he="26.59mm" height="106" id="EMI-C00063" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d4/48/71/3e79ccbfe4cc70/US20070232586A1-20071004-C00063.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00063.CDX" idref="CHEM-US-00063"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00063.MOL" idref="CHEM-US-00063"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0195]"> </para-num> <div class="description-line" id="p-0172" num="0195"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), a compound represented by formula (I-3E):  
<chemistry id="CHEM-US-00064" num="64"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/27/e9/7b/af2483fe478e03/US20070232586A1-20071004-C00064.png"><img alt="Figure US20070232586A1-20071004-C00064" class="patent-full-image" file="US20070232586A1-20071004-C00064.TIF" he="19.05mm" height="76" id="EMI-C00064" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/27/e9/7b/af2483fe478e03/US20070232586A1-20071004-C00064.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00064.CDX" idref="CHEM-US-00064"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00064.MOL" idref="CHEM-US-00064"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0196]"> </para-num> <div class="description-line" id="p-0173" num="0196"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0197]"> </para-num> <div class="description-line" id="p-0174" num="0197"> a compound represented by formula (I-3F):  
<chemistry id="CHEM-US-00065" num="65"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/f5/66/895446fdbc4e81/US20070232586A1-20071004-C00065.png"><img alt="Figure US20070232586A1-20071004-C00065" class="patent-full-image" file="US20070232586A1-20071004-C00065.TIF" he="42.67mm" height="171" id="EMI-C00065" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/a5/f5/66/895446fdbc4e81/US20070232586A1-20071004-C00065.png" wi="69.85mm" width="279"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00065.CDX" idref="CHEM-US-00065"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00065.MOL" idref="CHEM-US-00065"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0198]"> </para-num> <div class="description-line" id="p-0175" num="0198"> (wherein R<sup>y </sup>and R<sup>z </sup>is each independently a hydrogen atom or a substituent (having the same meaning as the substituent(s) in the above-described “(2) carbocyclic group which may have a substituent(s)”; p is 0 or an integer of 1-4; k is 0 or an integer of 1-4, and other symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0199]"> </para-num> <div class="description-line" id="p-0176" num="0199"> a compound represented by formula (I-3G):  
<chemistry id="CHEM-US-00066" num="66"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c2/dc/26/b42ec981fc559a/US20070232586A1-20071004-C00066.png"><img alt="Figure US20070232586A1-20071004-C00066" class="patent-full-image" file="US20070232586A1-20071004-C00066.TIF" he="31.41mm" height="126" id="EMI-C00066" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/c2/dc/26/b42ec981fc559a/US20070232586A1-20071004-C00066.png" wi="74.42mm" width="298"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00066.CDX" idref="CHEM-US-00066"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00066.MOL" idref="CHEM-US-00066"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0200]"> </para-num> <div class="description-line" id="p-0177" num="0200"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0201]"> </para-num> <div class="description-line" id="p-0178" num="0201"> a compound represented by formula (I-3H):  
<chemistry id="CHEM-US-00067" num="67"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/b5/28/eb20b56a087c8e/US20070232586A1-20071004-C00067.png"><img alt="Figure US20070232586A1-20071004-C00067" class="patent-full-image" file="US20070232586A1-20071004-C00067.TIF" he="44.37mm" height="177" id="EMI-C00067" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/aa/b5/28/eb20b56a087c8e/US20070232586A1-20071004-C00067.png" wi="75.61mm" width="302"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00067.CDX" idref="CHEM-US-00067"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00067.MOL" idref="CHEM-US-00067"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0202]"> </para-num> <div class="description-line" id="p-0179" num="0202"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0203]"> </para-num> <div class="description-line" id="p-0180" num="0203"> a compound represented by formula (I-3J):  
<chemistry id="CHEM-US-00068" num="68"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/37/79/0fbb7bab87ae9d/US20070232586A1-20071004-C00068.png"><img alt="Figure US20070232586A1-20071004-C00068" class="patent-full-image" file="US20070232586A1-20071004-C00068.TIF" he="31.24mm" height="125" id="EMI-C00068" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/b4/37/79/0fbb7bab87ae9d/US20070232586A1-20071004-C00068.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00068.CDX" idref="CHEM-US-00068"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00068.MOL" idref="CHEM-US-00068"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0204]"> </para-num> <div class="description-line" id="p-0181" num="0204"> (wherein all symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0205]"> </para-num> <div class="description-line" id="p-0182" num="0205"> a compound represented by formula (I-3K):  
<chemistry id="CHEM-US-00069" num="69"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/48/07/19dca91d302197/US20070232586A1-20071004-C00069.png"><img alt="Figure US20070232586A1-20071004-C00069" class="patent-full-image" file="US20070232586A1-20071004-C00069.TIF" he="27.35mm" height="109" id="EMI-C00069" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d8/48/07/19dca91d302197/US20070232586A1-20071004-C00069.png" wi="75.95mm" width="304"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00069.CDX" idref="CHEM-US-00069"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00069.MOL" idref="CHEM-US-00069"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0206]"> </para-num> <div class="description-line" id="p-0183" num="0206"> (wherein all symbols have the same meanings as described above, and wherein a hydrogen atom bound to a nitrogen atom may be replaced with R<sup>w</sup>), </div>
</li> <li> <para-num num="[0207]"> </para-num> <div class="description-line" id="p-0184" num="0207"> a compound represented by formula (I-4):  
<chemistry id="CHEM-US-00070" num="70"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/92/7e/0378230c05196e/US20070232586A1-20071004-C00070.png"><img alt="Figure US20070232586A1-20071004-C00070" class="patent-full-image" file="US20070232586A1-20071004-C00070.TIF" he="19.56mm" height="78" id="EMI-C00070" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/0a/92/7e/0378230c05196e/US20070232586A1-20071004-C00070.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00070.CDX" idref="CHEM-US-00070"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00070.MOL" idref="CHEM-US-00070"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0208]"> </para-num> <div class="description-line" id="p-0185" num="0208"> (wherein ring X<sup>P </sup>is a 5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring; T<sup>1P </sup>is a bond or a spacer having 1 or 2 atoms of the principle chain; ring 1<sup>P </sup>is a C5-7 monocyclic carbocyclic group or 5- to 7-membered monocyclic heterocyclic group which may have a substituent(s); and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0209]"> </para-num> <div class="description-line" id="p-0186" num="0209"> a compound represented by formula (I-5):  
<chemistry id="CHEM-US-00071" num="71"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/6b/ee/380d2b45a4df9e/US20070232586A1-20071004-C00071.png"><img alt="Figure US20070232586A1-20071004-C00071" class="patent-full-image" file="US20070232586A1-20071004-C00071.TIF" he="16.85mm" height="67" id="EMI-C00071" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/2b/6b/ee/380d2b45a4df9e/US20070232586A1-20071004-C00071.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00071.CDX" idref="CHEM-US-00071"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00071.MOL" idref="CHEM-US-00071"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0210]"> </para-num> <div class="description-line" id="p-0187" num="0210"> (wherein ring 1<sup>Q </sup>is a nitrogen-containing heterocyclic group which may have a substituent(s); and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0211]"> </para-num> <div class="description-line" id="p-0188" num="0211"> a compound represented by formula (I-6):  
<chemistry id="CHEM-US-00072" num="72"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9b/13/a3/bc98db97b8e367/US20070232586A1-20071004-C00072.png"><img alt="Figure US20070232586A1-20071004-C00072" class="patent-full-image" file="US20070232586A1-20071004-C00072.TIF" he="19.56mm" height="78" id="EMI-C00072" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/9b/13/a3/bc98db97b8e367/US20070232586A1-20071004-C00072.png" wi="73.91mm" width="296"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00072.CDX" idref="CHEM-US-00072"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00072.MOL" idref="CHEM-US-00072"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0212]"> </para-num> <div class="description-line" id="p-0189" num="0212"> (wherein T<sup>2P </sup>is a bond or a spacer having 1 or 2 atoms of the principle chain; ring 2<sup>P </sup>is a C5-7 monocyclic carbocyclic ring or 5- to 7-membered heterocyclic group which may have a substituent(s); and other symbols have the same meanings as described above.), etc. </div>
</li> <li> <para-num num="[0213]"> </para-num> <div class="description-line" id="p-0190" num="0213"> Furthermore, preferred is a compound represented by formula (I-1A) or a compound represented by formula (I-4). More preferred is a compound represented by formula (I-4-1):  
<chemistry id="CHEM-US-00073" num="73"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/13/7a/48/59e8180af5dda3/US20070232586A1-20071004-C00073.png"><img alt="Figure US20070232586A1-20071004-C00073" class="patent-full-image" file="US20070232586A1-20071004-C00073.TIF" he="22.94mm" height="92" id="EMI-C00073" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/13/7a/48/59e8180af5dda3/US20070232586A1-20071004-C00073.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00073.CDX" idref="CHEM-US-00073"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00073.MOL" idref="CHEM-US-00073"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0214]"> </para-num> <div class="description-line" id="p-0191" num="0214"> (wherein all symbols have the same meanings as described above). </div>
</li> <li> <para-num num="[0215]"> </para-num> <div class="description-line" id="p-0192" num="0215"> “5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring” represented by X<sup>P </sup>is a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated, contains one nitrogen atom and may further contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, and examples include tetrahydropyrimidine, dihyrdopyridazine, pyridazine, dihydropyrimidine, dihydropyrazine, dihydrotriazine, dihydropyrazole, diazepane, pyrrole, pyrimidine, pyrazine, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, thiadiazole, oxadiazole, azepane, azepine, dihydroazepine, tetrahydroazepine, diazepane, diazepine, dihydroazepine and tetrahydroazepine rings, and more preferred are pyrimidine, pyrazine, pyridazine, thiazole and oxazole rings. </div>
</li> <li> <para-num num="[0216]"> </para-num> <div class="description-line" id="p-0193" num="0216"> T<sup>1P </sup>is preferably a bond, C1-2 alkylene (e.g., —CH<sub>2</sub>—, —C(CH<sub>3</sub>)<sub>2</sub>—, etc.) which may have 1 or 2 substituents, —NH—, —N(CH<sub>3</sub>)—, etc. </div>
</li> <li> <para-num num="[0217]"> </para-num> <div class="description-line" id="p-0194" num="0217"> T<sup>2P </sup>is preferably a bond, C1-2 alkylene (e.g., —CH<sub>2</sub>—, —C(CH<sub>3</sub>)<sub>2</sub>—, etc.) which may have 1 or 2 substituents, —NH—, —N(CH<sub>3</sub>)—, etc. </div>
</li> <li> <para-num num="[0218]"> </para-num> <div class="description-line" id="p-0195" num="0218"> “C5-7 monocyclic carbocyclic group” represented by ring 1<sup>P </sup>and ring 2<sup>P </sup>is a C5-7 monocyclic aromatic carbocyclic group which may be partially or fully saturated, and “5- to 7-membered monocyclic heterocyclic group” is a 5- to 7-membered monocyclic aromatic heterocyclic group which may be partially or fully saturated and contains 1 to 3 hetero atoms selected from an oxygen atom(s), a nitrogen atom(s) and a sulfur atom(s) which may be oxidized. Ring 1<sup>P </sup>and ring 2<sup>P </sup>may be the same or different. </div>
</li> <li> <para-num num="[0219]"> </para-num> <div class="description-line" id="p-0196" num="0219"> For example, ring 1<sup>P </sup>is preferably a C5 or C6 monocyclic carbocyclic group such as benzene, cyclohexane, cyclopentane, cyclohexene or cyclopentene ring, or a 5- or 6-membered monocyclic heterocyclic group such as pyridine, thiazole, pyrrolidine, imidazolidine, dihyrdopyridine, piperidine, piperazine, tetrahydropyran, tetrahydrothiazole (thiazolidine), morpholine, or thiomorpholine ring, and is more preferably benzene, pyridine, pyrrolidine, piperidine, piperazine or morpholine ring. </div>
</li> <li> <para-num num="[0220]"> </para-num> <div class="description-line" id="p-0197" num="0220"> For example, ring 2<sup>P </sup>is preferably a C5 or C6 monocyclic carbocyclic group such as benzene, cyclohexane, cyclopentane, cyclohexene or cyclopentene ring, or a 5- or 6-membered monocyclic heterocyclic group, and is more preferably benzene, pyridine, imidazolidine, piperidine, piperazine, tetrahydropyran, morpholine or thiomorpholine ring. </div>
</li> <li> <para-num num="[0221]"> </para-num> <div class="description-line" id="p-0198" num="0221"> The “nitrogen-containing heterocyclic group” in the “nitrogen-containing heterocyclic group which may have a substituent(s)” represented by ring 1<sup>Q </sup>has the same meaning as the above-described “nitrogen-containing heterocyclic group” represented by ring B. For example, ring 1<sup>Q </sup>is preferably piperazine, 2,8-diazabispiro[4,5]decane or 3,9-diazaspiro[5,5]undecane ring, etc. </div>
</li> <li> <para-num num="[0222]"> </para-num> <div class="description-line" id="p-0199" num="0222"> Ring 1<sup>P</sup>, ring 2<sup>P </sup>and ring 1<sup>Q </sup>may have 1 to 3 substituents at substitutable positions, and the substituents includes the above-described “substituent” in the “cyclic group which may have a substituent(s)” represented by ring 1, ring 2 and ring 3. </div>
</li> <li> <para-num num="[0223]"> </para-num> <div class="description-line" id="p-0200" num="0223"> More specific embodiments include the following compounds, the compounds described in Examples and the like: 
</div> </li> <ul> <li id="ul0002-0001" num="0224"> (1) N′-(2-cyanopyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane-9-carbohydrazide, </li> <li id="ul0002-0002" num="0225"> (2) N′-(2-cyanopyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0003" num="0226"> (3) N′-(2-cyanopyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-4-[1-(2-methoxyethyl)piperidin-4-yl]benzohydrazide, </li> <li id="ul0002-0004" num="0227"> (4) N′-(2-cyanopyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0005" num="0228"> (5) 4-[2-(1-benzylpiperidin-4-ylidene)-1-(2,2-dimethylpropyl)hydrazino]pyrimidine-2-carbonitrile, </li> <li id="ul0002-0006" num="0229"> (6) N′-(3-chloro-6-cyanopyridin-2-yl)-N′-(2,2-dimethylpropyl)-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0007" num="0230"> (7) N′-(3-chloro-6-cyanopyridin-2-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0008" num="0231"> (8) N′-(3-chloro-6-cyanopyridin-2-yl)-N′-(2,2-dimethylpropyl)-4-[1-(2-methoxyethyl)piperidin-4-yl]benzohydrazide, </li> <li id="ul0002-0009" num="0232"> (9) N′-(6-cyano-3-(trifluoromethyl)pyridin-2-yl)-N′-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0010" num="0233"> (10) 6-[2-(1-benzylpiperidin-4-ylidene)-1-(2,2-dimethylpropyl)hydrazino]-5-(trifluoromethyl)pyridine-2-carbonitrile, </li> <li id="ul0002-0011" num="0234"> (11) N′-[2-cyano-4-(2,2-dimethylpropoxy)pyrimidin-5-yl]-2,5-dioxo-3-(pyridin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undecane-9-carbohydrazide, </li> <li id="ul0002-0012" num="0235"> (12) N′-[2-cyano-4-(2,2-dimethylpropoxy)pyrimidin-5-yl]-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0013" num="0236"> (13) N′-[2-cyano-4-(2,2-dimethylpropoxy)pyrimidin-5-yl]-4-[1-(2-methoxyethyl)piperidin-4-yl]benzohydrazide, </li> <li id="ul0002-0014" num="0237"> (14) N′-[2-cyano-4-(2,2-dimethylpropoxy)pyrimidin-5-yl]-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0015" num="0238"> (15) N′-[2-cyano-4-(2,2-dimethylpropoxy)pyrimidin-5-yl]-2,4-dioxo-1,3,8-triazaspiro[4,5]decane-8-carbohydrazide, </li> <li id="ul0002-0016" num="0239"> (16) 5-[2-(1-benzylpiperidin-4-ylidene)hydrazino]-4-(2,2-dimethylpropoxy)pyrimidine-2-carbonitrile, </li> <li id="ul0002-0017" num="0240"> (17) 5-bromo-4-[1-(2,2-dimethylpropyl)-2-(4-methoxybenzyl)hydrazino]pyrimidine-2-carbonitrile, </li> <li id="ul0002-0018" num="0241"> (18) 5-bromo-4-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylidene)hydrazino]pyrimidine-2-carbonitrile, </li> <li id="ul0002-0019" num="0242"> (19) N′-(5-bromo-2-cyanopyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-4-methylbenzenesulfonohydrazide, </li> <li id="ul0002-0020" num="0243"> (20) 5-bromo-4-{(2,2-dimethylpropyl)[1-methyl-2,5-dioxo-3-(pyridin-4-ylmethyl)-1,4,9-triazaspiro[5,5]undec-9-yl]amino}pyrimidine-2-carbonitrile, </li> <li id="ul0002-0021" num="0244"> (21) N′-(6-cyanopyradin-2-yl)-N′-(2,2-dimethylpropyl)-N,1,3-trimethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undecane-9-carbohydrazide, </li> <li id="ul0002-0022" num="0245"> (22) N-(6-cyanopyrazin-2-yl)-N′-(2,2-dimethylpropyl)-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzohydrazide, </li> <li id="ul0002-0023" num="0246"> (23) N′-(6-cyanopyrazin-2-yl)-N′-(2,2-dimethylpropyl)-4-[1-(2-methoxyethyl)piperidin-4-yl]-N-methylbenzohydrazide, </li> <li id="ul0002-0024" num="0247"> (24) 6-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4,5]dec-8-ylidene)hydrazino]pyrazine-2-carbonitrile, </li> <li id="ul0002-0025" num="0248"> (25) benzyl (1-{[2-(6-cyanopyrazin-2-yl)-2-(2,2-dimethylpropyl) hydrazino]carbonyl}-3-methylbutyl)carbamate, </li> <li id="ul0002-0026" num="0249"> (26) 4-{2-[(1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl)carbonyl]-4,4-dimethylpyrazolidin-1-yl}pyrimidine-2-carbonitrile, </li> <li id="ul0002-0027" num="0250"> (27) 4-(4,4-dimethyl-2-{4-[(4-methylpiperazin-1-yl)methyl]benzoyl}pyrazolidin-1-yl)pyrimidine-2-carbonitrile, </li> <li id="ul0002-0028" num="0251"> (28) benzyl (1-{[2-(2-cyanopyrimidin-4-yl)-4,4-dimethylpyrazolidin-1-yl]carbonyl}-3-methylbutyl)carbamate, </li> <li id="ul0002-0029" num="0252"> (29) 4-(2-{[4-(1H-imidazol-1-yl)phenyl]acetyl}-4,4-dimethylpyrazolidin-1-yl)pyrimidine-2-carbonitrile, </li> <li id="ul0002-0030" num="0253"> (30) 4-[2-(4-methoxybenzyl)-4,4-dimethylpyrazolidin-1-yl]pyrimidine-2-carbonitrile, </li> <li id="ul0002-0031" num="0254"> (31) N′-(2-cyano-5-methylpyrimidin-4-yl)-2-(1,3-dimethyl-2-oxo-1,3,9-triazaspiro[5.5]undec-9-yl)-N′-(2,2-dimethylpropyl)acetohydrazide, </li> <li id="ul0002-0032" num="0255"> (32) N′-(3-bromo-6-cyanopyridin-2-yl)-2-(1,3-dimethyl-2-oxo-1,3,9-triazaspiro[5.5]undec-9-yl)-N′-(2,2-dimethylpropyl)acetohydrazide, </li> <li id="ul0002-0033" num="0256"> (33) N′-(6-cyanopyrazin-2-yl)-N′-(2,2-dimethylpropyl)-2-[1-methyl-2-oxo-3-(pyridin-4-ylmethyl)-1,3,9-triazaspiro[5.5]undec-9-yl]acetohydrazide, </li> <li id="ul0002-0034" num="0257"> (34) N′-(4-cyano-1-methyl-1H-imidazol-2-yl)-N′-isobutyl-4-[1-(2-methoxyethyl)piperidin-4-yl]benzohydrazide, </li> <li id="ul0002-0035" num="0258"> (35) N′-(4-cyano-1-methyl-1H-imidazol-2-yl)-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)-N′-isobutylacetohydrazide, </li> <li id="ul0002-0036" num="0259"> (36) N′-(4-cyano-1-methyl-1H-imidazol-2-yl)-N-isobutyl-2-{4-[(4-methylpiperazin-1-yl)carbonyl]piperidin-1-yl}acetohydrazide, </li> <li id="ul0002-0037" num="0260"> (37) 2-[2-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylidene)-1-isobutylhydrazino]-1-methyl-1H-imidazole-4-carbonitrile, </li> <li id="ul0002-0038" num="0261"> (38) 2-[2-(1-benzylpiperidin-4-ylidene)-1-isobutylhydrazino]-1,3-thiazole-4-carbonitrile, </li> <li id="ul0002-0039" num="0262"> (39) 2-[(2,2-dimethylpropyl)(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)amino]-1,3-thiazole-4-carbonitrile, </li> <li id="ul0002-0040" num="0263"> (40) N′-[(2-cyanopyrimidin-4-yl)methyl]-N-isobutyl-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzohydrazide, </li> <li id="ul0002-0041" num="0264"> (41) N-[(2-cyanopyrimidin-4-yl)methyl]-N′-isopropyl-2-[1-oxo-2-(pyridin-4-ylmethyl)-2,7-diazaspiro[4.5]dec-7-yl]acetohydrazide, </li> <li id="ul0002-0042" num="0265"> (42) N′-[(2-cyanopyrimidin-4-yl)methyl]-N-isopropyl-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0043" num="0266"> (43) N′-[(6-cyanopyrazin-2-yl)methyl]-N′-isopropyl-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0044" num="0267"> (44) 4-{4,4-dimethyl-2-[(4-methylphenyl)sulfonyl]pyrazolidin-1-yl}pyrimidine-2-carbonitrile, </li> <li id="ul0002-0045" num="0268"> (45) 5-acetyl-6-(1-(2,2-dimethylpropyl)-2-{4-[3-(4-isopropylpiperazin-1-yl)prop-1-yn-1-yl]phenyl} hydrazino)pyridine-2-carbonitrile, </li> <li id="ul0002-0046" num="0269"> (46) N′-[(2-cyanopyrimidin-5-yl)methyl]-N′-isobutyl-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0047" num="0270"> (47) N′-[(2-cyanopyrimidin-5-yl)methyl]-N-(3,3-dimethylbutyl)-4-(1H-imidazol-1-yl)benzohydrazide, </li> <li id="ul0002-0048" num="0271"> (48) 2-cyano-N-(3,3-dimethylbutyl)-N′-{4-[(4-methylpiperazin-1-yl)methyl]benzoyl}pyrimidine-5-carbohydrazide, </li> <li id="ul0002-0049" num="0272"> (49) N′-[(2-cyanopyrimidin-5-yl)carbonyl]-N′-(3,3-dimethylbutyl)-2,4-dioxo-1, 3,8-triazaspiro[4,5]decane-8-carbohydrazide, </li> <li id="ul0002-0050" num="0273"> (50) 2-cyano-4-(2,2-dimethylpropoxy)-N′-{4-[1-(2-methoxyethyl)piperidin-4-yl]benzoyl}pyrimidine-5-carbohydrazide, </li> <li id="ul0002-0051" num="0274"> (51) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4,5]decane-8-carbohydrazide, </li> <li id="ul0002-0052" num="0275"> (52) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4,5]decane-8-carbohydrazide, </li> <li id="ul0002-0053" num="0276"> (53) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4,5]decane-8-carbohydrazide, </li> <li id="ul0002-0054" num="0277"> (54) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0055" num="0278"> (55) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0056" num="0279"> (56) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-1,3-dimethyl-2,5-dioxo-1,4,9-triazaspiro[5,5]undecane-9-carbohydrazide, </li> <li id="ul0002-0057" num="0280"> (57) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3,8-triazaspiro[4,5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0058" num="0281"> (58) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0059" num="0282"> (59) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)acetohydrazide, </li> <li id="ul0002-0060" num="0283"> (60) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-2-{4-[(4-methylpiperazin-1-yl)carbonyl]piperidin-1-yl}acetohydrazide, </li> <li id="ul0002-0061" num="0284"> (61) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-2-{4-[(4-methylpiperazin-1-yl)carbonyl]piperidin-1-yl}acetohydrazide, </li> <li id="ul0002-0062" num="0285"> (62) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-2-{4-[(4-methylpiperazin-1-yl)carbonyl]piperidin-1-yl}acetohydrazide, </li> <li id="ul0002-0063" num="0286"> (63) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0064" num="0287"> (64) N-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0065" num="0288"> (65) N-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0066" num="0289"> (66) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzohydrazide, </li> <li id="ul0002-0067" num="0290"> (67) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzohydrazide, </li> <li id="ul0002-0068" num="0291"> (68) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-4-[2-(4-methylpiperazin-1-yl)-1,3-thiazol-4-yl]benzohydrazide, </li> <li id="ul0002-0069" num="0292"> (69) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-4-[4-(2-methoxyethyl)piperazin-1-yl]benzohydrazide, </li> <li id="ul0002-0070" num="0293"> (70) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-4-[4-(2-methoxyethyl)piperazin-1-yl]benzohydrazide, </li> <li id="ul0002-0071" num="0294"> (71) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-4-[4-(2-methoxyethyl)piperazin-1-yl]benzohydrazide, </li> <li id="ul0002-0072" num="0295"> (72) N′-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-2-[1-oxo-2-(pyridin-4-ylmethyl)-2,7-diazaspiro[4.5]dec-7-yl]acetohydrazide, </li> <li id="ul0002-0073" num="0296"> (73) N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)-2-[1-oxo-2-(pyridin-4-ylmethyl)-2,7-diazaspiro[4.5]dec-7-yl]acetohydrazide, </li> <li id="ul0002-0074" num="0297"> (74) N′-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-N′-(2,2-dimethylpropyl)-2-[1-oxo-2-(pyridin-4-ylmethyl)-2,7-diazaspiro[4.5]dec-7-yl]acetohydrazide, </li> <li id="ul0002-0075" num="0298"> (75) N′-(1-cyanoimidazo[1,5-a]pyrazin-3-yl)-N′-(2,2-dimethylpropyl)-2-[1-oxo-2-(pyridin-4-ylmethyl)-2,7-diazaspiro[4.5]dec-7-yl]acetohydrazide, </li> <li id="ul0002-0076" num="0299"> (76) 7-{(2,2-dimethylpropyl)[1-methyl-2,5-dioxo-3-(pyridin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]amino}pyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0077" num="0300"> (77) 4-{(2,2-dimethylpropyl)[1-methyl-2,5-dioxo-3-(pyridin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]amino}pyrazolo[1,5-a][1,3,5]triazine-2-carbonitrile, </li> <li id="ul0002-0078" num="0301"> (78) 5-{(2,2-dimethylpropyl)[1-methyl-2,5-dioxo-3-(pyridin-4-ylmethyl)-1,4,9-triazaspiro[5.5]undec-9-yl]amino}imidazo[1,2-a]pyrimidine-7-carbonitrile, </li> <li id="ul0002-0079" num="0302"> (79) 7-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4,5]dec-8-ylidene)hydrazino]pyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0080" num="0303"> (80) 4-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylidene)hydrazino]pyrazolo[1,5-a][1,3,5]triazine-2-carbonitrile, </li> <li id="ul0002-0081" num="0304"> (81) 5-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylidene)hydrazino]imidazo[1,2-a]pyrimidine-7-carbonitrile, </li> <li id="ul0002-0082" num="0305"> (82) 5-[1-(2,2-dimethylpropyl)-2-(2,4-dioxo-1,3-diazaspiro[4.5]dec-8-ylidene)hydrazino]imidazo[1,2-c]pyrimidine-7-carbonitrile, </li> <li id="ul0002-0083" num="0306"> (83) 4-[1-(2,2-dimethylpropyl)-2-(4-methoxybenzyl)hydrazino]-7-isobutylpyrazolo[1,5-a][1,3,5]triazine-2-carbonitrile, </li> <li id="ul0002-0084" num="0307"> (84) 7-[1-(2,2-dimethylpropyl)-2-(4-methoxybenzyl)hydrazino]-2-isobutylpyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0085" num="0308"> (85) benzyl (1-{[2-(5-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-4,4-dimethylpyrazolidin-1-yl]carbonyl}-3-methylbutyl)carbamate, </li> <li id="ul0002-0086" num="0309"> (86) benzyl (1-{[2-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-4,4-dimethylpyrazolidin-1-yl]carbonyl}-3-methylbutyl)carbamate, </li> <li id="ul0002-0087" num="0310"> (87) benzyl (1-{[2-(7-cyanoimidazo[1,2-a]pyrimidin-5-yl)-4,4-dimethylpyrazolidin-1-yl]carbonyl}-3-methylbutyl)carbamate, </li> <li id="ul0002-0088" num="0311"> (88) 7-(1-(2,2-dimethylpropyl)-2-{4-[3-(4-isopropylpiperazin-1-yl)prop-1-yn-1-yl]phenyl}hydrazino)pyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0089" num="0312"> (89) 4-(1-(2,2-dimethylpropyl)-2-{4-[3-(4-isopropylpiperazin-1-yl)prop-1-yn-1-yl]phenyl}hydrazino)pyrazolo[1,5-a][1,3,5]triazine-2-carbonitrile, </li> <li id="ul0002-0090" num="0313"> (90) 5-(1-(2,2-dimethylpropyl)-2-{4-[3-(4-isopropylpiperazin-1-yl)prop-1-yn-1-yl]phenyl}hydrazino)imidazo[1,2-a]pyrimidine-7-carbonitrile, </li> <li id="ul0002-0091" num="0314"> (91) 7-(1-(2,2-dimethylpropyl)-2-{3-[4-(1-methylpiperidin-4-yl)benzyl]-1,3-thiazolidin-2-ylidene}hydrazino)pyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0092" num="0315"> (92) 4-(1-(2,2-dimethylpropyl)-2-{3-[4-(1-methylpiperidin-4-yl)benzyl]-1,3-thiazolidin-2-ylidene}hydrazino)pyrazolo[1,5-a][1,3,5]triazine-2-carbonitrile, </li> <li id="ul0002-0093" num="0316"> (93) 5-(1-(2,2-dimethylpropyl)-2-{3-[4-(1-methylpiperidin-4-yl)benzyl]-1,3-thiazolidin-2-ylidene} hydrazino)imidazo[1,2-a]pyrimidine-7-carbonitrile, </li> <li id="ul0002-0094" num="0317"> (94) 7-{1-(2,2-dimethylpropyl)-2-[(2,4-dioxo-1,3,8-triazaspiro[4.5]dec-8-yl)methyl]-2-methylhydrazino}pyrazolo[1,5-a]pyrimidine-5-carbonitrile, </li> <li id="ul0002-0095" num="0318"> (95) 2-(9-benzyl-1-methyl-2-oxo-1,3,9-triazaspiro[5,5]undec-3-yl)-N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-N′-(2,2-dimethylpropyl)acetohydrazide, </li> <li id="ul0002-0096" num="0319"> (96) N′-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carbohydrazide, </li> <li id="ul0002-0097" num="0320"> (97) N′-[2-cyano-8-(2,2-dimethylpropyl)pyrazolo[1,5-a][1,3,5]triazin-4-yl]-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0098" num="0321"> (98) N′-(1-cyanoimidazo[1,5-a]pyrazin-3-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0099" num="0322"> (99) N′-(2-cyanothieno[3,2-d]pyrimidin-4-yl)-N′-(2,2-dimethylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decane-8-carbohydrazide, </li> <li id="ul0002-0100" num="0323"> (100) N′-(2-cyanoquinazolin-5-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0101" num="0324"> (101) N′-(2-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-N′-(2,2-dimethylpropyl)-4-[(4-methylpiperazin-1-yl)methyl]benzohydrazide, </li> <li id="ul0002-0102" num="0325"> (102) 2-cyano-N-(2,2-dimethylpropyl)-N′-{4-[(4-methylpiperazin-1-yl)methyl]benzoyl}pyrazolo[1,5-a][1,3,5]triazine-4-carbohydrazide. </li> </ul>
<li> <para-num num="[0326]"> </para-num> <div class="description-line" id="p-0201" num="0326"> Furthermore, the compounds described in Examples, salts thereof solvates thereof, N-oxides thereof and prodrugs thereof are preferred. More preferred are 
</div> </li> <ul> <li id="ul0003-0001" num="0327"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide (Compound 15-1), </li> <li id="ul0003-0002" num="0328"> N′-(2-cyano-5-methyl-4-pyrimidinyl)-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide (Compound 15-3), </li> <li id="ul0003-0003" num="0329"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-(dimethylamino)-N′-neopentylacetohydrazide (Compound 15-13), </li> <li id="ul0003-0004" num="0330"> N′-(5-bromo-2-cyano-4-pyrimidinyl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide (Compound 17-1), </li> <li id="ul0003-0005" num="0331"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide (Compound 17-21), </li> <li id="ul0003-0006" num="0332"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-neopentylnicotinohydrazide (Compound 17-26), </li> <li id="ul0003-0007" num="0333"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-(4-morpholinylmethyl)-N′-neopentylbenzohydrazide (Compound 17-35), </li> <li id="ul0003-0008" num="0334"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4-[(dimethylamino)methyl]-3-fluoro-N′-neopentylbenzohydrazide (Compound 17-36), </li> <li id="ul0003-0009" num="0335"> N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide (Compound 17-37), </li> <li id="ul0003-0010" num="0336"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-methyl-2-[4-(1-methyl-4-piperidinyl)phenyl]-N′-neopentylpropanohydrazide (Compound 17-44), </li> <li id="ul0003-0011" num="0337"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide (Compound 17-48), </li> <li id="ul0003-0012" num="0338"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-2-{4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide (Compound 17-57), </li> <li id="ul0003-0013" num="0339"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[2-(dimethylamino)ethoxy]-N′-neopentylbenzohydrazide (Compound 17-69), </li> <li id="ul0003-0014" num="0340"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-2-{4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide (Compound 17-71), </li> <li id="ul0003-0015" num="0341"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-neopentyl-2-(1-pyrrolidinyl)acetohydrazide (Compound 17-74), </li> <li id="ul0003-0016" num="0342"> N-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-6-(4-methyl-1-piperazinyl)nicotinohydrazide (Compound 49-9), </li> <li id="ul0003-0017" num="0343"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-4-{[(2-methoxyethyl)(methyl)amino]methyl}benzohydrazide (Compound 50-4), </li> <li id="ul0003-0018" num="0344"> N′-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)benzohydrazide (Compound 50-18), </li> <li id="ul0003-0019" num="0345"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-3-(dimethylamino)-N′-(2,2-dimethylpropyl)propanohydrazide (Compound 50-19), </li> <li id="ul0003-0020" num="0346"> N′-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-{4-[(dimethylamino)methyl]phenyl}-N′-(2,2-dimethylpropyl)-2-methylpropanohydrazide (Compound 50-22), </li> <li id="ul0003-0021" num="0347"> N-(2-cyano-6-methyl-4-pyrimidinyl)-N′-(2,2-dimethylpropyl)-2-methyl-2-{4-[(4-methyl-1-piperazinyl)methyl]phenyl}propanohydrazide (Compound 50-25), </li> <li id="ul0003-0022" num="0348"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-4′-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-4-biphenylcarbohydrazide (Compound 50-26), </li> <li id="ul0003-0023" num="0349"> N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-3-methoxybenzohydrazide (Compound 50-30), </li> <li id="ul0003-0024" num="0350"> N′-[2-cyano-6-(trifluoromethyl-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-2-(methylamino)acetohydrazide (Compound 51), </li> </ul>
<li> <para-num num="[0351]"> </para-num> <div class="description-line" id="p-0202" num="0351"> tert-butyl 2-(2-cyano-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-2-(2,2-dimethylpropyl)hydrazinecarboxylate (Compound 55), </div>
</li> <li> <para-num num="[0352]"> </para-num> <div class="description-line" id="p-0203" num="0352"> salts thereof, solvates thereof, N-oxides thereof, prodrugs thereof and the like. </div>
</li> <li> <para-num num="[0353]"> </para-num> <div class="description-line" id="p-0204" num="0353"> In the present invention, isomers are included unless specified. For example, alkyl, alkoxy, alkylthio, alkenyl, alkynyl, alkylene, alkylidene, and alkenylidene include straight chain and branched ones. Furthermore, the present invention includes isomers in double bond, ring, fused ring (E, Z, cis, trans), isomers by the presence of asymmetric carbon (R-, S-form, α-, β-configuration, enantiomer, diastereomer), optical isomers having optical rotation (D, L, d, l, +, − form), polars by chromatography separation (more polar compound, less polar compound), equilibrium compound, a compound of arbitrary ratios of those and racemic mixture. An optically active compound in the present invention includes not only 100% optically pure compound and may include (an)other optical isomer(s) less than 50%. </div>
</li> <li> <div class="description-line" id="h-0007" num="0000"> Salt, N-Oxide, Solvate and Prodrug: </div>
</li> <li> <para-num num="[0354]"> </para-num> <div class="description-line" id="p-0205" num="0354"> The salt of the compound of formula (I) includes all of the salt which are pharmaceutically acceptable. With regard to the pharmaceutically acceptable salts, those which are low-toxic and soluble in water are preferred. Examples of appropriate salts are salt with alkaline metal (such as potassium, sodium and lithium), salt with alkaline earth metal (such as calcium and magnesium), ammonium salt (such as tetramethylammonium salt and tetrabutylammonium salt), salt with organic amine (such as triethylamine, methylamine, dimethylamine, cyclopentylamine, benzylamine, phenethylamine, piperidine, monoethanolamine, diethanolamine, tris(hydroxymethyl)methylamine, lysine, arginine and N-methyl-D-glucamine) and acid addition salt [such as inorganic acid salt (e.g., hydrochloride, hydrobromide, hydroiodide, sulfate, phosphate and nitrate, etc.) and organic acid salt (e.g., acetate, trifluoroacetate, lactate, tartrate, oxalate, fumarate, maleate, benzoate, citrate, methanesulfonate, ethanesulfonate, benzenesulfonate, toluenesulfonate, isethionate, glucuronate, gluconate, etc.), etc.]. </div>
</li> <li> <para-num num="[0355]"> </para-num> <div class="description-line" id="p-0206" num="0355"> An N-oxide of a compound of formula (I) means a compound of formula (I) which nitrogen is oxidized. An N-oxide of a compound of formula (I) may also be salt of alkaline (earth) metal, ammonium, organic amine, or acid addition salt. </div>
</li> <li> <para-num num="[0356]"> </para-num> <div class="description-line" id="p-0207" num="0356"> The proper solvate of the compound of formula (I) includes, for example, hydarate, alcoholate (ethanolate, etc.), etc. The solvate is preferably non-toxic and water-soluble. The solvate of the compound of formula (I) also includes solvates of the above-mentioned alkaline (earth) metal salt thereof, (quaternary) ammonium salt thereof, organic amine salt thereof, acid addition salt thereof, and N-oxide thereof. </div>
</li> <li> <para-num num="[0357]"> </para-num> <div class="description-line" id="p-0208" num="0357"> The compounds of formula (I) can be converted to salts thereof, N-oxide thereof, or solvate thereof by known methods. </div>
</li> <li> <para-num num="[0358]"> </para-num> <div class="description-line" id="p-0209" num="0358"> The prodrugs of the compound of formula (I) mean the compounds converted into the compound of formula (I) by the reactions of enzymes, gastric acid and the like in an organism. As the prodrugs of the compound of formula (I), when the compound of formula (I) has amino group, the amino group of the compound is acylated, alkylated, or phosphorylated, (e.g., the amino group of the compound of formula (I) is eicosanoylated, alanylated, pentylaminocarbonylated, (5-methyl-2-oxo-1, 3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, acetoxymethylated, tert-butylated and the like); when the compound of formula (I) has hydroxy group, the hydroxy group of the compound is acylated, alkylated, phosphorylated, borated (e.g., the hydroxy group of the compound of formula (I) is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylaminomethylcarbonylated and the like); when the compound of formula (I) has carboxy group, the carboxy group of the compounds are ethylesterified, phenylesterified, carboxymethylesterified, dimethylaminomethylesterified, pivaloyloxymethylesterified, ethoxycarbonyloxyethylesterified, phthalidylesterified, (5-methyl-2-oxo-1,3-dioxolen-4-yl)methylesterified, cyclohexyloxycarbonylethylesterified, methylamidated and the like); and the like. These compounds can be manufactured by the conventional methods per se. In addition, the prodrugs of the compounds of formula (I) may be hydrates or not. The prodrugs of the compound of formula (I) may be those ones which are converted to a compound of formula (I) in physiological conditions as described in Molecular Design, as Vol. 7 of Development of pharmaceutical drugs, 1990. 163-198, Hirokawa Publishing. The compounds represented by formula (I) may be labeled with an isotope (e.g., <sup>3</sup>H, <sup>14</sup>C, <sup>35</sup>S, <sup>125</sup>I, etc.) or the like. </div>
</li> <li> <div class="description-line" id="h-0008" num="0000"> Methods for the Preparation of the Compound of the Present Invention: </div>
</li> <li> <para-num num="[0359]"> </para-num> <div class="description-line" id="p-0210" num="0359"> The compound represented by formula (I), the salt thereof, the solvate thereof, the N-oxide thereof or a prodrug thereof (hereinafter referred to as the compound of the present invention) can be prepared by methods which properly improved and combined known methods, such as methods described in <i>Comprehensive Organic Transformations: A Guide to Functional Group Preparations, </i>2nd Edition (Richard C. Larock, John Wiley &amp; Sons Inc, 1999), methods described below, or methods described in Examples. In each method described below, a starting material can be used as a salt thereof. An example of the salt includes a pharmaceutically acceptable salt of the compound of formula (I) described above. </div>
</li> <li> <para-num num="[0360]"> </para-num> <div class="description-line" id="p-0211" num="0360"> A compound represented by formula (I) can be prepared by cyanation of a compound represented by formula (II):  
<chemistry id="CHEM-US-00074" num="74"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a2/10/6c/404b752bdf6784/US20070232586A1-20071004-C00074.png"><img alt="Figure US20070232586A1-20071004-C00074" class="patent-full-image" file="US20070232586A1-20071004-C00074.TIF" he="16.93mm" height="68" id="EMI-C00074" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/a2/10/6c/404b752bdf6784/US20070232586A1-20071004-C00074.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00074.CDX" idref="CHEM-US-00074"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00074.MOL" idref="CHEM-US-00074"> </attachment> </attachments> </chemistry>
<br/>
 (wherein Q is a leaving group (e.g., halogen atom, methylsulfonyl, 4-methylphenylsulfonyl, etc.), R<sup>A</sup>, R<sup>1A</sup>, R<sup>2A </sup>and R<sup>3A </sup>have the same meanings as R, R<sup>1</sup>, R<sup>2 </sup>and R<sup>3</sup>, respectively, and carboxy, hydroxy, amino or mercapto in the groups represented by R<sup>A</sup>, R<sup>1A</sup>, R<sup>2A </sup>and R<sup>3A </sup>is protected if the protection is necessary; and other symbols have the same meanings as described above) 
</div>
</li> <li> <para-num num="[0361]"> </para-num> <div class="description-line" id="p-0212" num="0361"> and if necessary, followed by removal of the protecting group. </div>
</li> <li> <para-num num="[0362]"> </para-num> <div class="description-line" id="p-0213" num="0362"> The cyanation is well known. For example, it may be carried out by reacting a compound represented by formula (II) with cyanation reagent (e.g., potassium cyamide, sodium cyamide, tetrabutylammonium cyamide, tetraethylammonium cyamide, etc.) in an organic solvent (e.g., dimethylsulfoxide, dimethylformamide, dioxane or mixed solvent thereof and water), in the presence of tertiary amine (e.g., 1,4-diazabicyclo[2.2.2]octane (DABCO), trimethylamine, dimethylaminopyridine, etc.) at 0 to 150° C. </div>
</li> <li> <para-num num="[0363]"> </para-num> <div class="description-line" id="p-0214" num="0363"> The reaction for removing the protective group for carboxy, hydroxy, amino or mercapto is known and its examples are as follows. </div>
</li> <li> <div class="description-line" id="h-0009" num="0000"> (1) a deprotection reaction by hydrolyzing reaction with an alkali; </div>
</li> <li> <div class="description-line" id="h-0010" num="0000"> (2) a deprotection reaction under an acidic condition; </div>
</li> <li> <div class="description-line" id="h-0011" num="0000"> (3) a deprotection reaction by hydrogenolysis; </div>
</li> <li> <div class="description-line" id="h-0012" num="0000"> (4) a deprotection reaction of silyl; </div>
</li> <li> <div class="description-line" id="h-0013" num="0000"> (5) a deprotection reaction using a metal; and </div>
</li> <li> <div class="description-line" id="h-0014" num="0000"> (6) a deprotection reaction using a metal complex. </div>
</li> <li> <para-num num="[0364]"> </para-num> <div class="description-line" id="p-0215" num="0364"> Those methods will be specifically illustrated as follows. </div>
</li> <li> <para-num num="[0365]"> </para-num> <div class="description-line" id="p-0216" num="0365"> (1) A deprotection reaction by hydrolyzing reaction with an alkali is carried out, for example, at 0 to 40° C. using a hydroxide of alkaline metal (e.g., sodium hydroxide, potassium hydroxide and lithium hydroxide, etc.), a hydroxide of alkaline earth metal (e.g., barium hydroxide and calcium hydroxide, etc.), a carbonate (e.g., sodium carbonate and potassium carbonate, etc.), or an aqueous solution thereof or a mixture thereof in an organic solvent (e.g., methanol, tetrahydrofuran and dioxane etc.). </div>
</li> <li> <para-num num="[0366]"> </para-num> <div class="description-line" id="p-0217" num="0366"> (2) A deprotection reaction under an acidic condition is carried out, for example, at 0 to 100° C. in an organic acid (e.g., acetic acid, trifluoroacetic acid, methanesulfonic acid or p-toluenesulfonic acid, etc.), an inorganic acid (e.g., hydrochloric acid and sulfuric acid, etc.) or a mixture thereof (e.g., hydrogen bromide/acetic acid) in an organic solvent (e.g., dichloromethane, chloroform, dioxane, ethyl acetate and anisole etc.) in the presence or absence of 2,2,2-trifluoroethanol. </div>
</li> <li> <para-num num="[0367]"> </para-num> <div class="description-line" id="p-0218" num="0367"> (3) A deprotection reaction by hydrogenolysis is carried out, for example, at 0 to 200° C. under a hydrogen atmosphere of ordinary pressure or high pressure or in the presence of ammonium formate in the presence of a catalyst (e.g., palladium-carbon, palladium black, palladium hydroxide-carbon, platinum oxide and Raney nickel, etc.) in a solvent [e.g., an ether (e.g., tetrahydrofuran, dioxane, dimethoxyethane and diethyl ether, etc.), an alcohol (e.g., methanol and ethanol, etc.), a benzene (e.g., benzene and toluene, etc.), a ketone (e.g., acetone and methyl ethyl ketone, etc.), a nitrile (e.g., acetonitrile, etc.), an amide (e.g., dimethylformamide, etc.), water, ethyl acetate, acetic acid or a mixed solvent comprising two or more thereof]. </div>
</li> <li> <div class="description-line" id="h-0015" num="0000"> (4) A deprotection reaction of silyl is carried out, for example, at 0 to 40° C. using tetrabutylammonium fluoride in an organic solvent miscible with water (e.g., tetrahydrofuran and acetonitrile etc.). </div>
</li> <li> <para-num num="[0368]"> </para-num> <div class="description-line" id="p-0219" num="0368"> (5) A deprotection reaction using metal is carried out, for example, at 0 to 40° C. with or without ultrasonic wave in the presence of powdery zinc in an acidic solvent (e.g., acetic acid, a buffer of pH 4.2 to 7.2 and a mixed solution of a solution thereof with an organic solvent such as tetrahydrofuran, etc.). </div>
</li> <li> <para-num num="[0369]"> </para-num> <div class="description-line" id="p-0220" num="0369"> (6) A deprotection reaction using a metal complex is carried out, for example, at 0 to 40° C. using a metal complex [e.g., tetrakis(triphenylphosphine) palladium (0), bis(triphenylphosphine) palladium (II) dichloride, palladium (II) acetate and tris(triphenylphosphine) rhodium (I) chloride, etc.] in the presence or absence of a phosphine agent (e.g., triphenylphosphine, etc.) in the presence of a trap reagent (e.g., tributyltin hydride, triethylsilane, dimedone, morpholine, diethylamine, pyrrolidine, etc.), an organic acid (e.g., acetic acid, formic acid, 2-ethylhexanoic acid, etc.) and/or an organic acid salt (e.g., sodium 2-ethylhexanoate, potassium 2-ethylhexanoate, etc.) in an organic solvent (e.g., dichloromethane, dimethylformamide, tetrahydrofuran, ethyl acetate, acetonitrile, dioxane, ethanol, etc.), water or a mixed solvent thereof. Except for the above, the deprotection may also be carried out, for example, according to the methods described in T. W. Greene, <i>Protective Groups in Organic Synthesis</i>, Wiley, New York, 1999. </div>
</li> <li> <para-num num="[0370]"> </para-num> <div class="description-line" id="p-0221" num="0370"> The protective group of carboxy includes, for example, methyl, ethyl, allyl, tert-butyl, trichloroethyl, benzyl (Bn) or phenacyl, p-methoxybenzyl, trityl, 2-chlorotrityl or polymer-supported group bound thereby, etc. </div>
</li> <li> <para-num num="[0371]"> </para-num> <div class="description-line" id="p-0222" num="0371"> The protecting group of hydroxy includes, for example, methyl, trityl, methoxymethyl (MOM), 1-ethoxyethyl (EE), methoxyethoxymethyl (MEM), 2-tetrahydropyranyl (THP), trimethylsilyl (TMS), triethylsilyl (TES), tert-butyldimethylsilyl (TBDMS), tert-butyldiphenylsilyl (TBDPS), acetyl (Ac), pivaloyl, benzoyl, benzyl (Bn), p-methoxybenzyl, allyloxycarbonyl (Alloc), and 2,2,2-trichloroethoxycarbonyl (Troc), etc. </div>
</li> <li> <para-num num="[0372]"> </para-num> <div class="description-line" id="p-0223" num="0372"> The protecting group of amino includes, for example, benzyloxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl (Alloc), 1-methyl-1-(4-biphenyl)ethoxycarbonyl (Bpoc), trifluoroacetyl, 9-fluorenylmethoxycarbonyl, benzyl (Bn), p-methoxybenzyl, benzyloxymethyl (BOM) or 2-(trimethylsilyl)ethoxymethyl (SEM), etc. </div>
</li> <li> <para-num num="[0373]"> </para-num> <div class="description-line" id="p-0224" num="0373"> The protective group of mercapto includes, for example, benzyl, methoxybenzyl, methoxymethyl (MOM), 2-tetrahydropyranyl (THP), diphenylmethyl and acetyl (Ac), etc. </div>
</li> <li> <para-num num="[0374]"> </para-num> <div class="description-line" id="p-0225" num="0374"> With regard to the protective group for carboxy, hydroxy, amino and mercapto, there is no particular limitation to the above ones so far as it is a group which is able to be easily and selectively removed. For example, a deprotection reaction may be carried out by a method described in “T. W. Greene, <i>Protective Groups in Organic Synthesis</i>, John Wiley &amp; Sons Inc, 1999”. </div>
</li> <li> <para-num num="[0375]"> </para-num> <div class="description-line" id="p-0226" num="0375"> As persons skilled in the art can easily understand that the aimed compound of the present invention is able to be easily produced by using appropriate ones among those deprotection reactions. </div>
</li> <li> <para-num num="[0376]"> </para-num> <div class="description-line" id="p-0227" num="0376"> The compound represented by formula (II) can be prepared, for example, by a method shown in the following reaction scheme 1. </div>
</li> <li> <para-num num="[0377]"> </para-num> <div class="description-line" id="p-0228" num="0377"> In the scheme, Q<sup>1 </sup>has the same meaning as Q, and other symbols have the same meanings as described above.  
<chemistry id="CHEM-US-00075" num="75"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/96/e0/572319755e217c/US20070232586A1-20071004-C00075.png"><img alt="Figure US20070232586A1-20071004-C00075" class="patent-full-image" file="US20070232586A1-20071004-C00075.TIF" he="55.80mm" height="223" id="EMI-C00075" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/16/96/e0/572319755e217c/US20070232586A1-20071004-C00075.png" wi="75.86mm" width="303"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00075.CDX" idref="CHEM-US-00075"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00075.MOL" idref="CHEM-US-00075"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0378]"> </para-num> <div class="description-line" id="p-0229" num="0378"> Among the compounds represented by formula (II), a compound in which Q is methylsulfonyl, that is, a compound represented by formula (II-1), can be prepared by a method shown in reaction scheme 2. In the reaction scheme 2, all symbols have the same meanings as described above.  
<chemistry id="CHEM-US-00076" num="76"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/09/00/717d69db8e944d/US20070232586A1-20071004-C00076.png"><img alt="Figure US20070232586A1-20071004-C00076" class="patent-full-image" file="US20070232586A1-20071004-C00076.TIF" he="89.49mm" height="358" id="EMI-C00076" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/f1/09/00/717d69db8e944d/US20070232586A1-20071004-C00076.png" wi="75.78mm" width="303"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00076.CDX" idref="CHEM-US-00076"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00076.MOL" idref="CHEM-US-00076"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0379]"> </para-num> <div class="description-line" id="p-0230" num="0379"> Also, among the compounds represented by formula (I), a compound in which ring X is a pyrimidine ring, for example, a compound represented by formula (IA) or formula (IA′) shown below, can be prepared by a method shown in reaction scheme 3. </div>
</li> <li> <para-num num="[0380]"> </para-num> <div class="description-line" id="p-0231" num="0380"> In the reaction scheme 3, R<sup>101 </sup>is a leaving group such as a halogen atom or methylsulfonyl; R<sup>102 </sup>is a protecting group of amino (e.g., tert-butoxycarbonyl, benzyloxycarbonyl, etc.); R′ and R″ each independently has the same meaning as R; and other symbols have the same meanings as described above.  
<chemistry id="CHEM-US-00077" num="77"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/ce/49/5ed21ebdd8593e/US20070232586A1-20071004-C00077.png"><img alt="Figure US20070232586A1-20071004-C00077" class="patent-full-image" file="US20070232586A1-20071004-C00077.TIF" he="193.29mm" height="773" id="EMI-C00077" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/da/ce/49/5ed21ebdd8593e/US20070232586A1-20071004-C00077.png" wi="75.78mm" width="303"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00077.CDX" idref="CHEM-US-00077"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00077.MOL" idref="CHEM-US-00077"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0381]"> </para-num> <div class="description-line" id="p-0232" num="0381"> Among the compounds represented by formula (I), a compound in which R<sup>3 </sup>is alkyl which may have a substituent(s), that is, a compound represented by formula (Ia):  
<chemistry id="CHEM-US-00078" num="78"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/16/85/dd772a76709b0e/US20070232586A1-20071004-C00078.png"><img alt="Figure US20070232586A1-20071004-C00078" class="patent-full-image" file="US20070232586A1-20071004-C00078.TIF" he="16.68mm" height="67" id="EMI-C00078" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/f3/16/85/dd772a76709b0e/US20070232586A1-20071004-C00078.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00078.CDX" idref="CHEM-US-00078"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00078.MOL" idref="CHEM-US-00078"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0382]"> </para-num> <div class="description-line" id="p-0233" num="0382"> (wherein R<sup>3-1 </sup>is alkyl which may have a substituent(s), and other symbols have the same meanings as described above), can be prepared by alkylation of a compound represented by formula (IV):  
<chemistry id="CHEM-US-00079" num="79"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/42/12/a5/9b700e76b429c4/US20070232586A1-20071004-C00079.png"><img alt="Figure US20070232586A1-20071004-C00079" class="patent-full-image" file="US20070232586A1-20071004-C00079.TIF" he="16.68mm" height="67" id="EMI-C00079" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/42/12/a5/9b700e76b429c4/US20070232586A1-20071004-C00079.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00079.CDX" idref="CHEM-US-00079"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00079.MOL" idref="CHEM-US-00079"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0383]"> </para-num> <div class="description-line" id="p-0234" num="0383"> (wherein all symbols have the same meanings as described above) with a compound represented by formula (V): 
<br/>
R<sup>3A-1</sup>-Q  (V) 
</div>
</li> <li> <para-num num="[0384]"> </para-num> <div class="description-line" id="p-0235" num="0384"> (wherein R<sup>3A-1 </sup>has the same meaning as R<sup>3-1</sup>, and carboxy, hydroxy, amino or mercapto in the group represented by R<sup>3A-1 </sup>is protected if the protection is necessary; and other symbols have the same meanings as described above), </div>
</li> <li> <para-num num="[0385]"> </para-num> <div class="description-line" id="p-0236" num="0385"> and if necessary, followed by removal of the protecting group. </div>
</li> <li> <para-num num="[0386]"> </para-num> <div class="description-line" id="p-0237" num="0386"> The alkylation is known and, for example, is carried out by a reaction at −20 to 100° C. in an organic solvent (dimethylformamide, dimethylacetamide, diethyl ether, tetrahydrofuran, dimethoxyethane, etc.), in the presence of a base (e.g., sodium hydroxide, potassium hydroxide, butyllithium, phenyllithium, lithium hexamethyldisilazide, potassium hexamethyldisilazide, etc.) and in the presence or absence of iodide (e.g., potassium iodide, sodium iodide, etc.). </div>
</li> <li> <para-num num="[0387]"> </para-num> <div class="description-line" id="p-0238" num="0387"> The removal of the protecting group can be carried out in the same manner as described above. </div>
</li> <li> <para-num num="[0388]"> </para-num> <div class="description-line" id="p-0239" num="0388"> Among the compounds represented by formula (I), a compound represented by formula (Ib):  
<chemistry id="CHEM-US-00080" num="80"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/ca/31/e17ffd31bebe45/US20070232586A1-20071004-C00080.png"><img alt="Figure US20070232586A1-20071004-C00080" class="patent-full-image" file="US20070232586A1-20071004-C00080.TIF" he="16.76mm" height="67" id="EMI-C00080" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/52/ca/31/e17ffd31bebe45/US20070232586A1-20071004-C00080.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00080.CDX" idref="CHEM-US-00080"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00080.MOL" idref="CHEM-US-00080"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0389]"> </para-num> <div class="description-line" id="p-0240" num="0389"> (wherein  
<chemistry id="CHEM-US-00081" num="81"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/7b/e1/1fb14d4ebc8753/US20070232586A1-20071004-C00081.png"><img alt="Figure US20070232586A1-20071004-C00081" class="patent-full-image" file="US20070232586A1-20071004-C00081.TIF" he="7.54mm" height="30" id="EMI-C00081" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/7b/7b/e1/1fb14d4ebc8753/US20070232586A1-20071004-C00081.png" wi="13.55mm" width="54"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00081.CDX" idref="CHEM-US-00081"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00081.MOL" idref="CHEM-US-00081"> </attachment> </attachments> </chemistry>
<br/>
 is a group wherein the group adjacent to the nitrogen atom described is carbonyl among R<sup>3</sup>; and other symbols have the same meanings as described above) can be prepared by hydrazidation of a compound represented by formula (IV) and a compound represented by formula (VI):  
<chemistry id="CHEM-US-00082" num="82"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/87/d4/92fa72a2c37a8a/US20070232586A1-20071004-C00082.png"><img alt="Figure US20070232586A1-20071004-C00082" class="patent-full-image" file="US20070232586A1-20071004-C00082.TIF" he="10.08mm" height="40" id="EMI-C00082" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/37/87/d4/92fa72a2c37a8a/US20070232586A1-20071004-C00082.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00082.CDX" idref="CHEM-US-00082"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00082.MOL" idref="CHEM-US-00082"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0390]"> </para-num> <div class="description-line" id="p-0241" num="0390"> (wherein R<sup>201A </sup>has the same meaning as R<sup>201</sup>, and carboxy, hydroxy, amino or mercapto in the groups represented by R<sup>201A </sup>is protected if the protection is necessary), </div>
</li> <li> <para-num num="[0391]"> </para-num> <div class="description-line" id="p-0242" num="0391"> and if necessary, followed by removal of the protecting group. </div>
</li> <li> <para-num num="[0392]"> </para-num> <div class="description-line" id="p-0243" num="0392"> The hydrazidation is known and its examples are as follows. </div>
</li> <li> <div class="description-line" id="h-0016" num="0000"> (1) a method using acid halide; </div>
</li> <li> <div class="description-line" id="h-0017" num="0000"> (2) a method using mixed acid anhydride; </div>
</li> <li> <div class="description-line" id="h-0018" num="0000"> (3) a method using a condensing agent; etc. </div>
</li> <li> <para-num num="[0393]"> </para-num> <div class="description-line" id="p-0244" num="0393"> Those methods will be specifically illustrated as follows. </div>
</li> <li> <para-num num="[0394]"> </para-num> <div class="description-line" id="p-0245" num="0394"> (1) The method using acid halide can be carried out, for example, by reacting carboxylic acid with an acid halidation agent (oxazalyl chloride, thionyl chloride, etc.) at −20° C. to the refluxing temperature in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent, and reacting the resulting acid halide with amine at 0 to 40° C. in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.) in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.). Furthermore, the reaction can also be carried out by reacting the resulting acid halide with amine at 0 to 40° C. in an organic solvent (dioxane, tetrahydrofuran, etc.) using an aqueous alkaline solution (aqueous sodium bicarbonate solution, aqueous sodium hydroxide solution, etc.). </div>
</li> <li> <para-num num="[0395]"> </para-num> <div class="description-line" id="p-0246" num="0395"> (2) The method using mixed acid anhydride can be carried out, for example, by reacting carboxylic acid with acid halide (pivaloyl chloride, tosyl chloride, mesyl chloride, etc.) or an acid derivative (ethyl chloroformate, isobutyl chloroformate, etc.) in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.) or without a solvent, in the presence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, diisopropylethylamine, etc.) at 0 to 40° C., and the resulting mixed acid anhydride with amine at 0 to 40° C. in an organic solvent (chloroform, dichloromethane, diethyl ether, tetrahydrofuran, etc.). </div>
</li> <li> <para-num num="[0396]"> </para-num> <div class="description-line" id="p-0247" num="0396"> (3) The method using a condensing agent can be carried out, for example, by reacting carboxylic acid with amine at 0 to 40° C. in an organic solvent (chloroform, dichloromethane, dimethylformamide, diethyl ether, tetrahydrofuran, etc.) or without a solvent in the presence or absence of a base (pyridine, triethylamine, dimethylaniline, dimethylaminopyridine, N-methylmorpholine, etc.) using a condensing agent (1,3-dicyclohexylcarbodiimide (DCC), 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (EDC), 1,1′-carbonyldiimidazole (CDI), 2-chloro-1-methylpyridinium iodide, 1-propanephosphonic acid cyclic anhydride (PPA), bis(2-oxo-3-oxazolidinyl)phoshinic chloride, etc.) and using or without using 1-hydroxybenzotriazole (HOBt) or 1-hydroxy-7-azabenzotriazole (HOAt). </div>
</li> <li> <para-num num="[0397]"> </para-num> <div class="description-line" id="p-0248" num="0397"> These reactions (1), (2) and (3) are preferably carried out under anhydrous conditions in inert gas (argon, nitrogen, etc.) atmosphere. </div>
</li> <li> <para-num num="[0398]"> </para-num> <div class="description-line" id="p-0249" num="0398"> The removal of the protecting group can be carried out in the same manner as described above. </div>
</li> <li> <para-num num="[0399]"> </para-num> <div class="description-line" id="p-0250" num="0399"> Among the compounds represented by formula (Ib), a compound represented by formula (Ic):  
<chemistry id="CHEM-US-00083" num="83"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/89/e0/6096781c1e948f/US20070232586A1-20071004-C00083.png"><img alt="Figure US20070232586A1-20071004-C00083" class="patent-full-image" file="US20070232586A1-20071004-C00083.TIF" he="16.76mm" height="67" id="EMI-C00083" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/78/89/e0/6096781c1e948f/US20070232586A1-20071004-C00083.png" wi="69.93mm" width="280"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00083.CDX" idref="CHEM-US-00083"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00083.MOL" idref="CHEM-US-00083"> </attachment> </attachments> </chemistry>
</div>
</li> <li> <para-num num="[0400]"> </para-num> <div class="description-line" id="p-0251" num="0400"> (wherein  
<chemistry id="CHEM-US-00084" num="84"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/5b/dc/c1385a0e4a10a4/US20070232586A1-20071004-C00084.png"><img alt="Figure US20070232586A1-20071004-C00084" class="patent-full-image" file="US20070232586A1-20071004-C00084.TIF" he="9.48mm" height="38" id="EMI-C00084" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/06/5b/dc/c1385a0e4a10a4/US20070232586A1-20071004-C00084.png" wi="19.13mm" width="77"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00084.CDX" idref="CHEM-US-00084"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00084.MOL" idref="CHEM-US-00084"> </attachment> </attachments> </chemistry>
<br/>
 is a group in which the group adjacent to the nitrogen atom described is  
<chemistry id="CHEM-US-00085" num="85"> <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d3/eb/be/c79a4eccdd9eea/US20070232586A1-20071004-C00085.png"><img alt="Figure US20070232586A1-20071004-C00085" class="patent-full-image" file="US20070232586A1-20071004-C00085.TIF" he="9.48mm" height="38" id="EMI-C00085" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/d3/eb/be/c79a4eccdd9eea/US20070232586A1-20071004-C00085.png" wi="17.02mm" width="68"/></a></div> <attachments> <attachment attachment-type="cdx" file="US20070232586A1-20071004-C00085.CDX" idref="CHEM-US-00085"> </attachment> <attachment attachment-type="mol" file="US20070232586A1-20071004-C00085.MOL" idref="CHEM-US-00085"> </attachment> </attachments> </chemistry>
<br/>
 in R<sup>3</sup>; and other symbols have the same meanings as described above) can be prepared by the following reaction of a compound represented by formula (IV) with a compound represented by formula (VII): 
<br/>
R<sup>202A</sup>-N═C═O  (VII) 
</div>
</li> <li> <para-num num="[0401]"> </para-num> <div class="description-line" id="p-0252" num="0401"> (wherein R<sup>202A </sup>has the same meaning as R<sup>202</sup>, and carboxy, hydroxy, amino or mercapto in the group represented by R<sup>202A </sup>is protected if the protection is necessary) </div>
</li> <li> <para-num num="[0402]"> </para-num> <div class="description-line" id="p-0253" num="0402"> and if necessary, followed by removal of the protecting group. </div>
</li> <li> <para-num num="[0403]"> </para-num> <div class="description-line" id="p-0254" num="0403"> This reaction is known and, for example, is carried out in an organic solvent (toluene, chloroform, tetrahydrofuran, etc.) at room temperature to the refluxing temperature. </div>
</li> <li> <para-num num="[0404]"> </para-num> <div class="description-line" id="p-0255" num="0404"> The removal of the protecting group can be carried out in the same manner as described above. </div>
</li> <li> <para-num num="[0405]"> </para-num> <div class="description-line" id="p-0256" num="0405"> Also, the compound represented by formula (Ic) can be prepared by the following reaction of a compound represented by formula (IV) with a compound represented by formula (VIII): 
<br/>
R<sup>202A</sup>—NH<sub>2</sub>  (VIII) 
</div>
</li> <li> <para-num num="[0406]"> </para-num> <div class="description-line" id="p-0257" num="0406"> (wherein R<sup>202A </sup>has the same meaning as described above) </div>
</li> <li> <para-num num="[0407]"> </para-num> <div class="description-line" id="p-0258" num="0407"> and if necessary, followed by removal of the protecting group. </div>
</li> <li> <para-num num="[0408]"> </para-num> <div class="description-line" id="p-0259" num="0408"> The reaction is known and, for example, is carried out at 0 to 40° C. in an organic solvent (tetrahydrofuran, N,N-dimethylformamide, etc.), in the presence of triphosgene, using a base (triethylamine, etc.). Moreover, for example, the reaction is also carried out at 0 to 80° C. in an organic solvent (methylene chloride, N,N-dimethylformamide, etc.), in the presence of 1,1′-carbonylbis-1H-imidazole (CDI) using or without using a base (triethylamine, N-methylmorpholine, etc.). </div>
</li> <li> <para-num num="[0409]"> </para-num> <div class="description-line" id="p-0260" num="0409"> The removal of the protecting group can be carried out in the same manner as described above. </div>
</li> <li> <para-num num="[0410]"> </para-num> <div class="description-line" id="p-0261" num="0410"> All reactions in each reaction scheme is well known. All starting materials and reagents in the reaction schemes are known compounds, or can be prepared easily by known methods. </div>
</li> <li> <para-num num="[0411]"> </para-num> <div class="description-line" id="p-0262" num="0411"> In each reaction of the present specification, reaction products may be purified by conventional techniques, for example, distillation under atmospheric or reduced pressure, high performance liquid chromatography, thin layer chromatography or column chromatography using silica gel or magnesium silicate, washing or recrystallization, etc. Purification may be carried out after each reaction, or after a series of reactions. </div>
</li> <li> <div class="description-line" id="h-0019" num="0000"> Pharmacological Activities of the Compounds of the Present Invention: </div>
</li> <li> <para-num num="[0412]"> </para-num> <div class="description-line" id="p-0263" num="0412"> The following methods can be used as pharmacological test besides the methods described in “Biological Examples.”</div>
</li> <li> <div class="description-line" id="h-0020" num="0000"> (1) Measurement of Cathepsin B Inhibitory Activity </div>
</li> <li> <para-num num="[0413]"> </para-num> <div class="description-line" id="p-0264" num="0413"> Cathepsin B inhibitory activity can be measured in the way prescribed hereinafter. </div>
</li> <li> <para-num num="[0414]"> </para-num> <div class="description-line" id="p-0265" num="0414"> 10 μL of synthesized substrate (carbobenzoxy-L-arginyl-L-arginine-4-methyl-chromanyl-7-amide or carbobenzoxy-L-phenylalanyl-L-arginine-4-methyl-chromanyl-7-amide) solution of several concentrations, 10 μl of cysteine protease inhibitor solution of several concentrations, 70 μl of cathepsin B enzyme reaction buffer (mixture of 400 mmol/L of acetic acid, 4 mmol/L of EDTA, 8 mmol/L of DDT to adjust to pH 5.5) and 10 μl of cathepsin B enzyme solution are mixed and the increase of fluorescence intensity is measured (λex (excitation wavelength)=355 nm, λem (fluorescence wavelength)=460 nm) when reacted at 37° C. </div>
</li> <li> <div class="description-line" id="h-0021" num="0000"> (2) Measurement of Cathepsin S Inhibitory Activity </div>
</li> <li> <para-num num="[0415]"> </para-num> <div class="description-line" id="p-0266" num="0415"> Cathepsin S inhibitory activity can be measured in the way prescribed hereinafter. </div>
</li> <li> <para-num num="[0416]"> </para-num> <div class="description-line" id="p-0267" num="0416"> 10 μl of synthesized substrate (carbobenzoxy-L-leucyl-L-leucyl-L-arguinine-4-methyl-chromanyl-7-amide) solution and 5 μl of cysteine protease inhibitor solution of several concentrations, 75 μl of cathepsin S enzyme reaction buffer (100 mmol/L of sodium phosphate, 2 mmol/L of EDTA, 2 mmol/L of DTT are mixed to adjust to pH 6.5) and 10 μl of cathepsin S enzyme solution are mixed and the increase of fluorescence intensity is measured (λex(excitation wavelength)=355 nm, λem (fluorescence wavelength)=460 nm) when reacted at 37° C. </div>
</li> <li> <div class="description-line" id="h-0022" num="0000"> (3) Measurement of Cathepsin L Inhibitory Activity </div>
</li> <li> <para-num num="[0417]"> </para-num> <div class="description-line" id="p-0268" num="0417"> Cathepsin L inhibitory activity can be measured in the way prescribed hereinafter. </div>
</li> <li> <para-num num="[0418]"> </para-num> <div class="description-line" id="p-0269" num="0418"> 5 μl of Synthesized substrate (carbobenzoxy-L-phenylalanyl-L-arguine-4-methylchromanyl-7-amide or L-prolyl-L-phenylalanyl-L-arginine-4-methylchromanyl-7-amide) solution and 5 μl of cysteine protease inhibitor solution of several concentrations, 80 μl of cathepsin L enzyme reaction buffer (400 mmol/L of acetic acid, 4 mmol/L of EDTA, 8 mmol/L of DTT are mixed to adjust to pH 5.5) and 10 μl of cathepsin L enzyme solution are mixed and the increase of fluorescence intensity is measured (λex (excitation wavelength)=355 nm, λem (fluorescence wavelength)=460 nm) when reacted at 37° C. </div>
</li> <li> <div class="description-line" id="h-0023" num="0000"> (4) Measurement of Calpain Inhibitory Activity </div>
</li> <li> <para-num num="[0419]"> </para-num> <div class="description-line" id="p-0270" num="0419"> The activity is measured according to the method described in Calcium-depending protease, <i>Seibutsukagaku</i>-<i>Jikkenhou </i>(<i>Biochemistry Experimental Method</i>) <i>Tanpakubunkaikouso </i>(<i>Protease</i>) 1, 57 (1993). </div>
</li> <li> <div class="description-line" id="h-0024" num="0000"> (5) Measurement of Caspase-1 Inhibitory Activity </div>
</li> <li> <para-num num="[0420]"> </para-num> <div class="description-line" id="p-0271" num="0420"> Caspase-1 inhibitory activity can be measured in the way prescribed hereinafter. </div>
</li> <li> <para-num num="[0421]"> </para-num> <div class="description-line" id="p-0272" num="0421"> 50 μl of caspase-1 enzyme reaction solution (20 mmol/L of 4-(2-hydroxyethyl)-1-piperazinethanesulfonate-sodium hydroxide buffer (pH 7.4), 10 mmol/L of potassium chloride, 1.5 mmol/L of magnesium chloride, 0.1 mmol/L EDTA, 10% glycerol) and 50 μl of cysteine protease inhibitor solution of several concentrations, 50 μl of caspase-1 enzyme solution and 100 μl of synthesized substrate (acetyl-L-tyrosinyl-L-valinyl-L-alanyl-L-aspartic acid-4-methylchromanyl-7-amide) solution of several concentrations are reacted at 37° C. and the fluorescence intensity is measured (λex (excitation wavelength)=355 nm, λem (fluorescence wavelength)=460 nm). </div>
</li> <li> <div class="description-line" id="h-0025" num="0000"> (6) Investigation in Bone Resorption Inhibitory Activity Using Mouse Calvaria Cultivation System </div>
</li> <li> <para-num num="[0422]"> </para-num> <div class="description-line" id="p-0273" num="0422"> Mouse neonatal calvaria is cultured in D-minimum essential medium containing cysteine protease inhibitor (mixture of Penicillin G potassium (final concentration 100 U/ml), streptomycin sulfate (final concentration 0.1 mg/ml), bovine serum albumin (final concentration 0.1%), glutamine (final concentration 0.3 mg/ml) in D-minimal essential medium) with incitant (parathyroid hormone (PTH) or arotinoid) at 37° C. and the calcium concentration in the culture medium is measured. </div>
</li> <li> <div class="description-line" id="h-0026" num="0000"> (7) Bone Resorption Pit Formation Test Using Rabbit Osteoclast Cells </div>
</li> <li> <para-num num="[0423]"> </para-num> <div class="description-line" id="p-0274" num="0423"> Osteoclast cells collected from rabbit bones are sowed over slices of bovine cortical bone, dentine or teeth of toothed whale and are cultured at 37° C. in α-minimal essential medium containing final concentration 5% of fetal bovine serum and various concentrations of cysteine protease inhibitor. The pits form on the slices by the osteoclast cells are observed and at the same time type-I collagen C-terminal telopeptide (CTx) concentration in culture medium can be measured. </div>
</li> <li> <div class="description-line" id="h-0027" num="0000"> (8) Investigation of Immune Reaction Inhibitory Effect Using Antigen-Sensitized Mouse Spleen Cells </div>
</li> <li> <para-num num="[0424]"> </para-num> <div class="description-line" id="p-0275" num="0424"> Spleen cells are collected from mice sensitized by ovalbumin (OVA) several times. Inhibitory effect of cysteine protease inhibitors against immune response induced by OVA stimulus can be investigated, using cytokine concentration and immunoglobulin concentration in culture solution as indicators. </div>
</li> <li> <div class="description-line" id="h-0028" num="0000"> (9) Investigation in Inhibitory Effect Against Bone Resorption Using the Rat PTH Hypercalcemia Model </div>
</li> <li> <para-num num="[0425]"> </para-num> <div class="description-line" id="p-0276" num="0425"> The effect of cysteine protease inhibitor (compulsory oral administration, intraperitoneal administration) on bone resorption which is promoted by intravenous administration of parathyroid hormone (PTH) solution (30 μg/ml) can be investigated in rats, using calcium concentration in blood as an indicator. </div>
</li> <li> <div class="description-line" id="h-0029" num="0000"> (10) Studies on Bone Resorption Inhibitory Effect Using TPTx rat PTHrP-Induced Hypercalcemia Model </div>
</li> <li> <para-num num="[0426]"> </para-num> <div class="description-line" id="p-0277" num="0426"> The effect of cysteine protease inhibitor (compulsory oral administration, intraperitoneal administration) on bone resorption, promoted by subcutaneous administration of parathyroid hormone related peptide (PTHrP) to a fasting rat (thyroparathyroidectomized; TPTx) can be investigated, using calcium concentration in blood as an indicator. </div>
</li> <li> <para-num num="[0427]"> </para-num> <div class="description-line" id="p-0278" num="0427"> (11) Measurement of Cathepsin H Inhibitory Activity </div>
</li> <li> <para-num num="[0428]"> </para-num> <div class="description-line" id="p-0279" num="0428"> Using Arg-MCA (4-methyl-chromanyl-7-amide) as synthetic substrate, according to the method described in <i>FEBS Lett. </i>280(2), 307-310/1991<i>, Methods Enzymol. </i>80, 535-561/1981, the activity can be measured. </div>
</li> <li> <div class="description-line" id="h-0030" num="0000"> (12) Measurement of Cathepsin C Inhibitory Activity </div>
</li> <li> <para-num num="[0429]"> </para-num> <div class="description-line" id="p-0280" num="0429"> Using Gly-Phe-CHN<sub>2 </sub>as synthetic substrate, according to the method described in <i>J. Immunol. </i>150, 4733-4742,1993, the activity can be measured. </div>
</li> <li> <div class="description-line" id="h-0031" num="0000"> Toxicity: </div>
</li> <li> <para-num num="[0430]"> </para-num> <div class="description-line" id="p-0281" num="0430"> The toxicity of the compound of the present invention was very low, so the compound is safe enough for pharmaceutical use. </div>
</li> <li> <div class="description-line" id="h-0032" num="0000"> Application to Pharmaceuticals: </div>
</li> <li> <para-num num="[0431]"> </para-num> <div class="description-line" id="p-0282" num="0431"> The compound of the present invention has an inhibitory activity against cysteine proteases (cathepsins such as K, L, S, B, F, H, C, V, O, W, Z, etc., caspases such as caspase-1, calpains such as calpain, etc.), and therefore it is useful as an agent for the prophylaxis and/or treatment of inflammatory diseases (periodontitis, arthritis, inflammatory bowel diseases, infectious diseases, pancreatitis, hepatitis, glomerulonephritis, endocarditis, myocarditis, ulcerative colitis, etc.), diseases induced by apoptosis (graft versus host diseases, rejection in transplantation, acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), adult T cell leukemia, hairy cells leukemia, spondylopathy, disorders of respiratory apparatus, arthritis, HIV or HTLV-1 related diseases (uveitis etc.), virus related diseases (hepatitis C etc.), cancer, collagenosis (systemic lupus erythematosus, rheumatoid arthritis, etc.), ulcerative colitis, Sjoegren syndrome, primary biliary cirrhosis, spontaneous thrombocytopenic purpura, autoimmune hemolytic anemia, myasthenia gravis, autoimmune diseases (insulin dependent (type I) diabetes, etc.), diseases accompanied by thrombocytopenia (myelodysplastic syndrome, cyclic thrombocytopenia, aplastic anemia, spontaneous thrombocytopenia, disseminated intravascular coagulation (DIC), etc.), viral hepatitis (A, B, C, F, etc.) or hepatitis medicamentosa and cirrhosis, etc., dementia such as Alzheimer's disease, Alzheimer-type senile dementia, cerebrovascular injury, neurodegenerative disease, adult acute respiratory distress syndrome, infectious diseases, prostatomegaly, hysteromyoma, bronchial asthma, arteriosclerosis, hyperlipidemia, all kinds of lusus naturae, nephritis, senile cataract, chronic fatigue syndrome, myodystrophy, peripheral nerve injury, etc.), diseases induced by immune response disorder (graft versus host diseases, rejection in transplantation, allergic diseases (asthmatic bronchitis, atopic dermatitis, allergic rhinitis, hay fever, diseases by house dust, hypersensitive pneumonia, food allergy, etc.), psoriasis, rheumatoid arthritis, etc.), autoimmune diseases (insulin dependent (type I) diabetes, systemic lupus erythematosus, Hashimoto's diseases, multiple sclerosis, etc.), diseases induced by decomposition of proteins which compose a body (myodystrophy, cataract, periodontitis, hepatocyte injury by bile acid (cholestatic cirrhosis etc.), etc., decomposition of alveolus elastica (emphysema etc.), ischemic diseases (brain ischemia, brain disorder by ischemic reperfusion, cardiac infarction, ischemic liver damage, etc.), etc.), shock (septic shock, systemic inflammatory responsive syndrome, endotoxin shock, acidosis, etc.), circulatory disorder (arteriosclerosis, restenosis after PTCA (percutaneous transluminal coronary angioplasty), etc.), disorder of blood coagulation system (thrombocytopenic purpura, hemolytic uremic syndrome, etc.), malignant tumor, acquired immune deficiency syndrome (AIDS, AIDS-related complex (ARC), etc.), parasitic diseases (malaria etc.), neurodegenerative disease (Alzheimer-type senile dementia, Huntington's chorea, Parkinson's disease, multiple sclerosis, traumatic encephalopathy, traumatic spondylopathy, etc.), lung disorder (fibroid lungs, etc.), bone diseases (osteoporosis, bone fracture, rheumatoid arthritis, arthritis, osteoarthritis, hypercalcaemia, osteometastasis of cancer, periodontitis, bone Paget's disease, etc.), endocrinesthenia (hyperthyroidism etc.), etc. As the compound of formula (I) has an inhibitory activity against cystein protease, it is also useful as a bone resorption inhibitor. </div>
</li> <li> <para-num num="[0432]"> </para-num> <div class="description-line" id="p-0283" num="0432"> Cysteine protease which the compound of the present invention inhibits is all preferable, for example, cathepsin K, cathepsin L, cathepsin S, cathepsin B, cathepsin H, cathepsin F, cathepsin Y, cathepsin C, calpain, caspase-1, etc. Among them, cathepsin K is most preferred. Of course, cysteine proteases other than them are included in the scope of the present invention and naturally so are those cysteine proteases to be discovered in the future. </div>
</li> <li> <para-num num="[0433]"> </para-num> <div class="description-line" id="p-0284" num="0433"> The compound of the present invention may also be administered as a concomitant agent in combination with other agents for </div>
</li> <li> <div class="description-line" id="h-0033" num="0000"> 1) supplement and/or reinforcement of preventive and/or treating effect(s) of the compound, </div>
</li> <li> <div class="description-line" id="h-0034" num="0000"> 2) improvement in kinetics and absorption of the compound of and reduction of dose and/or </div>
</li> <li> <div class="description-line" id="h-0035" num="0000"> 3) reduction of side effect of the compound. </div>
</li> <li> <para-num num="[0434]"> </para-num> <div class="description-line" id="p-0285" num="0434"> A concomitant agent of the compound of the present invention with other agents may be administered in a mode of compounded agent in which both components are compounded in a single preparation or in a mode of separate preparations. When administration is conducted using separate preparations, a simultaneous administration and administrations with time difference is included. In the case of administrations with time difference, the compound of the present invention may be firstly administered and then other drug may be administered, or the other drug may be firstly administered and then the compound of the present invention may be administered. Each of the methods for the administration may be the same or different. </div>
</li> <li> <para-num num="[0435]"> </para-num> <div class="description-line" id="p-0286" num="0435"> There is no particular limitation for the diseases for which the above-mentioned concomitant agent achieves the preventive and/or the treating effect but any disease will be acceptable so far as it supplements and/or enforces the preventive and/or treating effect of the compound of the present invention. </div>
</li> <li> <para-num num="[0436]"> </para-num> <div class="description-line" id="p-0287" num="0436"> For example, examples of the other drug for supplement and/or reinforcing the preventive and/or treating effect of the compound of the present invention to bone diseases include, for example, bisphosphonate formulations, Vitamin D and its derivatives, Vitamin K and its derivatives, calcitonin formulations, α-calcitonin gene-related peptide formulations, female hormone formulations, selective estrogen receptor modulators (SERM), ipriflavone formulations, calcium formulations, anabolic steroid formulations, parathyroid hormone (PTH) formulations, PTHrP derivatives, caspase-1 inhibitors, farnesoid X receptor agonists, Bone Morphogenetic Protein (BMP) formulations, anti-RANKL (receptor activator of NF-kappa B ligand) antibody, GSK inhibitors (GSK:glycogen synthase kinase), metalloprotease inhibitors, prostaglandin derivatives, strontium formulations, anti TNF-α antibody, anti-IL-6 antibody, HMG-CoA reductase inhibitors, steroidal drugs, and antiinflammatory drugs, etc. Nonsteroidal antiinflammatory agent, local anesthetic agent and/or muscle-relaxing drug can also be used together for the purpose of redress of pain accompanied by bone fracture and osteoporosis. </div>
</li> <li> <para-num num="[0437]"> </para-num> <div class="description-line" id="p-0288" num="0437"> Bisphosphonate formulations include, for example, minodronic acid (1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethylidenebisphosphonic acid, salt thereof, or hydrate thereof), alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (alendronic acid), or sodium salt thereof, or trihydrate thereof), incadronate (cycloheptylaminomethylene-1,1-diphosphoric acid (incadronic acid), or disodium salt thereof, hydrate thereof), clodronate (1,1-dichloromethylene-1,1-diphosphoric acid (clodronic acid), or disodium salt thereof), tiludronate ((4-chlorophenyl)thiomethylene-1,1-diphosphoric acid (tiludronic acid), or disodium salt thereof), etidronate (1-hydroxy-1,1-diphosphoric acid (etidronic acid), or disodium salt thereof,), ibandronate (1-hydroxy-3-(N-methyl-N-pentylamino)propylidene-1,1-bisphosphonic acid), risedronate (1-hydroxy-2-pyridin-3-ylethylidenediphosphoric acid (risedronic acid), or sodium salt thereof, sester hydrate thereof), piridronate ([2-(2-pyridinyl)ethylidene]-1,1-bisphosphonic acid), pamidronate (3-amino-1-hydroxypropylidene-1,1-bisphosphonic acid (pamidronic acid), or disodium salt thereof, or pentahydrate thereof), zoledronate (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene-1,1-bisphosphonic acid, or hydrate thereof), olpadronate (3-(dimethylamino)-1-hydroxypropylidene-1,1-bisphosphonic acid), neridronate (6-amino-1-hydroxyhexylidene-1,1-bisphosphonic acid), etc. </div>
</li> <li> <para-num num="[0438]"> </para-num> <div class="description-line" id="p-0289" num="0438"> Vitamin D include, for example, Vitamin D<sub>2 </sub>(ergocalciferol), Vitamin D<sub>3 </sub>(cholecalciferol), etc. </div>
</li> <li> <para-num num="[0439]"> </para-num> <div class="description-line" id="p-0290" num="0439"> Vitamin D derivatives include, for example, alfacalcidol, falecalcitriol, calcitriol, 1α,25-dihydroxycholecalciferol, dihydrotaxisterol, ST-630, KDR, ST-630, ED-71, rocaltrol (Ro44-7190), tacalcitol, maxacalcitol, etc. </div>
</li> <li> <para-num num="[0440]"> </para-num> <div class="description-line" id="p-0291" num="0440"> Vitamin K and its derivatives include, for example, vitamin K<sub>1 </sub>(phytonadione), vitamin K<sub>2 </sub>(menatetrenone), etc. </div>
</li> <li> <para-num num="[0441]"> </para-num> <div class="description-line" id="p-0292" num="0441"> Calcitonin formulations include, for example, calcitonin salmon (STH-32, SMC20-51), calcitonin chicken (MC1-536), secalciferol, elcatonin, TJN-135, etc. </div>
</li> <li> <para-num num="[0442]"> </para-num> <div class="description-line" id="p-0293" num="0442"> Female hormone formulations include, for example, estrogen preparations, progesterone preparations, etc. Estrogen preparations include, for example, estrogen, estradiol, estradiol benzoate, estradiol cypionate, estradiol dipropionate, estradiol enannthate, estradiol hexahydrobenzoate, estradiol phenylpropionate, estradiol undecanoate, estradiol valerate, estrone, ethinylestradiol, mestranol, estriol, chlormadinone acetate, norethisterone. Progesterone preparations include, for example, progesterone, hydroxyprogesterone caproate, medroxyprogesterone acetate, trimegestone, etc. </div>
</li> <li> <para-num num="[0443]"> </para-num> <div class="description-line" id="p-0294" num="0443"> Selective estrogen receptor modulators (SERM) include, for example, tamoxifen, lasofoxifene tartrate, raloxifene hydrochloride, bazedoxifene acetate, PSK-3471, etc. </div>
</li> <li> <para-num num="[0444]"> </para-num> <div class="description-line" id="p-0295" num="0444"> Ipriflavone formulations include, for example, ipriflavone, etc. </div>
</li> <li> <para-num num="[0445]"> </para-num> <div class="description-line" id="p-0296" num="0445"> Calcium formulations include, for example, calcium chloride, calcium gluconate, calcium glycerophosphate, calcium lactate, calcium L-aspartate, calcium hydrogen phosphate, etc. </div>
</li> <li> <para-num num="[0446]"> </para-num> <div class="description-line" id="p-0297" num="0446"> Anabolic steroid formulations include, for example, nandrolone decanoate, nandrolone phenylpropionate, nandrolone cyclohexylpropionate, metenolone enanthate, mestanolone, stanozolol, oxymetholone, etc. </div>
</li> <li> <para-num num="[0447]"> </para-num> <div class="description-line" id="p-0298" num="0447"> Parathyroid hormone (PTH) formulations include, for example, PTH, teriparatide acetate, MBRI-93.02, Ostabolin-C, etc. </div>
</li> <li> <para-num num="[0448]"> </para-num> <div class="description-line" id="p-0299" num="0448"> PTHrP derivatives include, for example, RS-66271, hPTHrP, etc. </div>
</li> <li> <para-num num="[0449]"> </para-num> <div class="description-line" id="p-0300" num="0449"> Caspase-1 inhibitors include, for example, pralnacasan, nitroflubiprofen, etc. </div>
</li> <li> <para-num num="[0450]"> </para-num> <div class="description-line" id="p-0301" num="0450"> Farnesoid X receptor agonists include, for example, SR-45023A, etc. </div>
</li> <li> <para-num num="[0451]"> </para-num> <div class="description-line" id="p-0302" num="0451"> Anti-RANKL antibody includes, for example, AMG162, etc. </div>
</li> <li> <para-num num="[0452]"> </para-num> <div class="description-line" id="p-0303" num="0452"> Metalloprotease inhibitors include, for example, minocycline hydrochloride, etc. </div>
</li> <li> <para-num num="[0453]"> </para-num> <div class="description-line" id="p-0304" num="0453"> Prostaglandin derivatives include, for example, EP2 agonist, EP4 agonist, EP4 antagonist, for example, ONO-4819, nitroflurbiprofen, etc. </div>
</li> <li> <para-num num="[0454]"> </para-num> <div class="description-line" id="p-0305" num="0454"> Strontium formulations include, for example, strontium ranelate, etc. </div>
</li> <li> <para-num num="[0455]"> </para-num> <div class="description-line" id="p-0306" num="0455"> Anti TNF-α antibody include, for example, infliximab, etanercept, etc. </div>
</li> <li> <para-num num="[0456]"> </para-num> <div class="description-line" id="p-0307" num="0456"> Anti-IL-6 antibody include, for example, MRA, etc. </div>
</li> <li> <para-num num="[0457]"> </para-num> <div class="description-line" id="p-0308" num="0457"> HMG-CoA reductase inhibitors include, for example, pravastatin, simvastatin, lovastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin, etc. </div>
</li> <li> <para-num num="[0458]"> </para-num> <div class="description-line" id="p-0309" num="0458"> Steroidal drugs include, for example, KB-889 (OD14, tibolone), Hipros (TZP-4238), etc. </div>
</li> <li> <para-num num="[0459]"> </para-num> <div class="description-line" id="p-0310" num="0459"> Antiinflammatory drugs include, for example, sasapyrine, sodium salicylate, aspirin, aspirin dialuminate formulation, diflunisal, indomethacin, suprofen, ufenamate, dimethylisopropyl azulen, bufexamac, felbinac, diclofenac, tolmetin sodium, Clinoril, fenbufen, napmetone, proglumetacin, indomethacin farnesil, acemetacin, proglumetacin maleate, amfenac sodium, mofezolac, etodolac, ibuprofen, ibuprofen piconol, naproxen, flurbiprofen, flurbiprofen axethyl, ketoprofen, fenoprofen calcium, tiaprofenen, oxaprozin, pranoprofen, loxoprofen sodium, aluminoprofen, zaltoprofen, mefenamic acid, aluminum mefenamate, tolfenamic acid, floctafenine, ketophenylbutazone, oxyfenbutazone, piroxicam, tenoxicam, anpiroxicam, napageln cream, epirizole, tiaramide hydrochloride, tinoridine hydrochloride, emorfazone, sulpyrine, Migrenin, Saridon, Sedes G, Amipylo N, Sorbon, pyrine system antipyretics, acetaminophen, phenacetin, dimethothiazine mesylate, simetride formulation, or antipyrine system antipyretics, etc. </div>
</li> <li> <para-num num="[0460]"> </para-num> <div class="description-line" id="p-0311" num="0460"> There is no limitation for the ratio by weight of the compound of the present invention to other agents. </div>
</li> <li> <para-num num="[0461]"> </para-num> <div class="description-line" id="p-0312" num="0461"> With regard to other agents, two or more agents may be administered in combination. </div>
</li> <li> <para-num num="[0462]"> </para-num> <div class="description-line" id="p-0313" num="0462"> Such other agents which supplement and/or reinforce the preventive and/or treating effect of the compound of the present invention include not only those which have been found on the basis of the above-mentioned mechanism but also those which will be found in future. </div>
</li> <li> <para-num num="[0463]"> </para-num> <div class="description-line" id="p-0314" num="0463"> The pharmaceutical composition comprising the compound of the present invention, a combination of the compound of the present invention and other drug as an active ingredient is generally administered systemically or topically and orally or parenterally when it is used for the above objects. </div>
</li> <li> <para-num num="[0464]"> </para-num> <div class="description-line" id="p-0315" num="0464"> The dosages are determined depending on age, body weight, symptom, therapeutic effect, administration route, duration of the treatment and the like. Generally, 1 mg to 1000 mg per adult is orally administered once to several times per day, or 0.1 mg to 100 mg per adult is parenterally administered (preferably by intravenous administration) once to several times per day, or continuously administered from vein for 1 to 24 hours per day. </div>
</li> <li> <para-num num="[0465]"> </para-num> <div class="description-line" id="p-0316" num="0465"> Since the dose changes depending on various conditions as described above, there are cases in which doses lower than or greater than the above ranges may be used. </div>
</li> <li> <para-num num="[0466]"> </para-num> <div class="description-line" id="p-0317" num="0466"> The pharmaceutical composition comprising the compound of the present invention, a concomitant agent of the compound of the present invention and other drug as an active ingredient may be administered in the form of solid compositions, liquid compositions and other compositions for oral administration, and injections, external preparations, suppositories, and the like for parenteral administration. </div>
</li> <li> <para-num num="[0467]"> </para-num> <div class="description-line" id="p-0318" num="0467"> Solid compositions for oral administration include tablets, pills, capsules, dispersible powders, granules and the like. Capsules include hard capsules and soft capsules. </div>
</li> <li> <para-num num="[0468]"> </para-num> <div class="description-line" id="p-0319" num="0468"> In such solid compositions, one or more of the active compound(s) may be admixed with vehicles (such as lactose, mannitol, glucose, microcrystalline cellulose or starch), binders (such as hydroxypropyl cellulose, polyvinylpyrrolidone or magnesium metasilicate aluminate), disintegrants (such as cellulose calcium glycolate), lubricants (such as magnesium stearate), stabilizing agents, and solution adjuvants (such as glutamic acid or aspartic acid) and prepared according to methods well known in normal pharmaceutical practice. The solid forms may, if desired, be coated with coating agents (such as sugar, gelatin, hydroxypropyl cellulose or hydroxypropylmethyl cellulose phthalate), or be coated with two or more films. And further, coating may include containment within capsules of absorbable materials such as gelatin. </div>
</li> <li> <para-num num="[0469]"> </para-num> <div class="description-line" id="p-0320" num="0469"> Liquid compositions for oral administration include pharmaceutically acceptable solutions, suspensions, emulsions, syrups and elixirs. In such forms, one or more of the active compound(s) may be dissolved, suspended or emulized into diluent(s) commonly used in the art (such as purified water, ethanol or a mixture thereof). Besides such liquid forms may also comprise some additives, such as wetting agents, suspending agents, emulsifying agents, sweetening agents, flavoring agents, aroma, preservative or buffering agent. </div>
</li> <li> <para-num num="[0470]"> </para-num> <div class="description-line" id="p-0321" num="0470"> Injections for parenteral administration in the present invention include solutions, suspensions and emulsions, and also solid injections which are to be dissolved or suspended in solvents upon use. Such an injection is prepared by dissolving, suspending or emulsifying one or more active substances in a solvent and then put to use. Examples of the solvent include distilled water for injection, physiological saline, plant oil, alcohols such as propylene glycol, polyethylene glycol and ethanol, and combinations thereof. Further, the injection may contain a stabilizer, a solubilizing auxiliary agent such as glutamic acid, aspartic acid and POLYSORBATE 80 (registered trade mark) etc.), suspending agent, emulsifying agent, soothing agent, buffering agent, preservative agent and the like. The injection may be sterilized in the final step of the preparation process or the whole preparation process may be operated under sterile conditions. Alternatively, the sterile product, for example a sterile freeze-dried product may be prepared, and upon use, the product may be dissolved in sterilized or aseptic distilled water for injection or other sterilized or aseptic solvents. </div>
</li> <li> <para-num num="[0471]"> </para-num> <div class="description-line" id="p-0322" num="0471"> Other compositions for parenteral administration include liquids for external use, ointments, endemic liniments, inhalants, spray compositions, suppositories for intrarectal administration, and pessaries for intravaginal administration and the like containing one or more active compound(s) which can be prepared by known methods. </div>
</li> <li> <para-num num="[0472]"> </para-num> <div class="description-line" id="p-0323" num="0472"> Spray compositions may contain stabilizing agents such as sodium hydrogen sulfate, buffering agents to give isotonicity, isotonic solutions such as sodium chloride, sodium citrate or citric acid, in addition to inert diluents. For preparation of such spray compositions, for example, the method described in the U.S. Pat. Nos. 2,868,691 and 3,095,355. </div>
</li> <heading id="h-0036">EFFECT OF THE INVENTION </heading>
<li> <para-num num="[0473]"> </para-num> <div class="description-line" id="p-0324" num="0473"> The compounds of the present invention have the inhibitory activity against cathepsin K, so they are useful for preventing and/or treating cathepsin K-related diseases. </div>
</li> </ul>
</div>
</section><section itemprop="claims" itemscope="">
<h2>Claims (<span itemprop="count">18</span>)</h2>
<div html="" itemprop="content"><div class="claims" lang="EN" load-source="patent-office" mxw-id="PCLM7762293">
<div class="claim"> <div class="claim" id="CLM-00001" num="00001">
<div class="claim-text"> <b>1</b>. A compound represented by formula (I): </div>
<div class="claim-text">
<chemistry id="CHEM-US-00086" num="86">
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/46/f8/ba83494994b3e9/US20070232586A1-20071004-C00086.png"><img alt="Figure US20070232586A1-20071004-C00086" class="patent-full-image" file="US20070232586A1-20071004-C00086.TIF" he="16.68mm" height="67" id="EMI-C00086" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/aa/46/f8/ba83494994b3e9/US20070232586A1-20071004-C00086.png" wi="69.93mm" width="280"/></a></div>
<attachments>
<attachment attachment-type="cdx" file="US20070232586A1-20071004-C00086.CDX" idref="CHEM-US-00086"> </attachment>
<attachment attachment-type="mol" file="US20070232586A1-20071004-C00086.MOL" idref="CHEM-US-00086"> </attachment>
</attachments>
</chemistry>
<div class="claim-text">wherein ring X is a heterocyclic group which may contain 1 to 4 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring; <div class="patent-image small-patent-image"><a href="https://patentimages.storage.googleapis.com/27/36/fd/dd5343f66ac704/US20070232586A1-20071004-P00001.png"><img alt="Figure US20070232586A1-20071004-P00001" class="patent-full-image" file="US20070232586A1-20071004-P00001.TIF" he="2.79mm" height="11" id="custom-character-00003" img-content="character" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/27/36/fd/dd5343f66ac704/US20070232586A1-20071004-P00001.png" wi="4.91mm" width="20"/></a></div> is a single bond or a double bond; J is a bond or a spacer having from 1 to 8 atoms of the principle chain; R is hydrogen atom or a substituent, and if R is plural, Rs are the same or different, and two Rs may form, together with the atom on the ring to which they bind, a cyclic group which may have a substituent(s); R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>is each independently a hydrogen atom or a substituent; n is 0 or an integer of 1 to 10, and wherein R<sup>1 </sup>and R<sup>2 </sup>may form, together with the nitrogen atom to which they bind, a cyclic group which may have a substituent(s), and R<sup>2 </sup>and R<sup>3 </sup>may form, together with the nitrogen atom to which they bind, a cyclic group which may have a substituent(s), </div>
<div class="claim-text">a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. </div>
</div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00002" num="00002">
<div class="claim-text"> <b>2</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ring X is a 5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00003" num="00003">
<div class="claim-text"> <b>3</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the ring X is </div>
<div class="claim-text">
<chemistry id="CHEM-US-00087" num="87">
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6c/91/fe/7e0265c2465aff/US20070232586A1-20071004-C00087.png"><img alt="Figure US20070232586A1-20071004-C00087" class="patent-full-image" file="US20070232586A1-20071004-C00087.TIF" he="12.87mm" height="51" id="EMI-C00087" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/6c/91/fe/7e0265c2465aff/US20070232586A1-20071004-C00087.png" wi="18.71mm" width="75"/></a></div>
<attachments>
<attachment attachment-type="cdx" file="US20070232586A1-20071004-C00087.CDX" idref="CHEM-US-00087"> </attachment>
<attachment attachment-type="mol" file="US20070232586A1-20071004-C00087.MOL" idref="CHEM-US-00087"> </attachment>
</attachments>
</chemistry>
<div class="claim-text">wherein ring A is a carbocyclic group or a heterocyclic group; ring B is a nitrogen-containing heterocyclic group; Y and Z is each independently a carbon atom or a nitrogen atom; and other symbols have the same meanings as described in <claim-ref idref="CLM-00001">claim 1</claim-ref>. </div>
</div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00004" num="00004">
<div class="claim-text"> <b>4</b>. The compound according to <claim-ref idref="CLM-00002">claim 2</claim-ref>, wherein the ring X is a ring selected from tetrahydropyrimidine, dihyrdopyridazine, pyridazine, dihydropyrimidine, dihydropyrazine, dihydrotriazine, dihydropyrazole, pyrrole, pyrimidine, pyrazine, imidazole, pyrazole, triazole, tetrazole, thiazole, oxazole, thiadiazole, oxadiazole, azepane, azepine, dihydroazepine, tetrahydroazepine, diazepane, diazepine, dihydrodiazepine and tetrahydrodiazepine. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00005" num="00005">
<div class="claim-text"> <b>5</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein J is a bond. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00006" num="00006">
<div class="claim-text"> <b>6</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>1 </sup>is C1-8 alkyl which may have a substituent(s). </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00007" num="00007">
<div class="claim-text"> <b>7</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein R<sup>2 </sup>is C1-8 alkyl which may have a substituent(s), C1-8 alkylcarbonyl which may have a substituent(s), C1-8 alkylsulfonyl which may have a substituent(s), carbamoyl which may have a substituent(s), a carbocyclic group which may have a substituent(s), a heterocyclic group which may have a substituent(s), </div>
<div class="claim-text">
<chemistry id="CHEM-US-00088" num="88">
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c5/c1/8b/ed8d7e93eb8c07/US20070232586A1-20071004-C00088.png"><img alt="Figure US20070232586A1-20071004-C00088" class="patent-full-image" file="US20070232586A1-20071004-C00088.TIF" he="9.65mm" height="39" id="EMI-C00088" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/c5/c1/8b/ed8d7e93eb8c07/US20070232586A1-20071004-C00088.png" wi="37.76mm" width="151"/></a></div>
<attachments>
<attachment attachment-type="cdx" file="US20070232586A1-20071004-C00088.CDX" idref="CHEM-US-00088"> </attachment>
<attachment attachment-type="mol" file="US20070232586A1-20071004-C00088.MOL" idref="CHEM-US-00088"> </attachment>
</attachments>
</chemistry>
<div class="claim-text">wherein T<sup>1 </sup>and T<sup>2 </sup>is each independently a bond or a spacer having from 1 to 3 atoms of the principle chain, and ring 1 and ring 2 is each independently a cyclic group which may have a substituent(s), or </div>
<div class="claim-text">
<chemistry id="CHEM-US-00089" num="89">
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/43/18/70c7e331ba1ae3/US20070232586A1-20071004-C00089.png"><img alt="Figure US20070232586A1-20071004-C00089" class="patent-full-image" file="US20070232586A1-20071004-C00089.TIF" he="9.65mm" height="39" id="EMI-C00089" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/5f/43/18/70c7e331ba1ae3/US20070232586A1-20071004-C00089.png" wi="30.31mm" width="121"/></a></div>
<attachments>
<attachment attachment-type="cdx" file="US20070232586A1-20071004-C00089.CDX" idref="CHEM-US-00089"> </attachment>
<attachment attachment-type="mol" file="US20070232586A1-20071004-C00089.MOL" idref="CHEM-US-00089"> </attachment>
</attachments>
</chemistry>
</div>
<div class="claim-text">wherein E is a substituent containing a nitrogen atom having basicity, and other symbols have the same meanings as above, and </div>
<div class="claim-text">R<sup>3 </sup>is hydrogen atom. </div>
</div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00008" num="00008">
<div class="claim-text"> <b>8</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, which is represented by formula (I-4): </div>
<div class="claim-text">
<chemistry id="CHEM-US-00090" num="90">
<div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c2/6f/09/26c01da4790148/US20070232586A1-20071004-C00090.png"><img alt="Figure US20070232586A1-20071004-C00090" class="patent-full-image" file="US20070232586A1-20071004-C00090.TIF" he="19.56mm" height="78" id="EMI-C00090" img-content="chem" img-format="tif" inline="no" orientation="portrait" src="https://patentimages.storage.googleapis.com/c2/6f/09/26c01da4790148/US20070232586A1-20071004-C00090.png" wi="69.93mm" width="280"/></a></div>
<attachments>
<attachment attachment-type="cdx" file="US20070232586A1-20071004-C00090.CDX" idref="CHEM-US-00090"> </attachment>
<attachment attachment-type="mol" file="US20070232586A1-20071004-C00090.MOL" idref="CHEM-US-00090"> </attachment>
</attachments>
</chemistry>
<div class="claim-text">wherein ring X<sup>P </sup>is a 5- to 7-membered monocyclic heterocyclic group which may contain 1 to 3 hetero atoms selected from a nitrogen atom(s), an oxygen atom(s) and a sulfur atom(s) which may be oxidized, in addition to the nitrogen atom in the ring; R<sup>1P </sup>is C1-8 alkyl which may have a substituent(s); T<sup>1P </sup>is a bond or a spacer having 1 or 2 atoms of the principle chain; T<sup>2 </sup>is each independently a bond or a spacer having from 1 to 3 atoms of the principle chain; ring 1<sup>P </sup>is a C5 to 7 membered monocyclic carbocyclic group which may have a substituent(s) or a 5- to 7-membered monocyclic heterocyclic group which may have a substituent(s); E is a substituent containing a nitrogen atom having basicity; and other symbols have the same meanings as described in <claim-ref idref="CLM-00001">claim 1</claim-ref>. </div>
</div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00009" num="00009">
<div class="claim-text"> <b>9</b>. The compound according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, which is 
<div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-(2-cyano-5-methyl-4-pyrimidinyl)-4-[(4-methyl-1-piperazinyl)methyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-2-(dimethylamino)-N′-neopentylacetohydrazide, </div> <div class="claim-text">N′-(5-bromo-2-cyano-4-pyrimidinyl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-N′-neopentylnicotinohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-4-(4-morpholinylmethyl)-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-4-[(dimethylamino)methyl]-3-fluoro-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-(2-cyanopyrazolo[1,5-a][1,3,5]triazin-4-yl)-4-[1-(2-methoxyethyl)-4-piperidinyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-2-methyl-2-[4-(1-methyl-4-piperidinyl)phenyl]-N′-neopentylpropanohydrazide, </div> <div class="claim-text">N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-2-{4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide, </div> <div class="claim-text">N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[2-(dimethylamino)ethoxy]-N′-neopentylbenzohydrazide, </div> <div class="claim-text">N′-(2-cyano-6-methyl-4-pyrimidinyl)-2-{4-[(dimethylamino)methyl]phenyl}-2-methyl-N′-neopentylpropanohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-N′-neopentyl-2-(1-pyrrolidinyl)acetohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-6-(4-methyl-1-piperazinyl)nicotinohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-4-{[(2-methoxyethyl)(methyl)amino]methyl}benzohydrazide, </div> <div class="claim-text">N′-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)benzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-3-(dimethylamino)-N′-(2,2-dimethylpropyl)propanohydrazide, </div> <div class="claim-text">N′-(2-cyano-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)-2-{4-[(dimethylamino)methyl]phenyl}-N′-(2,2-dimethylpropyl)-2-methylpropanohydrazide, </div> <div class="claim-text">N′-(2-cyano-6-methyl-4-pyrimidinyl)-N′-(2,2-dimethylpropyl)-2-methyl-2-{4-[(4-methyl-1-pyrimidinyl)methyl]phenyl} propanohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-4′-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-4-biphenylcarbohydrazide, </div> <div class="claim-text">N′-(2-cyano-6-methyl-4-pyrimidinyl)-4-[(dimethylamino)methyl]-N′-(2,2-dimethylpropyl)-3-methoxybenzohydrazide, </div> <div class="claim-text">N′-[2-cyano-6-(trifluoromethyl)-4-pyrimidinyl]-N′-(2,2-dimethylpropyl)-2-(methylamino)acetohydrazide, or </div> <div class="claim-text">tert-butyl 2-(2-cyano-5,7-dihydrofuro[3,4-d]pyrimidin-4-yl)-2-(2,2-dimethylpropyl)hydrazinecarboxylate. </div> </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00010" num="00010">
<div class="claim-text"> <b>10</b>. A pharmaceutical composition comprising the compound of formula (I) according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof as an active ingredient. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00011" num="00011">
<div class="claim-text"> <b>11</b>. The pharmaceutical composition according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, which is an agent for prevention and/or treatment for a cysteine protease-related disease. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00012" num="00012">
<div class="claim-text"> <b>12</b>. The pharmaceutical composition according to <claim-ref idref="CLM-00011">claim 11</claim-ref>, wherein a cysteine protease-related disease is a cathepsin K-related disease. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00013" num="00013">
<div class="claim-text"> <b>13</b>. The pharmaceutical composition according to <claim-ref idref="CLM-00012">claim 12</claim-ref>, wherein a cathepsin K-related disease is a bone disease. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00014" num="00014">
<div class="claim-text"> <b>14</b>. The pharmaceutical composition according to <claim-ref idref="CLM-00013">claim 13</claim-ref>, wherein a bone disease is at least one selected from osteoporosis, bone fracture, arthritis, rheumatoid arthritis, osteoarthritis, hypercalcaemia, osteometastasis of cancer, osteosarcoma, periodontitis, and bone Paget's disease. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00015" num="00015">
<div class="claim-text"> <b>15</b>. The pharmaceutical composition according to <claim-ref idref="CLM-00010">claim 10</claim-ref>, which is a bone resorption inhibitor. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00016" num="00016">
<div class="claim-text"> <b>16</b>. A drug comprising the compound of formula (I) according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof, combined with at least one selected from bisphosphonate formulations, vitamin D and its derivatives, vitamin K and its derivatives, calcitonin formulations, α-calcitonin gene-related peptide formulations, female hormone formulations, selective estrogen receptor modulators, ipriflavone formulations, calcium formulations, anabolic steroid formulations, parathyroid hormone formulations, PTHrP derivatives, caspase-1 inhibitors, farnesoid X receptor agonists, Bone Morphogenetic Protein formulations, anti-RANKL antibody, GSK inhibitor, metalloprotease inhibitors, prostaglandin derivatives, strontium formulations, anti TNF-α antibody, anti-IL-6 antibody, HMG-CoA reductase inhibitors, steroidal drugs, and antiinflammatory drugs. </div>
</div>
</div> <div class="claim-dependent"> <div class="claim" id="CLM-00017" num="00017">
<div class="claim-text"> <b>17</b>. A method for the prophylaxis and/or treatment of a cysteine protease-related disease in a mammal characterized by administering to a mammal an effective amount of the compound of formula (I) according to <claim-ref idref="CLM-00001">claim 1</claim-ref>, a salt thereof, a solvate thereof, or an N-oxide thereof, or a prodrug thereof. </div>
</div>
</div> <div class="claim"> <div class="claim" id="CLM-00018" num="00018">
<div class="claim-text"> <b>18</b>. (canceled)</div>
</div>
</div> </div>
</div>
</section>
                </article>
            </search-app>
        </body>
    </html>
    